

SCIENTIFIC PROGRAMME

Chairs

Andrea Antinori, Roma
Andrea De Luca, Siena
Maurizio Zazzi, Siena

9°
CONGRESSO
NAZIONALE



12-14 GIUGNO 2017

Università degli Studi di Siena
CENTRO DIDATTICO
POLICLINICO S. MARIA ALLE SCOTTE

**Italian Conference on
AIDS and Antiviral Research**

ICAR



Promoted by



and by

INMI, Istituto Nazionale per le Malattie Infettive
ISS, Istituto Superiore di Sanità
AMCLI, Associazione Microbiologi Clinici Italiani
SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
SIMET, Società Italiana di Medicina Tropicale
SITA, Società italiana per la Terapia Antinfettiva

SIV-ISV, Società Italiana di Virologia – Italian Society for Virology
ANLAIDS, Associazione Nazionale per la lotta all'AIDS
ARCIGAY, Associazione LGBT Italiana
EpaC Onlus, Associazione EpaC Onlus
LILA, Lega Italiana per la lotta contro l'AIDS
NADIR, Associazione Nadir Onlus
NPS Italia Onlus, Network Persone Sieropositive
PLUS Onlus, Persone LGBT sieropositive Onlus

Endorsements





CME PROVIDER and ORGANIZING SECRETARIAT

Effetti srl Via Gallarate, 106 - 20151 Milano, I

PHONE +39 02 3343281 FAX +39 02 38002105 MAIL: icar2017@effetti.it

CONGRESS VENUES

Università degli Studi di Siena

Centro Didattico Policlinico S. Maria alle Scotte
Strada Le Scotte, 4 - 53100 Siena I

OPENING SESSION

Teatro dei Rinnovati

Piazza del Campo - 53100 Siena I

QUICK LINKS

Organizing Secretariat icar2017@effetti.it

Abstract Secretariat abstract.icar2017@effetti.it

ICAR Website www.icar2017.it



www.facebook.com/ICAR2017



twitter.com/ICARSiena2017



Promoted by

SIMIT Società Italiana di Malattie Infettive e Tropicali

and by

INMI, Istituto Nazionale per le Malattie Infettive

ISS, Istituto Superiore di Sanità

AMCLI, Associazione Microbiologi Clinici Italiani

SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

SIMET, Società Italiana di Medicina Tropicale

SITA, Società italiana per la Terapia Antinfettiva

SIV-ISV, Società Italiana di Virologia - Italian Society for Virology

ANLAIDS, Associazione Nazionale per la lotta contro l'AIDS

ARCIGAY, Associazione LGBT Italiana

EpaC Onlus, Associazione EpaC Onlus

LILA, Lega Italiana per la lotta contro l'AIDS

NADIR, Associazione Nadir Onlus

NPS Italia Onlus, Network Persone Sieropositive

PLUS Onlus, Persone LGBT sieropositive Onlus

Endorsements

INSTITUTIONS

Ministero della Salute

AIFA, Agenzia Italiana del Farmaco

CNR, Consiglio Nazionale delle Ricerche

Regione Toscana

Provincia di Siena

Comune di Siena

Università degli Studi di Siena

Azienda Ospedaliera Universitaria Senese

SCIENTIFIC SOCIETIES AND ASSOCIATIONS

AIMI, Associazione Infermieri Malattie Infettive

AISF, Associazione Italiana per lo Studio del Fegato

ANIPIO, Società Scientifica Nazionale Infermieri Specialisti nel Rischio Infettivo

ASA, Associazione Solidarietà AIDS

ASPE, Associazione Studio Patologie Epatiche

Aviralia, Fondazione Aviralia Onlus

Cittadinanzattiva

SIMPIOS, Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie



Descovy® ▼

emtricitabina/tenofovir alafenamide
200/10mg e 200/25mg compresse



Cod. HIV1715

Depositato presso AIFA in data 10/03/2017





Scientific Committee Government Bodies

CHAIRS

- **Andrea Antinori**, Roma
- **Andrea De Luca**, Siena
- **Maurizio Zazzi**, Siena

SCIENTIFIC SECRETARIAT

- **Adriana Ammassari**, Roma
- **Marco Borderi**, Bologna
- **Maurizia Brunetto**, Pisa
- **Andrea Calcagno**, Torino
- **Antonella Castagna**, Milano
- **Francesca Ceccherini-Silberstein**, Roma
- **Paola Cinque**, Milano
- **Nicola Coppola**, Napoli
- **Maria Luisa Cosmaro**, Milano
- **Andrea Cossarizza**, Modena
- **Antonio Di Biagio**, Genova
- **Simona Di Giambenedetto**, Roma
- **Enrico Girardi**, Roma
- **Andrea Gori**, Monza
- **Sergio Lo Caputo**, Bari
- **Paolo Maggi**, Bari
- **Franco Maggiolo**, Bergamo
- **Giulia Marchetti**, Milano
- **Simone Marcotullio**, Roma
- **Cristina Mussini**, Modena
- **Massimo Puoti**, Milano
- **Stefano Rusconi**, Milano
- **Gloria Taliani**, Roma
- **Carlo Torti**, Catanzaro

ICAR GOVERNMENT

Coordinator

- **Andrea Antinori**, Roma

Secretary

- **Antonella d'Arminio Monforte**, Milano

Members

- **Massimo Andreoni**, Roma
- **Antonio Chirianni**, Napoli
- **Giulio Maria Corbelli**, Bologna
- **Adriano Lazzarin**, Milano
- **Carlo Federico Perno**, Roma
- **Massimo Puoti**, Milano
- **Maurizio Zazzi**, Siena

SPC (SCIENTIFIC PROGRAMME COMMITTEE)

- **Massimo Andreoni**, Roma
- **Gioacchino Angarano**, Bari
- **Andrea Antinori**, Roma
- **Guido Antonelli**, Roma
- **Francesco Benanti**, Catania
- **Marco Borderi**, Bologna
- **Michele Breveglieri**, Bologna
- **Raffaele Bruno**, Pavia
- **Stefano Buttò**, Roma
- **Maria R. Capobianchi**, Roma
- **Antonella Castagna**, Milano
- **Francesco Castelli**, Brescia
- **Anna Maria Cattelan**, Padova
- **Antonio Chirianni**, Napoli
- **Paola Cinque**, Milano
- **Massimo Clementi**, Milano
- **Giulio Maria Corbelli**, Bologna
- **Andrea Cossarizza**, Modena
- **Antonella d'Arminio Monforte**, Milano
- **Andrea De Luca**, Siena
- **Maria Grazia Di Benedetto**, Catania
- **Giovanni Di Perri**, Torino
- **Margherita Errico**, Milano
- **Vincenzo Esposito**, Napoli
- **Carlo Ferrari**, Parma
- **Giovanni Battista Gaeta**, Napoli
- **Massimo Galli**, Milano
- **Ivan Gardini**, Vercate MB
- **Enrico Girardi**, Roma
- **Andrea Gori**, Monza

- **Giuseppe Ippolito**, Roma
- **Adriano Lazzarin**, Milano
- **Sergio Lo Caputo**, Bari
- **Paolo Maggi**, Bari
- **Franco Maggiolo**, Bergamo
- **Bruno Marchini**, Roma
- **Claudio M. Mastroianni**, Latina
- **Francesco Mazzotta**, Firenze
- **Cristina Mussini**, Modena
- **Giorgio Palù**, Padova
- **Carlo Federico Perno**, Roma
- **Massimo Puoti**, Milano
- **Giovanni Rezza**, Roma
- **Giuliano Rizzardini**, Milano
- **Stefano Rusconi**, Milano
- **Filippo von Schloesser**, Roma
- **Guido Silvestri**, Atlanta USA
- **Giulio Starnini**, Viterbo
- **Barbara Suligoj**, Roma
- **Gloria Taliani**, Roma
- **Carlo Torti**, Catanzaro
- **Stefano Vella**, Roma
- **Claudio Viscoli**, Genova
- **Maurizio Zazzi**, Siena

CSC (COMMUNITY SUB-COMMITTEE)

- **Michele Breveglieri**, Bologna (Arcigay)
- **Giulio Maria Corbelli**, Bologna (PLUS Onlus)
- **Maria Grazia Di Benedetto**, Catania (LILA)
- **Margherita Errico**, Milano (NPS Italia Onlus)
- **Ivan Gardini**, Vercate MB (EpaC Onlus)
- **Bruno Marchini**, Roma (ANLAIDS)
- **Filippo von Schloesser**, Roma (Nadir Onlus)

ANNUAL PROGRAMME COMMITTEE

- **Andrea Antinori**, Roma
- **Guido Antonelli**, Roma
- **Michele Breveglieri**, Bologna
- **Antonella d'Arminio Monforte**, Milano
- **Andrea De Luca**, Siena
- **Margherita Errico**, Milano
- **Francesco Mazzotta**, Firenze
- **Maurizio Zazzi**, Siena

Faculty

- Chiara Agrati, Roma
- Adriana Ammassari, Roma
- Massimo Andreoni, Roma
- Giocchino Angarano, Bari
- Andrea Antinori, Roma
- Guido Antonelli, Roma
- Luca Arcaini, Pavia
- Orlando Armignacco, Viterbo
- Alexandre Aslan, Paris F
- Michele Aurigi, Siena
- Sergio Babudieri, Sassari
- Ferenc Bagyinszky, Berlin D
- Franco Baldelli, Perugia
- Alessandra Bandera, Monza
- Alessandro Battistella, Milano
- Francesca Belli, Paris F
- Francesco Benanti, Catania
- Alberto Bignardi, Modena
- Paolo Bonfanti, Lecco
- Stefano Bonora, Torino
- Marco Borderi, Bologna
- Mark Bower, London UK
- Michele Breveglieri, Bologna
- Maurizia Brunetto, Pisa
- Gianluca Bugnoli, Siena
- Andrea Calcagno, Torino
- Maria Rosaria Capobianchi, Roma
- Giampiero Carosi, Brescia
- Salvatore Casari, Brescia
- Antonio Cascio, Palermo
- Antonella Castagna, Milano
- Francesco Castelli, Brescia
- Anna Maria Cattelan, Padova
- Roberto Cauda, Roma
- Francesca Ceccherini-Silberstein, Roma
- Alessandra Cerioli, Bologna
- Antonio Chirianni, Napoli
- Nicoletta Ciccarelli, Roma
- Antonella Cingolani, Roma
- Paola Cinque, Milano
- Massimo Clementi, Milano
- Mario Clerici, Milano
- Nicola Coppola, Napoli
- Giulio Maria Corbelli, Bologna
- Maria Luisa Cosmaro, Milano
- Antonio Craxi, Palermo
- Antonella d'Arminio Monforte, Milano
- Gabriella d'Ettore, Roma
- Gianpiero D'Offizi, Roma
- Andrea De Luca, Siena
- Andrea De Maria, Genova
- Julia Del Amo Valero, Madrid E
- Maria Grazia Di Benedetto, Catania
- Antonio Di Biagio, Genova
- Simona Di Giambenedetto, Roma
- Giovanni Di Perri, Torino
- Margherita Errico, Milano
- Vincenzo Esposito, Napoli
- Massimo Farinella, Roma
- Carlo Ferrari, Parma
- Giovanni Battista Gaeta, Napoli
- Massimo Galli, Milano
- Ivan Gardini, Vercate MB
- Cristina Gervasoni, Milano
- Valeria Ghisetti, Torino
- Nicola Gianotti, Milano
- Daniela Ginanneschi, Siena
- Enrico Girardi, Roma
- Magnus Gisslén, Göteborg S
- Andrea Gori, Monza
- Giovanni Guaraldi, Modena
- Andrew Hill, Liverpool UK
- Priscilla Hsue, San Francisco USA
- Maria Rosaria Iardino, Milano
- Giuseppe Ippolito, Roma
- Adriano Lazzarin, Milano
- Miriam Lichtner, Latina
- Sergio Lo Caputo, Bari
- Lucia Lopalco, Milano
- Giordano Madeddu, Sassari
- Paolo Maggi, Bari
- Franco Maggiolo, Bergamo
- Giulia Marchetti, Milano
- Simone Marcotullio, Roma
- Renato Maserati, Pavia
- Claudio Maria Mastroianni, Latina
- Sandro Mattioli, Bologna
- Francesco Mazzotta, Firenze
- Valeria Micheli, Milano
- Maria Mongardi, Bologna
- Cristina Mussini, Modena
- Silvia Nozza, Milano
- Giuseppe Nunnari, Messina
- Massimo Oldrini, Como
- Giorgio Palù, Padova
- Giuseppe Pantaleo, Lausanne CH
- Paola Parenti, Milano
- Saverio Parisi, Padova
- Giustino Parruti, Pescara
- Valentina Penta, Napoli
- Carlo Federico Perno, Roma
- Patrizio Pezzotti, Roma
- Carla Pietrelli, Siena
- Guido Poli, Milano
- Massimo Puoti, Milano
- Vincenzo Puro, Roma
- Tiziana Quirino, Busto Arsizio VA
- Laura Rancilio, Milano
- Maria Carla Re, Bologna
- Umberto Restelli, Castellanza VA
- Giovanni Rezza, Roma
- Diego Ripamonti, Bergamo
- Giuliano Rizzardini, Milano
- Alison Rodger, London UK
- Riccardo Rondina, Ferrara



- **Barbara Rossetti**, Siena
- **Stefano Rusconi**, Milano
- **Teresa Santantonio**, Foggia
- **Maria Santoro**, Roma
- **Annalisa Saracino**, Bari
- **Filippo von Schloesser**, Roma
- **Laura Sighinolfi**, Ferrara
- **Guido Silvestri**, Atlanta USA
- **Francesco R. Simonetti**, Milano
- **Maria Stagnitta**, Firenze
- **Giulio Starnini**, Viterbo
- **Gloria Taliani**, Roma
- **Marcello Tavio**, Ancona
- **Carlo Torti**, Catanzaro
- **Armando Toscano**, Milano
- **Ombretta Turriziani**, Roma
- **Stefano Vella**, Roma
- **Marco Ventura**, Parma
- **Erica Villa**, Modena
- **Claudio Viscoli**, Genova
- **Yazdan Yazdanpanah**, Paris F
- **Mauro Zaccarelli**, Roma
- **Maurizio Zazzi**, Siena

- **Marco Borderi**, Bologna
- **Vanni Borghi**, Modena
- **Michele Breveglieri**, Bologna
- **Maurizia Brunetto**, Pisa
- **Andrea Calcagno**, Torino
- **Anna Paola Callegaro**, Bergamo
- **Leonardo Calza**, Bologna
- **Maria Rosaria Capobianchi**, Roma
- **Antonella Castagna**, Milano
- **Francesco Castelli**, Brescia
- **Francesca Ceccherini-Silberstein**, Roma
- **Benedetto Maurizio Celesia**, Catania
- **Massimo Cernuschi**, Milano
- **Antonella Cingolani**, Roma
- **Paola Cinque**, Milano
- **Mario Clerici**, Milano
- **Nicola Coppola**, Napoli
- **Giulio Maria Corbelli**, Bologna
- **Maria Luisa Cosmaro**, Milano
- **Andrea Cossarizza**, Modena
- **Gabriella d'Etторе**, Roma
- **Gianpiero D'Offizi**, Roma
- **Andrea De Maria**, Genova
- **Antonio Di Biagio**, Genova
- **Simona Di Giambenedetto**, Roma
- **Giovanni Di Perri**, Torino
- **Margherita Errico**, Milano
- **Carlo Ferrari**, Parma
- **Giovanni Battista Gaeta**, Napoli
- **Cristina Gervasoni**, Milano
- **Nicola Gianotti**, Milano
- **Enrico Girardi**, Roma
- **Andrea Gori**, Monza
- **Maria Rosaria Iardino**, Milano
- **Giuseppe Lapadula**, Monza
- **Adriano Lazzarin**, Milano
- **Miriam Lichtner**, Latina
- **Giuseppina Liuzzi**, Roma

- **Sergio Lo Caputo**, Bari
- **Giordano Madeddu**, Sassari
- **Paolo Maggi**, Bari
- **Franco Maggiolo**, Bergamo
- **Giulia Marchetti**, Milano
- **Bruno Marchini**, Roma
- **Simone Marcotullio**, Roma
- **Renato Maserati**, Pavia
- **Claudio Maria Mastroianni**, Latina
- **Alberto Matteelli**, Brescia
- **Laura Monno**, Bari
- **Cristina Mussini**, Modena
- **Emanuele Nicastrì**, Roma
- **Silvia Nozza**, Milano
- **Giuseppe Nunnari**, Messina
- **Giancarlo Orofino**, Torino
- **Lucia Palmisano**, Roma
- **Saverio Parisi**, Padova
- **Giustino Parruti**, Pescara
- **Stefania Piconi**, Milano
- **Massimo Puoti**, Milano
- **Vincenzo Puro**, Roma
- **Tiziana Quirino**, Busto Arsizio VA
- **Giuliano Rizzardini**, Milano
- **Stefano Rusconi**, Milano
- **Annalisa Saracino**, Bari
- **Loredana Sarmati**, Roma
- **Gabriella Scarlatti**, Milano
- **Alessandro Soria**, Monza
- **Nicola Squillace**, Monza
- **Gaetana Sterrantino**, Firenze
- **Valentina Svicher**, Roma
- **Gloria Taliani**, Roma
- **Marcello Tavio**, Ancona
- **Camilla Tincati**, Milano
- **Carlo Torti**, Catanzaro
- **Daria Trabattoni**, Milano
- **Francesca Vichi**, Firenze
- **Mauro Zaccarelli**, Roma

Abstract reviewers

- **Adriana Ammassari**, Roma
- **Mauro Andreotti**, Roma
- **Guido Antonelli**, Roma
- **Alessandra Bandera**, Monza
- **Marco Bartoli**, Roma
- **Teresa Bini**, Milano
- **Paolo Bonfanti**, Lecco
- **Stefano Bonora**, Torino



Dear Colleagues,

It's a great pleasure to welcome you to the [9th edition of ICAR, the Italian Conference on AIDS and Antiviral Research](#) which takes place this year in [Siena](#).

In keeping with the tradition of past editions and based on its characterization as abstract-driven congress, the purpose of the Conference is to present and discuss innovations and advances in the fields of prevention, diagnosis and treatment of the major viral infections. As usual, the Conference gathers epidemiologists, basic researchers, virologists, clinical researchers but also highlights the needs of patient associations and reserves great visibility to young researchers and representatives of the Community. In addition to the core scientific program, the Conference features supporting initiatives such as the [ICAR-CROI Awards](#) to the top young Italian investigators selected during the CROI 2017 Conference and the [Community Village](#) offering dedicated patient associations' meeting points.

In the last few years, ICAR has grown rapidly in the number of participants and abstracts as well as in the quality of submissions. With 389 abstract received, this year we have set a new record. In the three days of the Conference, ICAR treats a wide range of topics including basic science, clinical and virological research and benefits from significant contributions from the Community of patient associations: 44 Scientific Sessions, 7 Keynote Lectures, 92 Oral Communications, 36 Poster Discussions and 4 Advanced Courses. We expect around 1.500 participants among physicians, researchers, members of patient associations and health professionals.

In terms of public health, the aim of ICAR 2017 is to go beyond the academic and conference settings and to open up to societal and institutional players by acting as a boost for research, culture and communication and by stimulating a multi-faceted debate on public healthcare issues relating to treatment and prevention of viral infections. In this field the following activities are planned: [RaccontART Contest](#), the art competition launched by ICAR to students who are invited to present their views on HIV/AIDS through different forms of expression; [HIV and HCV rapid tests](#), performed during the Congress at the request of citizens; [ICARun](#), the non-competitive foot race, promoted by ICAR and the Community with the aim of involving citizens and raising public awareness on the issue of prevention.

Special thanks go to the [Scientific Secretariat](#) and the [Abstract Reviewers](#) for their commitment, to our [Faculty Members](#), to the [ICAR Governing Board](#), to [SIMIT](#), [Institutions](#), [Scientific Societies](#) and [Patient Associations](#), to the [schools](#) and students, to the [Siena University](#) and [University Hospital](#), to the [Municipality of Siena](#) and to our [Sponsors](#) who enabled us to involve and host hundreds of young researchers and representatives of the Community of patient associations.

We are greatly honored and pleased to welcome you in Siena and wish you a pleasant and interesting stay.

Welcome to ICAR 2017!

Andrea Antinori



The Chairs
Andrea De Luca



Maurizio Zazzi



LA LOTTA ALL'HIV HA

MILLE VOLTI.

ANCHE IL TUO.

PER FERMARLO

Se ne parla sempre meno ma il contagio da HIV è tuttora in corso. Ogni anno in Italia quasi 4.000 persone contraggono l'infezione, ma il virus si replica solo se lo permettiamo. L'unico modo per fermarlo è agire tutti insieme, avendo rapporti sessuali protetti e facendo il test.

La lotta all'HIV ha mille volti. Anche il tuo.



HIV Non fermiamoci →

HIV. Per fermarlo non dobbiamo fermarci.





9° CONGRESSO
NAZIONALE

12-14
GIUGNO 2017

Italian Conference on
AIDS and Antiviral Research



PROGRAMME AT A **GLANCE**



LUNEDÌ 12 GIUGNO

PROGRAMME AT A GLANCE

CENTRO DIDATTICO POLICLINICO S. MARIA ALLE SCOTTE				
09.30 12.30	Secretariat opening and registration			
	AULA 1	AULA 9	AULA 2	AULA 6
12.30 15.00	PRE-CONFERENCE ADVANCED COURSE LA VIROLOGIA CLINICA NEGLI ATTUALI CONTESTI DEL PAZIENTE IN TRATTAMENTO ANTIRETROVIRALE <i>pag. 20</i>	PRE-CONFERENCE ADVANCED COURSE PATIENT REPORTED OUTCOMES (PROS) IN HIV E HCV <i>pag. 21</i>	PRE-CONFERENCE ADVANCED COURSE CORRETTA PRESA IN CARICO "GLOBALE" DEL PAZIENTE HIV <i>pag. 22</i>	PRE-CONFERENCE ADVANCED COURSE CONOSCENZE E SFIDE FUTURE: UNA VISIONE SEMPRE PIÙ OLISTICA DEL PAZIENTE CON HIV/AIDS <i>pag. 22</i>
TEATRO DEI RINNOVATI				
16.00 17.00	SATELLITE SYMPOSIUM Evolving needs in HIV <i>pag. 24</i>			
17.10 20.30	ICAR 2017 Opening Session 17.10-17.30 Introducing ICAR 2017 <i>pag. 25</i> 17.30-17.45 Authorities' welcome addresses <i>pag. 25</i> 17.45-18.10 "RaccontART HIV" contest Awards <i>pag. 25</i> 18.10-19.00 Opening Lectures <i>pag. 25</i> 19.00-19.30 ICAR-CROI Awards 2017 for young Italian HIV investigators <i>pag. 26</i> 19.30-20.20 SPECIAL SESSION: The long way of HIV/AIDS across the Institutions <i>pag. 26</i> 20.20 -20.30 Closing remarks <i>pag. 26</i>			
20.30 22.30	ICAR 2017 Welcome Reception			SALA DELLE LUPE 19.30-22.00 Trent'anni di LILA, trent'anni insieme per i diritti, la salute e la dignità sociale <i>pag. 27</i>

MARTEDÌ 13 GIUGNO

PROGRAMME AT A GLANCE

AUDITORIUM				
09.00 10.00	<p>KEYNOTE LECTURES</p> <p>One size does not fit all: tailoring services on the needs of the specific target <i>Ferenc Bagyinszky (Berlin, D)</i> Host-microbiota cross-talk in humans: examples from bifidobacteria as key gut commensals <i>Marco Ventura (Parma)</i> <i>pag. 28</i></p>			
	AUDITORIUM	AULA 1	AULA 2	ROOM AGORÀ A
10.10 11.55	<p>10.10-11.50 SYMPOSIUM Future therapeutic strategies in HIV and HBV <i>pag. 28</i></p>	<p>10.15-11.55 ORAL COMMUNICATIONS Antiretroviral therapy <i>pag. 28</i></p>	<p>10.15-11.55 ORAL COMMUNICATIONS Immunology <i>pag. 29</i></p>	
12.00 12.45	<p>SATELLITE SYMPOSIUM INSTI: the core agent for long term antiretroviral therapy <i>pag. 30</i></p>	<p>SATELLITE SYMPOSIUM New treatment opportunities for patients with hepatitis C <i>pag. 31</i></p>		
13.00 13.45	<p>SATELLITE SYMPOSIUM Therapeutic innovation and the role of TAF in clinical practice <i>pag. 31</i></p>	<p>SATELLITE SYMPOSIUM HCV infection in DAAs era: a new revolution for your patients in 2017? <i>pag. 31</i></p>		
13.45 14.45	AUDITORIUM	AULA 1	AULA 2	ROOM AGORÀ A
	<p>13.50-14.40 POSTER DISCUSSION Clinical HIV I <i>pag. 32</i></p>	<p>14.00-14.45 SATELLITE SYMPOSIUM HIV self testing: the Italian experience <i>pag. 36</i></p>	<p>13.50-14.40 POSTER DISCUSSION Clinical HIV II <i>pag. 33</i></p>	<p>13.45-14.45 EXPERT MEETING Management of comorbidities during HIV infection: a possible role of CCR5-antagonism <i>pag. 32</i></p>
	AULA 6	AULA 9	AULA 10	AULA 11
	<p>13.50-14.40 POSTER DISCUSSION Hepatitis <i>pag. 33</i></p>	<p>13.50-14.40 POSTER DISCUSSION Community <i>pag. 35</i></p>	<p>13.50-14.40 POSTER DISCUSSION Basic science and virology <i>pag. 35</i></p>	<p>13.50-14.40 POSTER DISCUSSION Immunology <i>pag. 34</i></p>
	AUDITORIUM	AULA 1	AULA 2	ROOM AGORÀ A
14.45 16.05	<p>14.45-16.00 SYMPOSIUM Self-care in HIV and HCV: emerging issues and criticisms <i>pag. 36</i></p>	<p>14.50-16.05 ORAL COMMUNICATIONS Immunological response under cART and co-infections <i>pag. 37</i></p>	<p>14.50-16.05 ORAL COMMUNICATIONS Clinical Hepatitis I <i>pag. 37</i></p>	
16.15 18.00	<p>16.15-17.55 SYMPOSIUM New challenges in virus-associated lymphomas <i>pag. 38</i></p>	<p>16.20-18.00 ORAL COMMUNICATIONS Complication of cART <i>pag. 39</i></p>	<p>16.20-18.00 ORAL COMMUNICATIONS HIV & HCV: from education to care <i>pag. 40</i></p>	



MERCOLEDÌ 14 GIUGNO

PROGRAMME AT A GLANCE

AUDITORIUM			
08.30 09.00	<p>KEYNOTE LECTURE</p> <p>What an ID doctor should know to prevent CV events in HIV infected patients? <i>Priscilla Hsue (San Francisco, USA)</i> <i>pag. 41</i></p>		
AUDITORIUM	AULA 1	AULA 2	
09.00 10.30	<p>09.00-10.25 SYMPOSIUM</p> <p>HIV cure: State of art <i>pag. 41</i></p>	<p>09.05-10.30 ORAL COMMUNICATIONS</p> <p>Clinical Hepatitis II <i>pag. 41</i></p>	<p>09.05-10.30 ORAL COMMUNICATIONS</p> <p>HIV epidemiology and prevention <i>pag. 43</i></p>
10.30 11.55	<p>10.30-11.50 SYMPOSIUM ICAR-SIMIT-AISF</p> <p>HCV: new waves, new horizons? <i>pag. 44</i></p>	<p>10.35-11.55 ORAL COMMUNICATIONS</p> <p>Comorbidities <i>pag. 44</i></p>	<p>10.35-11.55 ORAL COMMUNICATIONS</p> <p>HIV: walking along the continuum of care <i>pag. 45</i></p>
12.00 12.45	<p>SATELLITE SYMPOSIUM</p> <p>HCV and Post-Hoc in real life experience in Italy <i>pag. 45</i></p>	<p>SATELLITE SYMPOSIUM</p> <p>PIs consolidated experience from the randomized studies to real world evidence <i>pag. 46</i></p>	
13.00 13.45	<p>SATELLITE SYMPOSIUM</p> <p>Sofosbuvir-based STRs: the answer to HCV infection <i>pag. 46</i></p>	<p>SATELLITE SYMPOSIUM</p> <p>Heart comes first <i>pag. 46</i></p>	
13.55 15.30	<p>13.55-15.25 SYMPOSIUM</p> <p>PrEPing today: critical issues and challenges <i>pag. 47</i></p>	<p>14.00-15.30 ORAL COMMUNICATIONS</p> <p>Hepatitis: epidemiology and basic research <i>pag. 47</i></p>	<p>14.00-15.30 ORAL COMMUNICATIONS</p> <p>Basic science and clinical virology <i>pag. 49</i></p>
AUDITORIUM			
15.30 16.00	<p>ICAR 2017 Best Poster and SIMIT Special Awards <i>pag. 50</i></p>		
16.00 16.30	<p>Closing remarks <i>pag. 50</i></p>		

Il nostro impegno contro l'**HIV**



LA RICERCA

- **Rispondere ai bisogni non soddisfatti** di chi vive con l'HIV in Italia e in tutto il mondo è il nostro obiettivo.
- **Ricerca e innovazione** guidano la nostra strada per sviluppare nuove cure, facilitare l'aderenza ai trattamenti, minimizzare il rischio di resistenze, consentire una gestione più semplice dell'infezione.



LA RESPONSABILITÀ SOCIALE

- Nel mondo con il programma Positive Action sosteniamo oltre **350 progetti per le comunità** collaborando con più di **230 partner**.
- In **Italia** collaboriamo al progetto EPIICAL, consorzio internazionale di ricerca nell'HIV pediatrico, che coinvolge **26 istituzioni accademiche in 4 continenti**.



ITA/HIV/0001/17



L'ACCESSO ALLE TERAPIE

- Per favorire l'accesso ai farmaci assicuriamo prezzi preferenziali e not for profit nei Paesi in via di sviluppo.
- Con il programma di licenze volontarie **14 molecole antiretrovirali** possono essere prodotte da aziende locali nelle aree meno sviluppate.

ViiV
Healthcare

ViiV Healthcare, unica azienda al mondo
dedicata al 100% all'HIV

abbvie

HCV

**UNA SFIDA GLOBALE
UN IMPEGNO DURATURO**

**LA NOSTRA MISSION È AVERE
UN IMPATTO SIGNIFICATIVO
SULLA VITA DEI PAZIENTI.**

www.abbvie.it



9° CONGRESSO
NAZIONALE

12-14
GIUGNO 2017

Italian Conference on
AIDS and Antiviral Research



PRE-CONFERENCE
ADVANCED COURSES

**PRE-CONFERENCE ADVANCED COURSE** 12.30-15.00**AULA 1****La virologia clinica negli attuali contesti del paziente in trattamento antiretrovirale**

Moderatori: V. Ghisetti (Torino), S. Parisi (Padova)

L'integrazione fra clinica e laboratorio nella gestione del paziente con infezione da HIV è indubbiamente una storia di successo nell'ambito dell'infettivologia. Gli strumenti e i servizi di laboratorio hanno accompagnato in modo particolare l'evoluzione della terapia antiretrovirale, fornendo l'apporto necessario al monitoraggio del trattamento. Lo scenario degli ultimi anni propone nuove sfide e opportunità per l'adeguamento del laboratorio alle esigenze cliniche. Il corso presenta i quesiti clinici attuali e le possibili risposte da parte della virologia clinica in un format che intende mettere direttamente a confronto relatori e discenti rappresentativi delle due realtà.

12.30-12.35 **Introduzione al corso** Francesca Ceccherini-Silberstein (Roma)**Il paziente virosoppresso, possiamo caratterizzarlo meglio?****Quali insidie nella seduzione dei less drug regimens?**12.35-12.50 **Il punto di vista del clinico** Franco Maggiolo (Bergamo)12.50-13.05 **Il punto di vista del virologo** Maria Santoro (Roma)13.05-13.20 **Discussione****Il paziente con fallimento a basso numero di copie, cosa fare?**13.20-13.35 **Il punto di vista del clinico** Antonio Di Biagio (Genova)13.35-13.50 **Il punto di vista del virologo** Valeria Micheli (Milano)13.50-14.05 **Discussione****Il paziente con virus multiresistente e non controllabile, quale aiuto dalle indagini virologiche?**14.05-14.20 **Il punto di vista del clinico** Nicola Gianotti (Milano)14.20-14.35 **Il punto di vista del virologo** Ombretta Turriziani (Roma)14.35-14.50 **Discussione**14.50-15.00 **Take home messages** Valeria Ghisetti (Torino), Saverio Parisi (Padova)



PRE-CONFERENCE ADVANCED COURSE 12.30-15.00

AULA 9

Patient Reported Outcomes (PROs) in HIV e HCV

Moderatori: A. Ammassari (Roma), E. Girardi (Roma), S. Marcotullio (Roma)

I PROs identificano un approccio concettuale e una metodologia specificamente orientata a cogliere il punto di vista dei destinatari della cura, cioè i pazienti, più che l'adozione della tradizionale prospettiva clinica sugli outcome di efficacia. Vengono definiti come qualsiasi indicazione riportata direttamente dal paziente senza l'interpretazione del dato da parte del medico o di qualunque altra figura professionale. Il corso ha la finalità di proporre una sintesi della materia applicata alle infezioni da HIV e da HCV, nonché di elaborare, grazie ad alcune declinazioni pratiche, la rilevanza e applicabilità delle specifiche tematiche agli occhi dei diversi "attori", ossia medici, infermieri, pazienti e operatori.

12.30-12.40	Introduzione al corso	Adriana Ammassari (Roma), Enrico Girardi (Roma), Simone Marcotullio (Roma)
12.40-12.55	PROs in HIV: stato dell'arte e principali aspetti teorici/metodologici	Antonella Cingolani (Roma)
12.55-13.10	PROs in HCV: stato dell'arte e principali aspetti teorici/metodologici	Gloria Taliani (Roma)
13.10-13.25	PROs in HIV e HCV: un'opportunità per guadagnare in salute globale	Simone Marcotullio (Roma)
13.25-13.40	Discussione	

Lavorare con i PROs

13.40-14.40 **I partecipanti al corso saranno divisi in tre sottogruppi di lavoro, a seconda dell'ambito di appartenenza: medici, infermieri, pazienti/associazioni di pazienti e/o comunità colpite dalle infezioni. Lo scopo è quello di:**

- Identificare le dimensioni relative ai PROs in HIV e HCV e darne una priorità
- Identificare gli strumenti idonei e gli opportuni momenti di somministrazione
- Comprendere il proprio ruolo e funzione nell'ambito del take in care del paziente

Gruppo medici	Adriana Ammassari (Roma)
Gruppo infermieri	Antonella Cingolani (Roma)
Gruppo pazienti/associazioni	Simone Marcotullio (Roma)

14.40-14.55	Report dell'elaborato dei sottogruppi a cura dei Conduttori	
14.55-15.00	Conclusioni: è ora di fare networking	Adriana Ammassari (Roma), Enrico Girardi (Roma), Simone Marcotullio (Roma)

**PRE-CONFERENCE ADVANCED COURSE** 12.30-15.00**AULA 2****Corretta presa in carico "globale" del paziente HIV**

Moderatori: M. Borderi (Bologna), P. Maggi (Bari), G. Starnini (Viterbo)

Il corso è inteso a fornire gli elementi essenziali per una corretta presa in carico dei pazienti HIV positivi allo scopo di ottimizzare la HIV treatment cascade dall'accesso al test alla gestione del risultato, fino all'inizio e monitoraggio della terapia antiretrovirale e alla gestione delle co-morbidità. Secondo un approccio 'olistico', non ci si limiterà agli aspetti più direttamente legati al classico obiettivo '90-90-90', inteso a ottenere il controllo viremico in almeno il 90% dei pazienti trattati, ma verrà data importanza anche al miglioramento della qualità di vita e all'aderenza dei pazienti a tutti gli interventi preventivi e terapeutici per ridurre l'impatto delle co-morbidità e degli effetti avversi delle terapie in un contesto di aging dei pazienti, sempre più frequentemente oggetto di prescrizioni poli-farmacologiche.

Medical checks in HIV/AIDS

12.30-12.45	Livelli essenziali di assistenza	Tiziana Quirino (Busto Arsizio, VA)
12.45-13.00	Popolazioni speciali	Mauro Zaccarelli (Roma)
13.00-13.20	Discussione	

La valutazione neuropsicologica

13.20-13.35	Accesso, assistenza al test e comunicazione della diagnosi	Salvatore Casari (Brescia)
13.35-13.50	Monitoraggio: come, quando, perché?	Nicoletta Ciccarelli (Roma)
13.50-14.10	Discussione	

Continuità di cura e aderenza ai programmi terapeutici

14.10-14.25	Ottimizzazione del "sistema salute" e del rapporto medico-paziente	Valentina Penta (Napoli)
14.25-14.40	Il ruolo delle associazioni nel mantenimento in cura dei pazienti	Maria Luisa Cosmaro (Milano)
14.40-15.00	Discussione	

PRE-CONFERENCE ADVANCED COURSE 12.30-15.00**AULA 6****Conoscenze e sfide future: una visione sempre più olistica del paziente con HIV/AIDS**

Moderatori: M. Aurigi (Siena), G. Bugnoli (Siena)

L'AIDS rappresenta tutt'oggi una grande sfida per l'infermiere, non solo di malattie infettive, ma per tutti i contesti sanitari in cui transita il paziente.

La ricerca ha permesso di trasformare l'AIDS da malattia a prognosi infausta a malattia cronica; ciò significa che i pazienti trattati sono nell'ordine di migliaia nei contesti ambulatoriali. Nello stesso tempo l'esordio, a volte molto grave dell'AIDS in alcuni pazienti, può creare uno stato di invalidità permanente con la necessità di ricovero presso strutture residenziali territoriali come le RSA o CASE ALBERGO. La mancanza di campagne informative, rivolte a tutte le generazioni, fa sì che oggi si presentino nuovi casi di AIDS conclamata con alta complessità assistenziale. Come gestire tutte le variabili?

12.30-12.50	Introduzione al Corso	Michele Aurigi (Siena), Gianluca Bugnoli (Siena)
12.50-13.10	Come la prevenzione delle infezioni correlate all'assistenza può rappresentare una strategia di prevenzione dal contagio da HIV nelle strutture sanitarie	Maria Mongardi (Bologna)
13.10-13.30	Conoscenza e formazione di nuove generazioni di infermieri: l'approccio ad una vecchia malattia sempre nuova	Daniela Ginanneschi (Siena)
13.30-13.50	Esperienze e innovazioni	Riccardo Rondina (Ferrara)
13.50-14.10	Approccio assistenziale al paziente avanzato con vecchia diagnosi di AIDS e complessità assistenziale delle nuove diagnosi	Carla Pietrelli (Siena)
14.10-15.00	Discussione	



9° CONGRESSO
NAZIONALE

12-14
GIUGNO 2017

**Italian Conference on
AIDS and Antiviral Research**



SCIENTIFIC **PROGRAMME**



SATELLITE SYMPOSIUM 16.00-17.00

Unrestricted educational grant of Gilead Sciences

Evolving needs in HIV

Chair: A. De Luca (Siena)

Since the beginning of AIDS, models of HIV care have needed to be invented or modified as the needs of patients evolved. Over the past decade, factors including aging, long-surviving population, multiple co-morbidities, polypharmacy, and the need for chronic disease management have led to a need for further evolution of HIV care models.

- | | | |
|-------------|--|----------------------------|
| 16.00-16.20 | Comorbidities and aging | Giovanni Guaraldi (Modena) |
| 16.20-16.40 | HIV population evolution in Europe and in the rest of the world | Sergio Lo Caputo (Bari) |
| 16.40-17.00 | Discussion | |

TEATRO DEI RINNOVATI



TEATRO DEI RINNOVATI ICAR 2017 OPENING SESSION

17.10-17.30

Introducing ICAR 2017

A. Antinori (Roma), A. Chirianni (Napoli), A. De Luca (Siena), M. Zazzi (Siena)

17.30-17.45

Authorities' welcome addresses

17.45-18.10

"RaccontART HIV" contest Awards

Chairs: A. Adriatico (Roma), A. De Luca (Siena), A. Dose (Siena), M. Errico (Milano)

Contest Finalists:

- Liceo Artistico "Artemisia Gentileschi", Carrara
- ITCG "E.F. Corinaldesi", Senigallia
- Liceo "G.B. Vico", Corsico
- Liceo Statale "Giovanni Pascoli", Firenze
- IIS "Leonardo da Vinci", Firenze
- IS "Puecher Olivetti", Rho

18.10-19.00

OPENING LECTURES

Chairs: A. d'Arminio Monforte (Milano), C.F. Perno (Roma)

18.10-18.15

Introduction

Carlo Federico Perno (Roma)

18.15-18.35

MAURO MORONI MEMORIAL LECTURE

The HIV cell reservoir and future perspectives
in HIV functional cure

Giuseppe Pantaleo (Lausanne, CH)

18.35-18.40

Introduction

Antonella d'Arminio Monforte (Milano)

18.40-19.00

HIV infection and migrants in Europe: mortality,
disparities and access to care

Julia Del Amo Valero (Madrid, E)



19.00-19.30

ICAR-CROI Awards 2017 for young Italian HIV investigators

Chair: G. Silvestri (Atlanta, USA)

Selected Italian Investigators:

- Two-year cART does not restore peripheral blood and intestinal HIV-related dysbiosis
- CSF to plasma HIV-RNA ratio ≥ 1 is associated with HAND in untreated HIV patients
- Effect of interferon free treatment on lipid and glucose metabolism in hepatitis C
- Effect of exogenous interferon alpha on HIV viral populations in vivo
- Discordant HIV RNA in olfactory mucosa of HIV-positive patients
- Unconventional t-cells in a PEG-INF-2 α add-on strategy for suppressed HBV infection
- SOCS-1/TRAF-6 up-regulation in bone impairment in HIV+ patients on effective cART
- Optimal efficacy of HCV-resistance-based retreatments after PI failure
- Inflammasome and pyroptosis are involved in the lack of immune response during cART
- DAA improve VACS but do not influence cognitive impairment in HIV/HCV coinfectd
- MAIT cells, microbial translocation and the microbiome in HIV/HCV chronic infections
- Liver microRNA HSA-MIR-125A-5P may exert an oncosuppressor effect on HCC
- Blood brain barrier function, ART neuroactivity and risk of CSF HIV escape
- Retinal layers thickness as marker of accelerated neurocognitive decay in HIV disease
- CB2-RR variant, associated to liver damage in HIV/HCV cases, may favor HIV acquisition
- Chronic HIV pulmonary disease (CHPD) in never smoking HIV patients
- Enrichment of defective proviruses lacking TAT-REV during long-term ART
- Additional screening tests for HIV-associated neurocognitive disorders

Giuseppe Ancona (Milano)
 Francesca Bai (Milano)
 Elisa Biliotti (Roma)
 Giorgio Bozzi (Milano)
 Andrea Calcagno (Torino)
 Elvira Cannizzo (Milano)
 Elvira Cannizzo (Milano)
 Valeria Cento (Roma)
 Michela Masetti (Milano)
 Iliaria Mastrorosa (Roma)
 Esther Merlini (Milano)
 Lorenzo Onorato (Napoli)
 Carmela Pinnetti (Roma)
 Chiara Resnati (Milano)
 Caterina Sagnelli (Napoli)
 Antonella Santoro (Modena)
 Francesco R. Simonetti (Milano)
 Mattia Trunfio (Torino)

19.30-20.20

SPECIAL SESSION

The long way of HIV/AIDS across the Institutions

Chairs: M.R. Iardino (Milano), G. Ippolito (Roma)

- | | | |
|-------------|--|--------------------------------|
| 19.30-19.35 | Introduction | Maria Rosaria Iardino (Milano) |
| 19.35-19.55 | Universal treatment access and pharmacologic innovation in HIV and HCV: two faces for an institutional plan | Stefano Vella (Roma) |
| 19.55-20.00 | Introduction | Giuseppe Ippolito (Roma) |
| 20.00-20.20 | The HIV/AIDS National Plan of the Italian Ministry of Health | Massimo Galli (Milano) |

20.20-20.30

Closing remarks

A. Antinori (Roma), A. De Luca (Siena), M. Zazzi (Siena)

20.30-22.30

ICAR 2017 Welcome Reception



SPECIAL EVENT

19.30-22.00

TEATRO DEI RINNOVATI - SALA DELLE LUPE

TRENT'ANNI DI LILA

Trent'anni insieme per i diritti, la salute e la dignità sociale

Impegni e proposte a sostegno degli obiettivi ONU per sconfiggere l'HIV AIDS entro il 2030

Chair: A. Cerioli (Attivista e già Presidente LILA)

19.30-19.50 **Saluto istituzionale**

19.50-20.10 **Apertura**

Luigi Ciotti (Presidente Gruppo Abele e Primo presidente LILA)

20.10-20.30 **Oggi abbiamo gli strumenti per garantire la dignità della persona con HIV**

Simone Marcotullio (Vicepresidente NADIR)


20.40-22.00

TAVOLA ROTONDA

Fast Track to end AIDS by 2030: le sfide che ci attendono nel nostro paese

Moderatore: A. Adriatico (Regista, Giornalista e Direttore LILA NEWS)

- **Andrea Antinori** (Coordinatore Direzione ICAR e INMI Spallanzani, Roma)
- **Antonella Castagna** (Ospedale San Raffaele, Milano)
- **Massimo Galli** (Vicepresidente SIMIT, ANLAIDS, Ospedale Sacco e coordinatore della sez M del CTS, Milano)
- **Michele Breveglieri** (Responsabile Area Salute ARCIGAY e componente sez L del CTS, Verona)
- **Maria Stagnitta** (Presidente Forum Droghe, Consigliera Nazionale CNCA e componente sez M del CTS, Firenze)
- **Massimo Oldrini** (Presidente LILA)

**KEYNOTE LECTURES** 09.00-10.00

Chairs: A. Cerioli (Bologna), A. Gori (Monza)

- | | | |
|-------------|---|-------------------------------|
| 09.00-09.30 | One size does not fit all: tailoring services on the needs of the specific target | Ferenc Bagyinszky (Berlin, D) |
| 09.30-10.00 | Host-microbiota cross-talk in humans: examples from bifidobacteria as key gut commensals | Marco Ventura (Parma) |

AUDITORIUM**SYMPOSIUM** 10.10-11.50**Future therapeutic strategies in HIV and HBV**

President: A. Lazzarin (Milano)

Chairs: G. Di Perri (Torino), G.B. Gaeta (Napoli)

Virologic treatments are rapidly evolving both in terms of new drugs and innovative strategies. The symposium offers a perspective window on the future of HIV and HBV treatments.

- | | | |
|-------------|--|--------------------------|
| 10.10-10.30 | HBV infection: managing the present, looking at the future | Maurizia Brunetto (Pisa) |
| 10.30-10.50 | Dual therapy: starting from rationale, reaching clinical evidence | Massimo Andreoni (Roma) |
| 10.50-11.10 | Long-acting drugs: a pathway to future cART? | Stefano Bonora (Torino) |
| 11.10-11.50 | Discussion | |

AUDITORIUM**ORAL COMMUNICATION** 10.15-11.55**Antiretroviral Therapy**

Chairs: P. Bonfanti (Lecco), G. Carosi (Brescia), A.M. Cattelan (Padova)

- | | | |
|-------------|---|------------------------------------|
| 10.15-10.30 | Pharmacoeconomic models including generic ARV drugs for cost containment | Umberto Restelli (Castellanza, VA) |
|-------------|---|------------------------------------|

AULA 1**OC 1** 10.30-10.37 **Early start of antiretroviral therapy during Primary HIV Infection is associated with faster optimal immunological recovery - Final results of Italian Network of ACuTe HIV Infection (INACTION) retrospective study**

A. Muscatello¹, A. Bandera¹, M. Fabbiani¹, I. De Benedetto¹, A. Ammassari², A. Antinori², A. Calcagno³, M. Campus⁴, F. Carli⁵, B.M. Ceslasia⁶, A. Cingolani⁷, L. Cosco⁸, G. d'Ettore⁹, M. Ferrara⁹, E. Focà¹⁰, A. Franco¹¹, N. Gandolfo¹², E. Girard², A. Gori¹, R. Gulminetti¹³, S. Lamonica⁷, G. Madeddu¹⁴, G. Marchetti¹⁵, C. Mussini⁵, S. Nozza¹⁶, G. Orofino¹⁷, M. Ripa¹⁶, D. Ripamonti¹⁸, S. Rusconi¹⁹, G. Tambussi¹⁶, C. Torti²⁰ on behalf of INACTION study group

¹San Gerardo Hospital ASST di Monza - Milano-Bicocca University - Monza, ²INMI L. Spallanzani - Rome, ³Amedeo di Savoia Hospital - University of Turin, ⁴Santissima Trinità Hospital, Cagliari, ⁵University Hospital Modena, ⁶ARNAS Garibaldi Hospital - Catania, ⁷A. Gemelli University Hospital, Catholic University of Sacred Heart, Rome, ⁸Pugliese-Ciaccio Hospital - Catanzaro, ⁹Umberto I Hospital - La Sapienza University of Rome, ¹⁰Department of Infectious and Tropical Diseases - University of Brescia, ¹¹Hospital of Siracusa, ¹²San Martino Hospital, Genova, ¹³San Matteo Hospital, Pavia, ¹⁴Sassari University, ¹⁵San Paolo Hospital - University of Milan, ¹⁶San Raffaele Hospital, Milan, ¹⁷Amedeo di Savoia Hospital, Turin, ¹⁸Papa Giovanni XXIII Hospital, Bergamo, ¹⁹Sacco Hospital - University of Milan, ²⁰MaterDomini Hospital, Catanzaro

OC 2 10.40-10.47 **Virological control in patients early switching versus maintaining initial antiretroviral therapy (ART) during primary HIV-1 infection (PHI): experience from an Italian cohort**

A. Mondì¹, C. Pinnetti¹, M.M. Plazzi¹, I. Abbate², G. Rozera², R. Libertone¹, S. Menichetti¹, V. Mazzotta¹, P. Lorenzin¹, A. Antinori¹, A. Ammassari¹

¹Clinical Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, ²Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy

OC 3 10.50-10.57 **2-years efficacy and durability of simplification to Single Tablet Regimen (STR): a comparison between co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir**

R. Gagliardini¹, A. Bandera², S. Rusconi³, M. Colafigli⁴, G. Sterrantino⁵, M. Zaccarelli⁶, A. Giannetti⁶, A. Capetti⁷, R. Cauda¹, A. Gori², S. Di Giambenedetto¹, M. Fabbiani²

¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, ²San Gerardo Hospital, University of Milano-Bicocca, Division of Infectious Diseases, Department of Internal Medicine, Monza, ³Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, ⁴Infectious Dermatology and Allergology IRCCS IFO, Roma, ⁵Clinic of Infectious and Tropical Diseases, Azienda Ospedaliera Universitaria Careggi, Firenze, ⁶National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, ⁷Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan



- OC 4 11.00-11.07 A preliminary pharmacoeconomics analysis of the impact of ABC/3TC/DTG and TDF/FTC/EVG/cobi in HIV+, virologically suppressed patients**
U. Restelli^{1,2}, A. Borghetti³, D. Croce^{1,2}, R. Gagliardini³, A. Ciccullo³, G. Baldin³, A. Emiliozzi³, D. Moschese³, D. Faliero³, F. Lombardi³, S. Belmonti³, S. Della Monica³, S. Di Giambenedetto³
¹Centre for Research on Health Economics, Social and Health Care Management (CREMS), LIUC – Università Cattaneo, Castellanza (VA), ²School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, ³Institute of Clinical Infectious Disease, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy
- OC 5 11.10-11.17 Time spent with residual viremia after virological suppression according to type of first-line antiretroviral regimen**
N. Gianotti¹, L. Galli¹, N. Galizzi^{1,2}, M. Ripa^{1,2}, A. Andolina^{1,2}, S. Nozza¹, V. Spagnuolo^{1,2}, A. Poli¹, A. Lazzarin^{1,2}, A. Castagna^{1,2}
¹Infectious Diseases, IRCCS San Raffaele, ²Università Vita-Salute San Raffaele, Milan
- OC 6 11.20-11.27 Factors related to over-time viral failure in HIV-infected patients with previous C-ART failures**
S. Rusconi¹, M.M. Santoro², A. Cozzi-Lepri³, A. Antinori⁴, S. Bonora⁵, A. Cingolani⁶, N. Gianotti⁷, F. Ceccherini Silberstein², A. Tavelli⁸, A. d'Arminio Monforte⁹, for the Icona Foundation Study Group
¹University of Milan, DIBIC Luigi Sacco, Milan, Italy, ²University of Rome Tor Vergata, Rome, Italy, ³University College London, UK, ⁴National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ⁵University of Turin, Turin, Italy, ⁶Catholic University, Rome, Italy, ⁷San Raffaele Hospital, IRCCS, Milan, Italy, ⁸Icona Foundation, Milan, Italy, ⁹University of Milan, ASST Santi Paolo e Carlo, Milan, Italy
- OC 7 11.30-11.37 48-week results of a dual therapy with Darunavir/rtv plus Rilpivirine QD vs triple therapy in patients with suppressed viraemia: virological efficacy and non-HIV related morbidity evaluation**
S. Rusconi¹, V. Di Cristo¹, F. Adorni², R. Maserati³, M. Annovazzi Lodi³, N. Ladisa⁴, P. Maggi⁴, P. Vitello⁵, C. Abeli⁵, S. Bonora⁶, M. Ferrara⁶, M.V. Cossu⁷, E. Colella¹, M. Galli¹
¹University of Milan, DIBIC Luigi Sacco, Milan, Italy, ²ITB-CNR, Segrate (MI), Italy, ³Policlinico San Matteo Foundation, IRCCS, Pavia, Italy, ⁴University of Bari, Bari, Italy, ⁵ASST Valle Olona, Ospedale di Circolo, Busto Arsizio (VA), Italy, ⁶University of Turin, Turin, Italy, ⁷ASST Fatebenefratelli-Sacco, Milan, Italy
- OC 8 11.40-11.47 Efficacy and discontinuation of dual regimens with 3TC plus PI/r in patients from clinical practice enrolled in ARCA**
D. Di Carlo¹, D.F. Bavaro², A. Battisti¹, S. Giachè³, E. Salomoni³, F. Incardona^{4,5}, P. Zuccalà⁶, F. Bai⁷, R. Gagliardini⁸, S. Di Giambenedetto⁸, M. Pecorari⁹, M. Zazzi¹⁰, A. De Luca¹⁰, A. Bezenchek⁵, S. Lo Caputo²
¹University of Rome "Tor Vergata", Experimental Medicine and Surgery, Rome, Italy, ²University of Bari "Aldo Moro", Clinic of Infectious Disease, Bari, Italy, ³University of Florence, Tropical and Infectious Diseases, Florence, Italy, ⁴EuResist GEIE, Rome, Italy, ⁵IPRO - InformaPRO S.r.l., Rome, Italy, ⁶University of Rome "Sapienza", Department of Public Health and Infectious Diseases, Rome, Italy, ⁷University of Milan, Clinic of Infectious Diseases and Tropical Medicine, ASST Santi Paolo e Carlo, Department of Health Sciences, San Paolo Hospital, Milan, Italy, ⁸University of Rome "Cattolica", Institute of Infectious Diseases, Rome, Italy, ⁹Polyclinic of Modena, Modena, Italy, ¹⁰University of Siena, Department of Medical Biotechnologies, Siena, Italy


ORAL COMMUNICATION 10.15-11.55

AULA 2

Immunology

Chairs: A. De Maria (Genova), L. Lopalco (Milano), G. Marchetti (Milano)

- 10.15-10.30 **The interferon activity in viral infections: a double edged sword** Guido Antonelli (Roma)
- OC 9 10.30-10.37 Innate immune remodelling in advanced and non-advanced HIV presenters after two years of effective antiretroviral therapy**
S. Savinelli¹, M. Iannetta¹, S. Vita¹, C. Mascia¹, R. Rossi¹, R. Marocco², P. Zuccalà¹, A. Zingaropoli¹, G. d'Ettore¹, F. Schiavone¹, C.M. Mastroianni², V. Vullo¹, M. Lichtner²
¹Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, ²Infectious Disease Unit, "Sapienza" University, Latina, Italy
- OC 10 10.40-10.47 Toll like receptors, type I/III interferon and retroviral restriction factors in HIV-1 infected patients: expression in gut mucosa and in peripheral blood mononuclear cells and their modification upon probiotics supplementation**
C. Pinacchio¹, G. Corano Scheri¹, M. Statzu², L. Santinelli², C. Selvaggi², I. Schietroma¹, S. Najafi Fard¹, M. Andreotti³, G. Ceccarelli⁵, V. Vullo¹, G. Antonelli², C. Scagnolari^{2,4}, G. d'Ettore¹
¹Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Rome, Italy, ²Department of Molecular Medicine, Laboratory of Virology, University of Rome "Sapienza", Rome, Italy, ³Department of Therapeutic Research and Medicines Evaluation, Italian Institute of Health, Rome, Italy, ⁴Pasteur Institute Italia, Cenci-Bolognetti Foundation, Rome, Italy, ⁵Department of Infectious Diseases, Policlinico Umberto I, University of Rome "Sapienza", Rome, Italy
- OC 11 10.50-10.57 The expression of host restriction factors was affected by ageing and was not associated to residual viremia in HIV-1 infected patients on long-term antiretroviral therapy**
M. Statzu¹, G. Corano Scheri², C. Selvaggi¹, C. Pinacchio², L. Santinelli¹, S. Sbarra¹, F. Falasca¹, I. Mezzaroma³, O. Turriziani¹, G. Antonelli¹, G. d'Ettore², C. Scagnolari¹
¹Department of Molecular Medicine, Laboratory of Virology affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Sapienza University, Rome, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, ³Department of Clinical Medicine, Sapienza University, Rome, Italy



- OC 12 11.00-11.07 Dynamic modulation of immune activation in the peripheral blood and in the GUT of HIV infected patients after probiotic supplementation**
I. Schietroma¹, G. Corano Scheri¹, S. Najafi Fard¹, C. Pinacchio¹, E. Nelson Cavallari¹, G. Fanello⁴, G. De Girolamo¹, A. Mastrangelo¹, G. Rossi⁵, C. Scagnolari³, G. Ceccarelli², G. d'Ettore¹, V. Vullo¹
¹Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Rome, Italy, ²Department of Infectious Diseases, Policlinico Umberto I, University of Rome "Sapienza", Rome, Italy, ³Department of Molecular Medicine, Laboratory of Virology, University of Rome "Sapienza", Rome, Italy; Pasteur Institute, Cenci Bolognietti Foundation, Rome, Italy, ⁴Department of Emergency Surgery, Emergency Endoscopic Unit, Policlinico Umberto I, University of Rome "Sapienza", Rome, Italy, ⁵School of Biosciences and Veterinary Medicine University of Camerino, Matelica, Italy
- OC 13 11.10-11.17 Immunological non-response in HIV-infected patients under effective ART is associated with increased circulating Th17 T helper cells**
I. De Benedetto¹, M. Masetti², M. Fabbiani¹, M. Biasin², A. Muscatello¹, N. Squillace¹, M. Clerici³, A. Gori¹, D. Trabattoni², A. Bandera¹
¹Infectious Diseases Unit, S. Gerardo Hospital, Monza, Italy and University of Milano-Bicocca, Milan, Italy, ²Chair of Immunology, Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, ³Department of Physiopathology Medical-Surgery and Transplantation, University of Milan, Milan, and Don C. Gnocchi Foundation ONLUS, IRCCS, Milan, Italy
- OC 14 11.20-11.27 Role of phosphorylation in the CCR5 signalosome formation by antibodies to CCR5 in HIV-infected Long Term Non Progressors subjects**
A. Venuti¹, C. Pastori¹, G. Siracusano¹, R. Pennisi², A. Riva³, M. T. Sciortino², L. Lopalco¹
¹Division of Immunology, Transplantation and Infectious Diseases, DIBIT - San Raffaele Scientific Institute, Milan, Italy, ²Department of Chemical Biological Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy, ³Third Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy
- OC 15 11.30-11.37 Dynamics of CD4/CD8 ratio evolution and predictors of its normalization after initiation of antiretroviral therapy in naïve HIV infected patients**
M. Fabbiani¹, R. Gagliardini², M. Colafigli³, A. Muscatello¹, A. Ciccullo², N. Squillace¹, J. Czepiel¹, A. Latini³, R. Cauda², A. De Luca^{2,4}, A. Gori¹, S. Di Giambenedetto², A. Bandera¹
¹Clinica di Malattie Infettive, Ospedale San Gerardo, ASST Monza, Monza, Italy, ²Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ³Unità di Dermatologia Infettiva, Ospedale San Gallicano, Roma, Italy, ⁴UOC Malattie Infettive, Dipartimento di Biotecnologie Mediche, Università degli Studi di Siena, Siena, Italy
- OC 16 11.40-11.47 HBV vaccination in HIV-infected people: immunogenicity and immunomodulatory role of vitamin D**
L.A. Nicolini¹, A. Parodi², R. Pincino¹, P. Tatarelli¹, C. Saffioti¹, M. Mikulska¹, A. Di Biagio¹, D. Fenoglio²
¹Infectious Diseases, Department of Health Sciences (DISSAL), IRCCS San Martino-IST, University of Genoa, ²Center of Excellence for Biomedical Research, University of Genoa

SATELLITE SYMPOSIUM 12.00-12.45

AUDITORIUM

Unrestricted educational grant of ViiV Healthcare

INSTI: the core agent for long term antiretroviral therapy

Chair: M. Zazzi (Siena)

Over the past 30 years, outstanding advances in ART have transformed HIV/AIDS from a deadly pandemic to a treatable and potentially preventable disease. Now ART treatment goals will require more robust and long-duration first-line regimens in term of virological efficacy, safety and tolerability, and consequently treatment paradigms to define the core agent in ARV therapy has to be clinically reconsidered. INSTIs are the newest class of drugs and particularly the second generation INSTI drug, are favored for ART-naïve HIV-infected person, based on virological efficacy, high genetic barrier to resistance, improved tolerability, better drug-drug interaction profile and pill burden. An update on the role of INSTI as leading class for the new treatment paradigm will be discussed.

- | | | |
|-------------|--|---------------------------------------|
| 12.00-12.15 | Role of high genetic barrier agents as starting therapy: modernizing old dogmas to prevent resistance development | Carlo Federico Perno (Roma) |
| 12.15-12.30 | High genetic barrier booster free regimens: the start of a lifelong journey in clinical practice | Antonella d'Arminio Monforte (Milano) |
| 12.30-12.45 | Discussion | |

SATELLITE SYMPOSIUM 12.00-12.45

AULA 1

Unrestricted educational grant of AbbVie

New treatment opportunities for patients with hepatitis C

Chair: G. Di Perri (Torino)

Hepatitis C virus still represents a severe health problem worldwide. In the last few years, the introduction of DAAs (Direct-Acting Antiviral Agents) in clinical practice dramatically changed the landscape of the treatment of patients with hepatitis C. The availability of these new antiviral agents considerably increased virological response rates contributing to increasing eradication rates of HCV. Although these new antiviral agents reduced the treatment duration, the impact and the frequency of adverse events, as compared to IFN-based regimens, the recent widening of eligibility criteria offers new interesting opportunities to shorten the treatment duration for patients with less advanced liver disease.

12.00-12.45 **New treatment opportunities for patients with hepatitis C**

Massimo Puoti (Milano)

SATELLITE SYMPOSIUM 13.00-13.45

AUDITORIUM

Unrestricted educational grant of Gilead Sciences

Therapeutic innovation and the role of TAF in clinical practice

Chair: A. Antinori (Roma)

Tenofovir alafenamide is a new prodrug of tenofovir: it circulates systemically as the prodrug, undergoing conversion to tenofovir diphosphate intracellularly. As a result, higher concentrations of the active metabolite are achieved in lymphocytes, and plasma exposure is 90% lower than with tenofovir disoproxil fumarate. The higher intracellular concentration allows for much lower doses and increases antiviral activity. Tenofovir alafenamide, emtricitabine, cobicistat and elvitegravir is the first STR with TAF: this session will be a clinical data overview and will focus on patients management with F/TAF based regimens.

13.00-13.15 **The innovation of the first STR TAF-based**

Antonella Castagna (Milano)

13.15-13.30 **Strategy with TAF-based regimens**

Antonio Di Biagio (Genova)

13.30-13.45 **Discussion**

SATELLITE SYMPOSIUM 13.00-13.45

AULA 1

Unrestricted educational grant of MSD Italy

HCV infection in DAAs era: a new revolution for your patients in 2017?

Chair: M. Galli (Milano)

Discussant: A. De Luca (Siena)

In recent years, HCV treatment has changed radically with the introduction of new direct antiviral agents (DAAs). Indeed, state of the art IFN-free DAA therapy achieves 90-95% SVR12 in most patient populations. However, some patients remain difficult to treat including those with cirrhosis, comorbidities such as chronic kidney disease, cardiovascular diseases, diabetes, hematological disorders, HIV coinfection, and OAT/PWID patients. The aim of this Symposium is to discuss comprehensively the management of difficult-to-treat HCV patients through appropriate personalized medicine interventions.


13.00-13.15 **HCV GT1 & GT4 treatment: a patient at center approach**

Gloria Taliani (Roma)

13.15-13.30 **Management of HIV/HCV coinfecting patients in new DAAs era**

Massimo Andreoni (Roma)

13.30-13.45 **Discussion**



EXPERT MEETING 13.45-14.45

Unrestricted educational grant of ViiV Healthcare

Management of comorbidities during HIV infection: a possible role of CCR5-antagonism

Chair: A. Lazzarin (Milano)

Facing the growing occurrence of concomitant diseases during HIV infection is an additional feature of the current scenario of patients care. Besides its virologic effects, CCR5 antagonism has shown to be involved in the control of the biological mechanisms of specific comorbidities. Aim of the meeting is to present some recent Italian research suggesting how CCR5-antagonism could contribute to manage hepato-logic and cardiovascular co-morbidities in HIV-infected patients and give insights on possible ARV regimens containing CCR5 antagonists.

- | | | |
|-------------|---|---------------------------|
| 13.45-14.00 | Effects of treatment with maraviroc a CCR5 inhibitor on a human hepatic stellate cell line | Nicola Coppola (Napoli) |
| 14.00-14.15 | Durability of a dual therapy in HIV-patients with R5-tropic virus stably viro-suppressed beyond 48 weeks of treatment with maraviroc plus darunavir/ritonavir | Barbara Rossetti (Siena) |
| 14.15-14.30 | a randomized, crossover study to evaluate the efficacy of maraviroc in reducing the cardiovascular risk in hiv viro-suppressed patients. a pilot, explorative, study | Franco Baldelli (Perugia) |
| 14.30-14.45 | Discussion | |

ROOM AGORÀ A

POSTER DISCUSSION 13.50-14.40

Clinical HIV I

Chairs: V. Esposito (Napoli), A. Saracino (Bari)

AUDITORIUM

- PD 1 13.50-13.55 Impact of M184V resistance mutation on virological efficacy of lamivudine-based dual therapies: an Italian ARCA cohort study**
R. Gagliardini¹, A. Ciccullo¹, A. Borghetti¹, F. Maggiolo², D. Bartolozzi³, V. Borghi⁴, M. Pecorari⁵, A. Di Biagio⁶, A. Callegaro⁷, B. Bruzzone⁸, F. Saladini⁹, S. Paolucci¹⁰, L. Bellazzi¹¹, A. De Luca¹², S. Di Giambenedetto¹
¹Istituto di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, ²Divisione di Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, ³Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera Universitaria Careggi, Firenze, ⁴Clinica Malattie Infettive e Tropicali, Azienda Ospedaliera Universitaria di Modena, Modena, ⁵Unità di Microbiologia e Virologia, Azienda Ospedaliera Universitaria di Modena, Modena, ⁶Unità di Malattie Infettive, IRCCS AOU San Martino-IST, Genova, ⁷Unità di Microbiologia e Virologia, ASST Papa Giovanni XXIII, Bergamo, ⁸Unità di Igiene, IRCCS AOU San Martino-IST, Genova, ⁹Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, ¹⁰Virologia Molecolare, Fondazione IRCCS Policlinico San Matteo, Pavia, ¹¹Clinica di Malattie Infettive, S. Matteo Hospital, Pavia, ¹²Unità di Malattie Infettive, Ospedale Universitario di Siena, Siena
- PD 2 13.57-14.02 Budget impact analysis of the simplification to ATV+r+3TC of ATV+r+2NRTI therapy in Italy, based on the ATLAS-M Trial results at 96 weeks**
U. Restelli^{1,2}, M. Fabbiani³, S. Di Giambenedetto³, C. Nappi⁴, D. Croce^{1,2}
¹Centre for Research on Health Economics, Social and Health Care Management (CREMS), LIUC – Università Cattaneo, Castellanza (VA), ²School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, ³Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, ⁴Health Economics, Bristol Myers Squibb S.r.l., Rome
- PD 3 14.04-14.09 Efficacy, tolerability and pharmacokinetics of dual therapy based on dolutegravir (DTG) and darunavir/ritonavir (DRV/r) qd in the clinical setting**
M. Ferrara¹, L. Marinaro¹, C. Alcantarini¹, C. Montrucchio¹, M. Milesi¹, A. Barco¹, C. Costa¹, B. Granozzi¹, M.C. Tettoni¹, G. Orofino¹, A. Ariaudo¹, A. De Nicolò¹, A. D'Avolio¹, G. Di Perri¹, S. Bonora¹
 Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy
- PD 4 14.11-14.16 Prevalence of and risk factors for potential drug-drug interactions (PDDIs) between antiretroviral (ARV) and non-antiretroviral (non-ARV) medications in patients aged ≥50 years**
A. Ranzani¹, L. Oreni¹, M. Agrò¹, G. Bozzi¹, L. Van den Bogaart¹, C. Resnati¹, T. Formenti¹, C. Gervasoni¹, D. Cattaneo¹, M. Galli¹, A.L. Ridolfo¹
 Department of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy
- PD 5 14.18-14.23 Polypharmacy and cART in HIV pts: different levels of adherence**
A. Calamo¹, C. Marotta², G. De Vita¹, N. De Gennaro¹, F. Di Gennaro¹, N. Ladisa¹, P. Maggi¹, L. Monno¹, A. Saracino¹, S. Lo Caputo¹, G. Angarano¹
¹Clinic of Infectious Diseases, University of Bari, Bari, Italy, ²Department of Science for Health Promotion and Mother-Child Care "G. D'Alessandro", University of Palermo, Palermo, Italy

- PD 6 14.25-14.30 Inflammation markers and low levels viremia: gender difference in ARV treated HIV-1 patients**
F. Falasca¹, L. Mazzuti¹, E. Cinquina¹, G. Tranquilli¹, G. d'Ettorre², C. Fimiani³, I. Mezzaroma³, M. Bucci¹, G. Antonelli¹, O. Turriziani¹
¹Sapienza University of Rome; Department of Molecular Medicine, ²Sapienza University of Rome; Department of Infectious Diseases, ³Sapienza University of Rome; Department of Clinical Medicine

POSTER DISCUSSION 13.50-14.40

AULA 2

Clinical HIV II

Chairs: G. Madeddu (Sassari), D. Ripamonti (Bergamo)

- PD 7 13.50-13.55 Effect of aspirin therapy on Abacavir-associated platelet hyperreactivity in HIV-infected patients: a randomized, double-blind, placebo-controlled, cross-over study**
E. Schiaroli¹, E. Falcinelli², D. Francisci¹, P. Gresele², F. Baldelli¹
¹Division of Infectious Diseases, Department of Experimental Medicine, University of Perugia, Italy, ²Department of Medicine, Section of Internal and Cardiovascular Medicine, University Perugia, Italy
- PD 8 13.57-14.02 Evaluation of eGFR by cystatin C formulas in HIV-1-infected patients with a decreased eGFR, treated with dolutegravir, rilpivirine or cobicistat**
N. Galizzi^{1,2}, L. Galli¹, A. Poli¹, V. Spagnuolo^{1,2}, M. Guffanti¹, L. Fumagalli¹, A. Castagna^{1,2}, N. Gianotti¹
¹Infectious Diseases, IRCCS San Raffaele, Milano, Italy, ²Università Vita-Salute San Raffaele, Milano, Italy
- PD 9 14.04-14.09 Cerebrospinal Fluid HIV RNA and Neurocognitive Deficits: Are Lumbar Punctures Needed in Impaired Subjects with Undetectable Plasma Viral Load?**
M. Trunfia¹, T. Allice², D. Vai³, C. Atzori³, A. Romito⁴, V. Pirriatore¹, C. Montrucchio¹, M.C. Tettoni¹, D. Imperiale³, S. Bonora¹, V. Ghisetti², G. Di Perri¹, A. Calcagno¹
¹Department of Medical Science, Amedeo di Savoia hospital, University of Torino, Torino, ²Laboratory of Microbiology and Virology, Amedeo di Savoia hospital, ASLTO2, Torino, ³Unit of Neurology, Maria Vittoria hospital, ASLTO2, Torino, ⁴Laboratory of Immunology, Maria Vittoria hospital, ASLTO2, Torino
- PD 10 14.11-14.16 Neurocognitive impairment (NCI) and hypovitaminosis D in a large cohort of HIV-infected persons**
A. Vergori¹, A. Ammassari¹, M. Ricottini¹, P. Balestra¹, P. Lorenzini¹, R. Libertone¹, I. Mastrorosa¹, V. Mazzotta¹, S. Cicalini¹, A. Antinori¹, C. Pinnetti¹
HIV/AIDS Department, National Institute for Infectious Diseases, IRCCS L. Spallanzani, Rome
- PD 11 14.18-14.23 Joint effect of HPV-16 infection and multiple HPV Genotypes as a Risk Factor for Anal Grade Squamous Intraepithelial Lesions in HIV-1 Infected Males**
S. Nozza¹, L. Galli¹, S. Bossolasco¹, A. Poli¹, M. Cernuschi¹, E. Messina¹, C. Muccini^{1,2}, N. Galizzi^{1,2}, A. Lazzarin^{1,2}, A. Castagna^{1,2}
¹Ospedale San Raffaele, Milano, Department of Infectious Diseases, ²Università Vita Salute, Ospedale San Raffaele, Milano
- PD 12 14.25-14.30 Lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio predict survival in HIV-infected patients with non-Hodgkin lymphomas**
A. Bandera¹, A. Cozzi-Lepri², L. Galli³, N. Galizzi³, G.M. Baldin⁴, L. Teofili⁴, V. Mazzotta⁵, L. Alba⁵, A. Castagna³, A. Gori¹, A. d'Arminio Monforte⁶, A. Antinori⁵, A. Cingolani⁴ for the Icona Foundation Study Group
¹San Gerardo Hospital, Monza, Italy, ²University College London, London, UK, ³HSR, San Raffaele Hospital, Milano, Italy, ⁴Catholic University, Roma, Italy, ⁵National Institute for Infectious Diseases, L. Spallanzani, Roma, Italy, ⁶San Paolo Hospital, University of Milano, Milano, Italy


POSTER DISCUSSION 13.50-14.40

AULA 6

Hepatitis

Chairs: F. Benanti (Catania), A. Cascio (Palermo)

- PD 13 13.50-13.55 Sustained virological response in HCV patients treated with daclatasvir+sofosbuvir, with or without ribavirin: a multicenter, field-practice experience**
R. Sacco¹, E. Salomoni², S. Parodi³, E. Gianni³, L. Gragnani³, G. Andreotti⁴, M.R. Brunetto⁵, A.L. Zignego³, R. Gattai⁵, I. Vivaldi⁶, A. De Luca⁷, D. Bartolozzi², R. Cinelli⁶, M. Pozzi², B. Coco⁵, G. Tapete¹, P. Forte⁸, R. Puntilli⁸, L. Ricciardi⁹, S. Sani⁶, S. Luchi⁹, B. Valoriani⁷, M.P. Riccardi⁴, C. Nencioni⁴, D. Aquilini¹⁰, A. Nerli¹⁰, F. Esperti¹¹, F. Mazzotta¹¹, G. Bresci¹, P. Colombatto⁵ on behalf of Epatologi Toscani (ET)
¹U.O. Gastroenterologia e Malattie del Ricambio, Azienda Ospedaliera Universitaria Pisana, Pisa, ²Malattie Infettive e Tropicali, AOU Careggi, Firenze ³Centro MASVE, Medicina Sperimentale e Clinica, AOU Careggi, Firenze, ⁴Malattie Infettive, Ospedale Misericordia, Grosseto, ⁵U.O. Epatologia, Azienda Ospedaliera Universitaria Pisana, Pisa, ⁶Malattie Infettive, Spedali Riuniti di Livorno, Livorno, ⁷Malattie Infettive, Azienda Ospedaliera Universitaria Senese, Siena, ⁸Gastroenterologia 2, AOU Careggi, Firenze, ⁹Malattie Infettive e Epatologia, Ospedale San Luca, Lucca, ¹⁰Malattie Infettive, Nuovo Ospedale di Prato, Prato, ¹¹Malattie Infettive, Ospedale S. Jacopo, Pistoia, Italy
- PD 14 13.57-14.02 HCC development in a cohort of HCV patients treated with DAAs, mono or co-infected with HIV**
G. Cuomo¹, A. Bianchi¹, M. Digaetano¹, C. Puzzolante¹, V. Borghi¹, G. Guaraldi¹, C. Mussini¹
Azienda Ospedaliero-Universitaria Policlinico di Modena, Clinica delle Malattie Infettive



- PD 15** 14.04-14.09 **Long-term Follow Up of HIV/HBV Co-infected Patients Treated with Different Antiviral Drugs**
M. Carlin, L. Boglione, A. Calcagno, V. Ghisetti, P. Cariti, L. Trentini, M.C. Tettoni, S. Mornese Pinna, G. Di Perri, S. Bonora
Department of medical sciences unit of infectious diseases Amedeo di Savoia Hospital, Turin
- PD 16** 14.11-14.16 **Treatment with SOF/VEL is well tolerated and results in high SVR12 in genotype 1-6 HCV infected patients with minimal fibrosis: a retrospective analysis of the ASTRAL clinical studies**
L. Chessa¹, E. Lawitz², M. Bourlière³, P. Gallinari⁴, L. Han⁴, J. McNally⁴, L.M. Stamm⁴, D.M. Brainard⁴, G.M. Subramanian⁴, S.L. Flamm⁵, K.R. Reddy⁶
¹University Hospital of Cagliari, Italy, ²Texas Liver Institute, University of Texas Health Science Center, San Antonio, United States, ³Hospital Saint Joseph, Marseille, France, ⁴Gilead Sciences, Inc., Foster City, ⁵Northwestern University, Chicago, ⁶University of Pennsylvania, Philadelphia, United States
- PD 17** 14.18-14.23 **Effect of direct-acting antivirals for HCV on lipid profile in HIV-HCV coinfecting patients**
M. Rinaldi¹, L. Bussini¹, V. Guardigni^{1,2}, L. Badia^{1,2}, E. Francalanci¹, P. Viale¹, G. Verucchi^{1,2}
¹UO Malattie Infettive, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna, ²Centro di Ricerca per lo Studio delle Epatiti, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna
- PD 18** 14.25-14.30 **Distribution of different HBV DNA forms in plasma and PBMCs of chronically infected patients**
B. Rossetti^{1,2}, I. Vicenti³, S. Mariano¹, M. Zazzi³, A. De Luca¹
¹Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ²Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ³Medical Biotechnology Department, University of Siena, Siena, Italy

POSTER DISCUSSION 13.50-14.40**AULA 11****Immunology**

Chairs: C. Agrati (Roma), G. Nunnari (Messina)

- PD 19** 13.50-13.55 **Characterisation Microparticles NK cells derived from Progressor and Non Progressors HIV infected patients compared to Healthy Donors**
F. Bozzano^{1,2}, F. Marras³, F. Antonini³, A. Di Biagio⁴, L.A. Nicolini⁴, L. Taramasso⁴, G. Cenderello⁵, L. Moretta⁶, A. De Maria^{2,5}
¹Department of Experimental Medicine, University of Genoa, Italy, ²Center of Excellence for Biomedical Research, University of Genoa, Italy, ³G Gaslini Institute, Genoa, Italy, ⁴Clinical Infectious Diseases, IRCCS AOU San Martino-IST Genova, Italy, ⁵Infectious Diseases Unit, EO Galliera, Genoa, Italy, ⁶Area di Ricerca Immunologica, IRCCS Ospedale Bambino Gesù, Rome, Italy
- PD 20** 13.57-14.02 **Immunological predictors of successful and safe anti-rejection therapy in HIV+ patients who underwent liver transplantation**
E. Franceschini¹, M. Digaetano¹, S. De Biasi², E. Bianchini², M. Nasi², L. Gibellini², M. Pinti², V. Borghi¹, M. Codeluppi¹, F. Di Benedetto³, G. Guaraldi⁴, A. Cossarizza², C. Mussini⁴
¹Azienda Ospedaliero-Universitaria Policlinico di Modena, Infectious Disease Clinic, ²University of Modena and Reggio Emilia, Department of Medical and Surgical Sciences of Children and Adults, ³University of Modena and Reggio Emilia, Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, ⁴University of Modena and Reggio Emilia, Infectious Disease Clinic
- PD 21** 14.04-14.09 **High CD4:CD8 ratio and length of treatment independently correlate to the HIV-DNA intracellular content in different subsets of CD4+ T cells from virologically suppressed HIV+ patients**
S. Pecorini¹, S. De Biasi², E. Bianchini³, M. Digaetano^{3,4}, M. Pinti², L. Gibellini³, D. Lo Tartaro², V. Borghi⁴, C. Mussini^{3,4}, A. Cossarizza⁵, M. Nasi³
¹Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ⁴Infectious Diseases Clinics, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, ⁵Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
- PD 22** 14.11-14.16 **Cytokines-lymphoid progenitors interplay in treated acute HIV infection**
V. Bordoni, D. Viola, C. Pinnetti, A. Sacchi, R. Casetti, E. Cimini, N. Tumino, A. Antinori, A. Ammassari, C. Agrati
INMI L.Spallanzani, Rome
- PD 23** 14.18-14.23 **Interleukin -21/microRNA-29 axis in natural resistance to HIV-1 infection**
P.A. Serna Ortega¹, I. Saule¹, V. Mercurio¹, E.M. Lori¹, D. Trabattoni¹, S. Lo Caputo², F. Vichi², F. Mazzotta², M. Clerici³, M. Biasin¹
¹Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, ²S. Maria Annunziata Hospital, Florence, Italy, ³Don C. Gnocchi Foundation ONLUS, IRCCS, Milan, Italy
- PD 24** 14.25-14.30 **Alteration in the expression of inflammasome components AIM2, PYCARD and IL-1 β in HIV-infected patients with low CD4/CD8 ratio**
S. Pecorini¹, S. De Biasi², E. Bianchini³, M. Digaetano^{3,4}, M. Pinti², L. Gibellini³, D. Lo Tartaro², V. Borghi⁴, C. Mussini^{3,4}, A. Cossarizza⁵, M. Nasi²
¹Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ⁴Infectious Diseases Clinics, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, ⁵Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy

POSTER DISCUSSION 13.50-14.40

AULA 10

Basic science and virology

Chairs: G. d'Ettore (Roma), M. Santoro (Roma)

- 13.50-13.57 **Is transmitted drug resistance to integrase inhibitors becoming a concern in Italy? A new case report** Maria Santoro (Roma)
- PD 25** 13.57-14.02 **New drug combinations and latest prescription guidelines are associated with a decrease in acquired resistance to antiretrovirals overtime**
A. Lai¹, M. Franzetti¹, G. Bozzi¹, F. Saladini², B. Bruzzone³, S. Di Giambenedetto⁴, A. Di Biagio⁵, S. Lo Caputo⁶, M.M. Santoro⁷, F. Maggiolo⁸, S. Parisi⁹, S. Rusconi¹, N. Gianotti¹⁰, C. Balotta¹
¹Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Hygiene Unit, IRCCS AOU San Martino - IST, Genoa, Italy, ⁴Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart of Rome, Rome, Italy, ⁵Infectious Disease Clinic, IRCCS San Martino - IST Hospital, Genoa, Italy, ⁶S. Maria Annunziata Hospital, Florence, Italy, ⁷University of Rome Tor Vergata, Rome, Italy, ⁸Clinic of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy, ⁹Clinical Microbiology and Virology Unit, Padua University Hospital, Padua, Italy, ¹⁰Infectious Diseases, IRCCS San Raffaele, Milan, Italy
- PD 26** 14.04-14.09 **Impact of the HIV-1 integrase natural polymorphism E157Q on susceptibility to integrase inhibitors**
F. Saladini, A. Giannini, A. Boccuto, D. Tiezzi, I. Vicenti, M. Zazzi
 Department of Medical Biotechnologies, University of Siena
- PD 27** 14.11-14.16 **Analysis of HIV DNA levels in HIV positive patients treated with dolutegravir-containing regimen**
D. Di Carlo¹, F. Falasca¹, E. Cinquina¹, T. Melengu¹, C. Fimiani², G. d'Ettore², I. Mezzaroma³, G.I. Schietroma², G. Antonelli¹, O. Turriziani¹
¹Sapienza University of Rome; ²Department of Molecular Medicine, ³Sapienza University of Rome; Department of Infectious Diseases, ⁴Sapienza University of Rome; Department of Clinical Medicine
- PD 28** 14.18-14.23 **Effect of exogenous interferon alpha on HIV viral populations in vivo**
G. Bozzi¹, W. Shao³, R. Dewar³, V. Pathak², B. Desimmie², R.C. Burdick², S. Jones³, C. Balotta¹, M.E. Wright⁴, F. Maldarelli²
¹Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, ²Dynamic and Replication Program, NCI, NIH, Frederick, ³Leidos Inc. Frederick, United States, ⁴Division of Clinical Research, NIAID, NIH, Bethesda, United States
- PD 29** 14.25-14.30 **Is the management of HIV-1 drug-resistance still a clinical concern? A large Italian real life update in the modern antiretroviral era**
D. Armenia¹, D. Di Carlo¹, V. Borghi², F. Forbici³, A. Bertoli¹, C. Gori³, C. Alteri¹, L. Fabeni³, W. Gennari², F. Continenza³, C. Pinnetti³, M. Zaccarelli³, A. Mondri³, S. Cicalini³, G. Maffongelli⁴, F. Montella⁵, M. Colafigli⁶, R. Marocco⁷, C.M. Mastroianni⁷, F. Ceccherini-Silberstein¹, M. Andreoni⁴, C. Mussini², A. Antinori³, C.F. Perno³, M.M. Santoro¹
¹University of Rome "Tor Vergata", Rome, Italy, ²Polyclinic of Modena, Modena, Italy, ³National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ⁴University Hospital of Rome Tor Vergata, Rome, Italy, ⁵San Giovanni Addolorata Hospital, Rome, Italy, ⁶San Gallicano Dermatological Institute, IRCCS, Rome, Italy, ⁷La Sapienza University Polo Pontino, Latina, Italy
- PD 30** 14.32-14.37 **HIV genotypic resistance test in Italy: difficulties in application and their impact in clinical practice**
S. Lo Caputo¹, S. Rusconi², A. Di Biagio³, A. Chirianni⁴, M. Andreoni⁵, M. Zazzi⁶, I. Bon⁷, M.C. Re⁷
¹U.O. Malattie Infettive, A.O.U. Policlinico Bari, ²Div. Clinica Malattie Infettive, DIBIC Luigi Sacco, Università degli Studi di Milano, ³U.O. Clinica Malattie Infettive, IRCCS AOU San Martino-IST, Genova, ⁴Dipartimento di Malattie Infettive ed Urgenze infettivologiche, Azienda Ospedali dei Colli di Napoli, ⁵Dipartimento di Medicina dei Sistemi, Università Tor Vergata, Roma, ⁶Dipartimento di Biotechnologie Mediche, Università di Siena, ⁷Unità Operativa di Microbiologia, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna


POSTER DISCUSSION 13.50-14.40

AULA 9

Community

Chairs: S. Mattioli (Bologna), L. Rancilio (Milano)

- PD 31** 13.50-13.55 **The new anti HCV oral Interferon-free drugs (DAA) and the Drug-Drug Interactions (DDIs): data from a multi-center cohort of HCV monoinfected and HIV co-infected patients (DAADDI 2 study)**
C. Coco¹, M. Gussio¹, A. Saracino², L. Larocca³, G. Madeddu⁴, F. Luciani⁵, M. Maresca¹, V. Fiore⁴, A. Onorante¹, R.S. Grasso¹, B. Cacopardo¹, F. Benanti¹, B.M. Celesia¹
¹Unit of Infectious Diseases University of Catania, ARNAS Garibaldi Catania, ²Unit of Infectious Diseases University of Bari, ³Unit of Infectious Diseases AO OVE Policlinico Catania, ⁴Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, ⁵Unit of Infectious Diseases Cosenza
- PD 32** 13.57-14.02 **Preliminary Italian results in the COBA Cohort study, a pan-European cohort of HIV negative MSM enrolled in community-based voluntary counselling and testing services**
M.L. Cosmaro¹, M. Oldrini¹, N. Lorente^{2,3}, R. Fuentetaja⁴, P. Meireles⁵, R. Lucas^{5,6}, F. Pichon⁷, P. Slaaen Kaye⁷, B. Cigan⁸, S. Chanos⁹, G. Polkas⁹, S. Morel¹⁰, D. Rojas Castro^{10,11,12}, C. Agustí^{2,3,13}, L. Fernández-López^{2,3,13}, J. Casabona^{2,3,13}, Euro HIV EDAT Study group
¹Fondazione LILA Milano ONLUS, ²Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Departament de Salut, Generalitat de Catalunya, Badalona, Spain, ³Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Spain, ⁴GAT-Grupo de Activistas em Tratamentos, Lisbon, Portugal, ⁵EPIUnit-Institute of Public Health, University of Porto, Porto, Portugal, ⁶Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical School, Porto, Portugal, ⁷AIDS-Fondet, Copenhagen, Denmark, ⁸Društvo informacijski center Legebitra, Ljubljana, Slovenia, ⁹Positive Voice, Ath-Thess Checkpoints, Athens, Greece, ¹⁰AIDES (MIRE-Mission Innovation Recherche Expérimentation), Pantin, France, ¹¹Groupe de Recherche en Psychologie, Sociale (GrEPS) EA4163, Université de Lyon 2, Bron, France, ¹²INSERM, UMR912 (SESSTIM), Marseille, France, ¹³CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain



- PD 33** 14.04-14.09 **Physical activity is associated with frailty levels in HIV patients**
 A. Malagoli¹, A. Caselgrandi¹, M. Pacchioni², M. Orsini³, F. Carli¹, M. Menozzi¹, S. Zona¹, O. Theou², L. Wallace², C. Mussini¹, G. Guaraldi¹
¹University of Modena and Reggio Emilia, Department of Medical and Surgical Sciences for Children & Adults, ²Geriatric Medicine Research Unit, Dalhousie University/Nova Scotia Health Authority, ³DataRiver srl
- PD 34** 14.11-14.16 **HIV test in an associaton. An opportunity of risk behaviour screening and use of chem**
 A. Bianchi, F.M. Esposito, A. Antonino, G. Fracca, M. Meneghin, F. Rossi, M. Lanza, D. Zagato, R. Repossi, M. Ruggieri, M. Cernuschi
 ASA Associazione Solidarietà AIDS Onlus, Milan, Italy
- PD 35** 14.18-14.23 **Clinical needs of PLWHA: how are they changing?**
 F. Maggiolo¹, R. Teocchi², E. Di Filippo¹, L. Comi¹, A. Callegaro³, D. Valenti¹, M. Rizzi¹
¹USC of Infectious Diseases, ²Informatc Department, ³Laboratory of Microbiology and Virology, ASST Papa Giovanni XXIII, Bergamo
- PD 36** 14.25-14.30 **Complexity and transmission dynamics of the HIV-1 epidemic in Italy are influenced by transgender sex workers**
 A. Lai¹, G. Bozzi¹, A. Bergna¹, P. Cattaneo¹, M. Franzetti¹, F.R. Simonetti¹, F. Binda¹, V. Micheli², C. Aztori³, M. Galli¹, C. Balotta¹
¹Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, ²Clinical Microbiology Virology and Diagnosis of Bioemergency, L Sacco University Hospital, Milan, Italy, ³1rd Division of Infectious Diseases, L. Sacco University Hospital, Milan, Italy

SATELLITE SYMPOSIUM 14.00-14.45

AULA 1

Unrestricted educational grant of Mylan

ROUND TABLE "HIV self-testing: the Italian experience"

Chairs: A. Antinori (Roma), A. Bignardi (Modena)

Speakers: A. Battistella (Milano), A. Gori (Monza), P. Parenti (Milano), A. Toscano (Milano)

More than 14 million people worldwide do not know they are HIV-positive. It has been estimated that in Italy 12.000 to 18.000 HIV-positive people remain undiagnosed.

Therefore, to reduce the number of people diagnosed late or unaware of their infection, there is an urgent need for new strategies to expand HIV early detection services. The new WHO guidelines on HIV testing services recommend all countries to increase HIV self-testing supply, as an integral part of self-diagnosis services, to the point of considering it crucial as innovative way to reach more HIV-positive people and to contribute achieving the global goal, launched in 2014, to make 90% of HIV-positive people aware of their status by 2020.

SYMPOSIUM 14.45-16.00

AUDITORIUM

Self-care in HIV and HCV: emerging issues and criticisms

Chairs: A. Ammassari (Roma), M.R. Iardino (Milano), G. Parruti (Pescara)

In recent years, the term "self-care" has become more popular in the management of various diseases including HIV and HCV infections. In the field of diagnosis, "self-testing" tools are now available to be used by patients without the health worker mediation. As far as treatments are concerned, healthcare systems, also due to the increasing costs of new drugs, may limit access to reimbursement to a considerable part of the people who could benefit from them, thus promoting "self-medication" initiatives which could pose new critical issues. The Symposium deals with some of the daily issues in both HIV and HCV infection.

- | | | |
|-------------|--|-------------------------------|
| 14.45-15.00 | Is self-testing in HIV a keystone to achieve the first 90 target? The UK experience | Alison Rodger (London, UK) |
| 15.00-15.15 | HIV self-testing in Italy: from the experience to new possible protecting models | Michele Breveglieri (Bologna) |
| 15.15-15.30 | London's buyer clubs: understanding the main and critical issues both in HIV (PrEP) and HCV | Andrew Hill (Liverpool, UK) |
| 15.30-15.45 | Picturing the transition from self-medication to universal access to HCV drugs in Italy | Ivan Gardini (Vimercate, MB) |
| 15.45-16.00 | Discussion | |

ORAL COMMUNICATION 14.50-16.05

AULA 1

Immunological response under cART and co-infections

Chairs: O. Armignacco (Viterbo), F. Maggiolo (Bergamo)

14.50-15.05 **Is search and treat for latent TB still valid in the undetectability era?** Enrico Girardi (Roma)

OC 17 15.05-15.12 CD4/CD8 ratio in patients who switch therapy: better triple therapy than dual/mono?

C. Mussini¹, P. Lorenzini², S. Rusconi³, G. Marchetti⁴, A. Gori⁵, S. Nozza⁶, M.M. Santoro⁷, A. Calcagno⁸, A. Saracino⁹, M. Lichtner¹⁰, A. Antinori², A. d'Arminio Monforte⁴ for the Icona Foundation Study Group

¹University of Modena and Reggio Emilia, Modena, Italy, ²National Institute for Infectious Disease, "L. Spallanzani", Rome, Italy, ³University of Milan, DIBIC Luigi Sacco, Milan, Italy, ⁴ASST Santi Paolo e Carlo, Clinic of Infectious Diseases, University of Milan, Milan, Italy, ⁵San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, ⁶San Raffaele Hospital, Milan, Italy, ⁷Università degli Studi di Roma "Tor Vergata", Rome, Italy, ⁸Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ⁹Clinic of Infectious Diseases, University of Bari, Bari, Italy, ¹⁰Sapienza University, Public Health and Infectious Diseases, Rome, Italy

OC 18 15.15-15.22 CD4/CD8 ratio matters to age related health outcomes in HIV infected patients with comorbidities, frailty and disability

M. Menozzi¹, A. Dominguez da Silva², A. Malagoli¹, G. Dolci¹, A. Santoro¹, C. Mussini¹, G. Guaraldi¹

¹Modena HIV Metabolic Clinic - Infectious Disease Clinic, AOU Policlinico di Modena, Modena, Italy, ²Infectious Disease Department, Hospital Beatriz Ângelo, Loures, Portugal

OC 19 15.25-15.32 Value of CD4 count nadir and of time since occurrence of CD4 count nadir to predict viral rebound in a selected population who underwent a therapy switch after achieving viral suppression

M. Zaccarelli¹, A. Antinori¹, A. Saracino², G. Madeddu³, G. Rizzardini⁴, S. Lo Caputo⁵, A. Castagna⁶, A. Tavelli⁷, A. d'Arminio Monforte⁸, A. Cozzi-Leperi⁹

¹National Institute for Infectious Diseases, "lazzaro Spallanzani, IRCCS, Rome, Italy, ²Unit of Infectious Diseases, University of Bari, Italy, ³Infectious Diseases Division, University of Sassari, Italy, ⁴1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy, ⁵Unit of Infectious Diseases, Policlinico di Bari, Bari, Italy, ⁶San Raffaele Hospital, Università Vita-Salute San Raffaele, Milan, Italy, ⁷Icona Foundation, Milan, Italy, ⁸Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University Hospital San Paolo, University of Milan, Milan, Italy, ⁹Department of Infection and Population Health, Royal Free Campus, University College London, London, UK

OC 20 15.35-15.42 Altered intestinal microbiota in successfully cART-treated HIV-infected males with high-risk HPV genotypes and anal HPV-related cytological abnormalities

E. Merlini¹, A. Pandolfo¹, G. Ancona¹, B. Cassani², C. Tincati¹, F.A. Cazzaniga¹, G. Bulfamante², A. d'Arminio Monforte¹, G. Marchetti¹

¹Clinic of Infectious Diseases, Dept Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, ²Pathology Unit, Dept Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy

OC 21 15.45-15.52 Predictive factors for HPV infection and neoplastic cervical lesions among 321 HIV+ women at Santa Maria Annunziata Hospital, Florence, 2006-2016

F.M. Fusco¹, F. Vichi¹, S. Bisanzi², A. degli Esposti¹, C. Blè¹, B. Del Pin¹, F. Carozzi², C. Sani², P. Blanc¹

¹SOC Malattie Infettive 1, Azienda USL Toscana Centro, Ospedale S. Maria Annunziata, Bagno a Ripoli (FI), ²SS Laboratorio Regionale HPV e Biologia Molecolare, Laboratorio Regionale Prevenzione Oncologica, ISPO, Firenze

OC 22 15.55-16.02 Multi-site HPV infection in HIV-positive men

A. Vergori¹, A.R. Garbuglia², P. Piselli³, M. Gentile¹, F. Lupi¹, C. Cimaglia³, D. Lapa², F. Del Nonno⁴, A. Baiocchi⁴, A. Antinori¹, M.R. Capobianchi², A. Ammassari¹

¹HIV/AIDS Department, INMI L.Spallanzani, Rome, ²Laboratory of Virology, INMI L.Spallanzani, Rome, ³Clinical Epidemiology Unit, INMI L.Spallanzani, Rome, ⁴Laboratory of Pathology, INMI L.Spallanzani, Rome

ORAL COMMUNICATION 14.50-16.05

AULA 2

Clinical Hepatitis I

President: F. Mazzotta (Firenze)


Chairs: C. Ferrari (Parma), M. Puoti (Milano), M. Tavio (Ancona)

OC 23 14.50-14.57 Treatment with DAAs in a multicenter cohort of HCV-infected prisoners in Italy

E. Pontali¹, A.M. Ialungo², S. Dell'Isola², E. Rastrelli², R. Ranieri³, O. Mollaretti⁴, G. Leo⁴, S. Babudieri⁵, G. Barbarini⁶, D. Marri⁷, R. Monarca², S. Panese⁸, T. Prestileo⁹, A. d'Arminio Monforte³, G. Starnini²

Gruppo di lavoro infettivologi penitenziari: G. Accardi, N. Bobbio, R. Buonomo, M. Casana, C. Cuccu, E.R. Dalle Nogare, F. Di Lorenzo, A. Foschi, M.D. Iannece, B. Koehler, S. Marcellini, S. Martuscelli, L. Taschini

¹S.C. Malattie Infettive-E.O. Ospedali Galliera-Genova & S.S. Programma Aziendale Tutela Salute In Carcere - ASL 3 Genovese - Genova, ²UOC Medicina Protetta-Malattie Infettive, Ospedale Belcolle, Viterbo, ³Unità Infettivologia Penitenziaria e Cattedra Malattie Infettive Ospedale Santi Paolo e Carlo, Milano, ⁴SD Day Hospital Centralizzato, Malattie Infettive II, Ospedale Amedeo di Savoia, Torino, ⁵UOC Malattie Infettive e Tropicali, AOU Sassari, ⁶Dipartimento Malattie Infettive e Tropicali Fondazione IRCCS Policlinico San Matteo Pavia, ⁷UOC Malattie Infettive ed Epatologia, AOUS Senese, Siena, ⁸U.O. Malattie Infettive e Tropicali, ULSS 3 Serenissima, Mestre, ⁹UOC Malattie Infettive, ARNAS Ospedale Civico e Benfratelli, Palermo. Istituti Penitenziari: Casa di Reclusione Bollate di Milano, Casa di Reclusione Milano Opera, Casa Circondariale San Vittore Milano, Casa Circondariale Marassi di Genova, Casa Circondariale Genova Pontedecimo, Casa Circondariale Le Vallette Torino, Casa Circondariale Rebibbia Nuovo Complesso, Casa Circondariale Femminile Rebibbia, Casa di Reclusione Rebibbia, Casa Circondariale Regina Coeli, Casa Circondariale Civitavecchia, Casa Circondariale Velletri, Casa Circondariale Paliano, Casa Circondariale Frosinone, Casa Circondariale Cassino, Casa Circondariale Viterbo, Casa di Reclusione Venezia-Giudecca, Casa di Reclusione Ucciardone Palermo, Casa Circondariale Pagliarelli Palermo, Casa di Reclusione San Gimignano, Casa Circondariale Siena, Casa Circondariale Pavia, Casa di Reclusione Vigevano, Casa Circondariale Voghera, Casa Circondariale di Sassari Bancali, Casa di Reclusione Tempio Pausania, Casa di Reclusione S. Soro Massama Oristano



- OC 24 15.00-15.07 Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens: a prospective study**
L. Boglione, S. Mornese Pinna, J. Cusato, A. De Nicolò, G. Cariti, A. D'Avolio, G. Di Perri
 Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
- OC 25 15.10-15.17 Successful DAA treatment of HCV in a complete clinical series with advanced fibrosis, including a high success rate of retreatment using HCV resistance guidance**
B. Rossetti^{1,2}, S. Mercinelli¹, A. Gonnelli¹, L. Toscano¹, D. Marri¹, P. Galluzzi¹, F. Pippi¹, N. Carnicelli¹, L. Migliorini¹, G. Zanelli^{1,3}, A. De Luca^{1,3}
¹Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ²Clinic of Infectious Diseases, Catholic University of Sacred Heart, Roma, Italy, ³Department of Medical Biotechnologies, University of Siena, Italy
- OC 26 15.20-15.27 Sustained virological response in HIV/HCV co-infected patients: long term impact on liver disease progression and renal performance**
D. Barbanotti¹, E. Messina^{1,2}, S. Salpietro¹, M.R. Parisi¹, L. Della Torre¹, G. Morsica¹, S. Bagaglio¹, C. Uberti Foppa^{1,2}, A. Lazzarin¹, H. Hasson¹
¹Dipartimento di Malattie Infettive, Ospedale San Raffaele, Milano, ²Università Vita-Salute San Raffaele, Milano
- OC 27 15.30-15.37 Renal function changes in HCV-infected patients with CKD during and after treatment with direct antiviral agents (DAAs)**
R. Dell'Acqua, G. De Vita, A. Procopio, G. Bruno, C. Fabrizio, L. Monno, M. Milella, A. Saracino, G. Angarano
 Clinic of Infectious Diseases, University of Bari
- OC 28 15.40-15.47 Effect of interferon free antiviral therapy on glomerular and tubular kidney involvement in HCV Child-A cirrhosis**
D. Palazzo¹, E. Biliotti¹, R. Esvan¹, F. Tinti², A. Bachetoni³, S. Grieco¹, A. Cappoli², M. Subic⁴, M.D. D'Alessandro³, R. Labriola³, P. Perinelli¹, I. Umbrò², L. Volpicelli¹, P. Rucci⁵, A.P. Mitterhofer², G. Taliani¹
¹Clinic of Infectious and Tropical Diseases; Sapienza University of Rome, ²Nephrology and Dialysis unit; Department of Clinical Medicine; Sapienza University of Rome, ³Laboratory of Clinical Pathology Department of General Surgery Paride Stefanini; Sapienza University of Rome, ⁴Department of Internal Medicine; Sapienza University of Rome, ⁵Department of Biomedical and Neuromotor Sciences; University of Bologna
- OC 29 15.50-15.57 Evolution of eGFR and proteinuria in HCV+ patients treated with DAA regimen containing ledipasvir with or without tenofovir disoproxil fumarate**
R. Gagliardini¹, C. Malcontenti^{2,3}, B. Rossetti², D. Marri², M. Fabbiani⁴, A. Soria⁴, A. Bandera⁴, D. Moschese¹, B. Valoriani^{2,3}, S. Di Giambenedetto¹, G. Lapadula⁴, A. De Luca^{2,3}, A. Gori⁴
¹Istituto di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, ²UOC Malattie Infettive, AOU Senese, Siena, ³Dipartimento di Biotechnologie Mediche, Università di Siena, ⁴San Gerardo Hospital, University of Milano-Bicocca, Division of Infectious Diseases, Department of Internal Medicine, Monza

SYMPOSIUM 16.15-17.55**New challenges in virus-associated lymphomas**

President: C. Viscoli (Genova)

Chairs: F. Castelli (Brescia), A. Cingolani (Roma), N. Coppola (Napoli)

HIV infection is associated with an increased risk of lymphomas, some of which are strongly correlated to the severity of the underlying immune-deficiency. Introduction of combined antiretroviral therapy has reduced the incidence of lymphoma among HIV infected individuals; however, due to the decrease of other causes of death, lymphoma has become one of the most frequent causes of death among persons with HIV. Also patients with chronic active HCV infection have an increased risk of lymphoma compared with HCV-negative population. Remarkably, clearance of HCV infection with antiviral therapy has been shown to lead to regression of the tumor burden in patients with HCV, supporting a causal relationship between HCV chronic antigenic stimulation and lymphomagenesis. Scope of this symposium is to review modern aspect of HIV- and HCV-associated lymphoma.

16.15-16.35	Epidemiology, clinical aspects and treatment of HIV-related lymphomas	Mark Bower (London, UK)
16.35-16.55	Management of HCV-related non-Hodgkin lymphomas in the era of DAAs	Luca Arcaini (Pavia)
16.55-17.15	The role of HIV and related immune dysregulation on lymphoma emergence and prognosis	Alessandra Bandera (Monza)
17.15-17.55	Discussion	

AUDITORIUM

ORAL COMMUNICATION 16.20-18.00

AULA 1

Complication of cART

Chairs: R. Cauda (Roma), C. Gervasoni (Milano), R. Maserati (Pavia)

16.20-16.35 **Frailty in aging with HIV infection**

Giovanni Guaraldi (Modena)

OC 30 16.35-16.42 Risk of low anti-Mullerian Hormone (AMH) in HIV-positive women on virologically-suppressive antiretroviral therapy

E. Merlini¹, V. Sacchi², E.S. Cannizzo¹, L. Gazzola¹, A. d'Arminio Monforte¹, M. Ravizza², G. Marchetti¹

¹Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, ²Clinic of Obstetrics and Gynecology, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan

OC 31 16.45-16.52 Prevalence and predictors of early menopause in a cohort of HIV-infected climacteric women: comparison with sero-negative patients and effects on BMD

A. D'Avino, A.P. Lassandro, L. Gargiulo, S. Lamonica, A. Borghetti, A. Pontecorvi, G. Baldin, E. Visconti, R. Cauda, S. Di Giambenedetto

Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome

OC 32 16.55-17.02 Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study

A. Antinori¹, S. Rusconi², N. Gianotti³, T. Bini⁴, G. Airoldi⁵, D. Mancusi⁶, R. Termini⁶

¹HIV/AIDS Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy, ²Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Italy, ³Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, ⁴Clinic of Infectious Diseases, ASST "Santi Paolo e Carlo" Hospital, Milan, Italy, ⁵Studio Associato Airoldi, Cicogna e Ghirri, Milan, Italy, ⁶Janssen-Cilag SpA, Medical Affairs Department, Infectious Diseases, Cologno Monzese (MI), Italy

OC 33 17.05-17.12 Clinical impact of HIV-1 coreceptor tropism: a sylogistic linkage with old (CD4/CD8 ratio) and new (VACS Index) tools

A. Leone¹, N. De Gennaro¹, L. Scudeller², L. Lepore¹, C. Fabrizio¹, A. Saracino¹, L. Monno¹, G. Angarano¹

¹Clinic of Infectious Diseases, Policlinico Bari, ²Clinical Epidemiology Unit, IRCCS San Matteo Foundation, Pavia

OC 34 17.15-17.22 Switching to dolutegravir-based regimens is beneficial in HIV positive patients experienced to cART

P. Nasta¹, M. Giralda¹, C. Pezzoli¹, F. Maggiolo³, E. De Filippo³, S. Digiambenedetto⁴, A. Gori⁵, A. Saracino⁶, B. Del Pin⁷, L. Sighinolfi⁸, F. Zacchi⁹, F. Castelnuovo¹⁰, N. Mazzini², G. Carosi² and the MASTER study group

¹University Division of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy, ²M.I.S.I. Foundation, ³Clinic of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy, ⁴Institute of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ⁵Clinic of Infectious Diseases, Ospedale S. Gerardo, Monza, Italy, ⁶Institute of Infectious Diseases Policlinico di Bari, Bari, Italy, ⁷Clinic of Infectious Diseases, S. M. Annunziata Hospital, Florence, Italy, ⁸Clinic of Infectious Diseases, S. Anna Hospital, Ferrara, Italy, ⁹Clinic of Infectious Diseases, Istituti Ospitalieri, Cremona, Italy, ¹⁰Clinic of Infectious Diseases, ASST Spedali Civili di Brescia, Brescia, Italy

OC 35 17.25-17.32 Lipid profile changed after switch to Dolutegravir+3TC/ABC in HIV-infected patients with undetectable HIV-RNA: results from the SCOLTA cohort

P. Bagella¹, G. Madeddu¹, E. Ricci², N. Squillace³, B. Menzaghi⁴, R. Gulminetti⁵, A. Di Biagio⁶, G. De Socio⁷, G. Orofino⁸, G. Pellicano⁹, C. Dentone¹⁰, B.M. Cesia¹¹, F. Vichi¹², P. Maggi¹³, S. Passerini², L. Valsecchi², G. Penco¹⁴, S. Rusconi¹⁵, L. Calza¹⁶, P. Bonfanti¹⁷ C.I.S.A.I. Group, Italy

¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Italy, ²Department of Infectious Diseases, ASST Fatebenefratelli-Sacco Milan, Italy, ³Infectious Diseases Unit, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, ⁴Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Italy, ⁵Department of Infectious Diseases, IRCCS Policlinico San Matteo Foundation University of Pavia, ⁶Unit of Infectious Diseases, IRCCS San Martino Hospital - IST, Genoa, Italy, ⁷Infectious Diseases Unit Department of Medicine, Azienda Ospedaliero-Universitaria di Perugia, Santa Maria Hospital, Perugia, Italy, ⁸Amedeo di Savoia Hospital Unit of Infectious Diseases Torino, Italy, ⁹Unit of Infectious Diseases, G. Martino Hospital, University of Messina, Italy, ¹⁰Unit of Infectious Diseases, Sanremo Hospital, Sanremo, Italy, ¹¹Unit of Infectious Diseases, Garibaldi Hospital Catania Italy, ¹²Infectious Diseases Unit, Santa Maria Annunziata Hospital Florence, Italy, ¹³Infectious Diseases Clinic, University of Bari, Italy, ¹⁴Infectious Diseases Unit, Galliera Hospital, Genoa, Italy, ¹⁵Infectious Diseases Unit, University of Milan, DIBIC Luigi Sacco, Milan, Italy, ¹⁶University of Bologna, Department of Infectious Diseases, S. Orsola Malpighi Hospital, Bologna Italy, ¹⁷Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy

OC 36 17.35-17.42 Efficacy and discontinuation rates of tenofovir/emtricitabine/elvitegravir/cobicistat in routine clinical practice: data from a multicenter cohort


M. Fabbiani¹, C. Resnati², G. Sterrantino³, S. Ferrara⁴, M. Colafigli⁵, L. Taramasso⁶, F. Di Sorà⁷, A. Bandera¹, A. Borghetti⁸, A. Gori¹, S. Di Giambenedetto⁸, A. De Luca⁸.

¹Clinica di Malattie Infettive, Ospedale San Gerardo, ASST Monza, Monza, Italy, ²Infectious Diseases Unit, L. Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy, ³Istituto di Malattie Infettive, Azienda Ospedaliera Careggi, Firenze, Italy, ⁴SC Malattie Infettive, Az. Ospedaliero-Universitaria OO.RR. Foggia, Foggia, Italy, ⁵Unità di Dermatologia Infettiva, Ospedale San Galliciano, Roma, Italy, ⁶Università degli studi di Genova, Clinica di malattie Infettive, IRCCS San Martino-IST, Genova, Italy, ⁷UOS Immunologia Clinica, AO San Giovanni Addolorato, Roma, Italy, ⁸Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ⁹Clinica di Malattie Infettive, Università degli Studi di Siena, Siena, Italy

OC 37 17.45-17.52 Effects of cobicistat on tenofovir tolerability: is it time to rethink at TAF trials?

C. Gervasoni¹, S. Baldelli², D. Minisci¹, C. Mazzali³, A. Giacomelli¹, L. Milazzo¹, P. Meraviglia¹, G. Rizzardini¹, E. Clementi², M. Galli¹, D. Cattaneo²

¹Department of Infectious Disease and ²Unit of Clinical Pharmacology, L. Sacco University Hospital, Milan, Italy, ³Department of Management, Economics and Industrial Engineering (DIG), Politecnico di Milano

**ORAL COMMUNICATION** 16.20-18.00**AULA 2****HIV & HCV: From education to care**

Chairs: M.G. Di Benedetto (Catania), M. Errico (Milano), M. Stagnitta (Firenze)

- OC 38** 16.20-16.27 **Educational and training initiatives increase participants' awareness about HIV**
L. Rancilio^{1,3}, *T. Lanzani*¹, *P. Farina*², *the AIDS network of Caritas Italiana*³
¹Caritas Ambrosiana, ²Università di Milano Bicocca, ³Caritas Italiana
- OC 39** 16.30-16.37 **Sexual health (SH), adherence to antiretroviral therapy, and virologic suppression: a descriptive study in HIV sero-discordant couples (Passion Study)**
C. Pinnetti, *S. Menichetti*, *A. Giannetti*, *M. Ricottini*, *P. Balestra*, *M.M. Plazzi*, *S. Ottou*, *R. Libertone*, *A. Antinori*, *A. Ammassari*
 National Institute for Infectious Diseases, IRCCS, L. Spallanzani, HIV/AIDS Department, Rome
- OC 40** 16.40-16.47 **A project of health education in schools: knowledge on HIV/AIDS of a sample of teenagers in Rome**
*G. Nedi*¹, *M. Farinella*², *R. Galipò*³, *S. Taglia*⁴
¹Specialista in Igiene e Medicina Preventiva, ²Circolo di cultura omosessuale "M.Mieli", ³Anlaid Lazio, Roma, ⁴Lila Lazio, Roma
- OC 41** 16.50-16.57 **Facilitators of treatment adherence with direct acting antivirals in HCV genotype 3 infected people who inject drugs: the key to success?**
*E. Ciraci*¹, *S. Semeraro*¹, *F. Camilli*², *G. Loverre*³, *C. Pennetta*⁴, *P. Gatti*¹
¹Internal Medicine Unit, Ostuni Hospital, ASL BR, ²Molecular Biology Unit, Perrino Hospital, ASL BR, ³Surgery Unit, Ostuni Hospital, ASL BR, ⁴Pharmacy Unit, Ostuni Hospital, ASL BR
- OC 42** 17.00-17.07 **Fear for HIV-stigma as a driver for invisibility within the MSM community in Italy: results from a national survey**
*R. Lelleri*¹, *G.M. Corbelli*^{2,3}, *S. Mattioli*², *M. Degli Esposti*²
¹Independent researcher, Bologna, ²Plus onlus, Bologna, ³European AIDS Treatment Group, Rome
- OC 43** 17.10-17.17 **Epidemiological evaluation of people tested for HIV in Perugia in 2015-2016: what can be done better?**
*C. Pallozzo*¹, *E. Albertini*², *G. Angeli*¹, *L. Ciaccarini*², *C. Gabrielli*¹, *P. Diana*², *R. Mauri*², *M.G. Gaggini*², *A. Patacca*¹, *F. Baldelli*¹, *C. Sfara*¹
¹Infectious Diseases Unit, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, ²Omphalos LGBTI, Perugia, Italy
- OC 44** 17.20-17.27 **Predictors of retention in care in HIV-infected patients: data from San Martino hospital cohort in Genoa**
R. Prinapori^{1,2}, *B. Giannini*³, *N. Riccardi*², *F. Bovis*⁴, *M. Giacomini*³, *C. Viscoli*², *S. Artioli*¹, *A. Di Biagio*²
¹Infectious Diseases and Hepatology Unit Sant'Andrea Hospital La Spezia, ²Infectious Diseases Clinic, University of Genoa (DISSAL) AOU IRCCS San Martino-IST, Genova, ³Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS); University of Genoa, Genoa, Italy, ⁴Department of Biostatistics, University of Genoa, Genoa, Italy
- OC 45** 17.30-17.37 **HIV positive people not-retained in care in Piedmont: an evaluation of data from the regional surveillance**
*L. Camoni*¹, *P. Pezzotti*¹, *C. Paqualini*², *C. Alcantarini*³, *O. Bargiacchi*¹⁰, *M. Busso*³, *M. Desaraca*⁷, *M. Farenga*³, *C. Gabiano*⁴, *M. Gobber*¹², *G. Leo*³, *E. Mantia*⁵, *G.C. Orofino*³, *F. Poletti*¹¹, *G. Schettino*⁸, *C. Tettoni*³, *L. Trentini*³, *M. Valle*⁶, *D. Vitullo*⁹, *M. Zoppi*⁵
¹Istituto Superiore di Sanità, ²SEREMI, Alessandria, ³Malattie Infettive - Ospedale Amedeo di Savoia di Torino - ASL Città di Torino, ⁴Centro di riferimento per l'infezione da HIV in età pediatrica del Piemonte e Valle d'Aosta - AOU Città della Salute e della Scienza di Torino, ⁵Malattie Infettive-Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria, ⁶Malattie Infettive - Ospedale Cardinal Massaia - ASL AT, ⁷Malattie Infettive - Nuovo Ospedale degli Infermi - ASL BI, ⁸Malattie Infettive - Ospedale Santo Spirito di Casale Monferrato - ASL AL, ⁹Malattie Infettive - Azienda Ospedaliera S. Croce e Carle di Cuneo, ¹⁰Malattie Infettive- AOU Maggiore della Carità di Novara, ¹¹Malattie Infettive - Ospedale Castelli - ASL VCO, ¹²Malattie Infettive - Ospedale S. Andrea - ASL VC
- OC 46** 17.40-17.47 **Villa Maraini Foundation's HIV/HCV Continuum of Care Model Among Hard to Reach Drug Addicts and Sex Workers in Rome: the Need for Targeted Interventions**
*E. Teti*², *E. Rossi*¹, *D. Masci*¹, *P. Sammarco*¹, *R. Sista*¹, *S. Capasso*¹, *B. Coladarce*¹, *G. Rodoquino*¹, *M. Patti*¹, *M. Andreoni*², *M. Barra*¹
¹Villa Maraini Foundation ONLUS, Rome, Italy, ²Clinical Infectious Diseases, Tor Vergata University, Rome, Italy

KEYNOTE LECTURE 08.30-09.00

Chairs: A. Castagna (Milano), M. Galli (Milano)

AUDITORIUM

08.30-09.00 **What an ID doctor should know to prevent CV events in HIV infected patients?**

Priscilla Hsue (San Francisco, USA)

SYMPOSIUM 09.00-10.25

HIV cure: State of art

President: C.F. Perno (Roma)

Chairs: G. Angarano (Bari), M.R. Capobianchi (Roma), G. Palù (Padova)

Back in 2011, the "Berlin patient" opened a new field of possibility for curing HIV infection. Now, some years later, a certain number of patho-physiological mechanisms have been elucidated in order to direct therapeutic weapons more carefully. In parallel, multiple strategies have been started combining antivirals, immunological therapies and vaccines. A discrete sum of evidences is still being accumulated, with the help of precise and intense studies in animals.

09.00-09.15 **Animal models in discovering the way to HIV cure**

Guido Silvestri (Atlanta, USA)

09.15-09.30 **Myeloid cells as active reservoir of HIV**

Guido Poli (Milano)

09.30-09.45 **How the immune system can be elicited to prevent and cure HIV/AIDS**

Mario Clerici (Milano)

09.45-10.00 **Advances in therapies leading to HIV eradication**

Francesco R. Simonetti (Milano)

10.00-10.25 **Discussion**

ORAL COMMUNICATION 09.05-10.30

Clinical Hepatitis II

Chairs: G. D'Offizi (Roma), G. Rizzardini (Milano), C. Torti (Catanzaro)

AULA 1

09.05-09.20 **Cost-effectiveness of eradication models in HCV and HIV-HCV**

Yazdan Yazdanpanah (Paris, F)


OC 47 09.20-09.27 Specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlate with high viremia and hamper HBsAg detection and quantification

R. Salpini¹, L. Piermatteo¹, D. Di Carlo¹, A. Battisti¹, L. Colagrossi¹, A. Bertoli¹, L. Fabeni², V. Fini¹, A. Iuvara³, A. Ricciardi⁴, C. Cerva⁴, C. Sarrecchia⁴, M. Lichtner⁵, C. Mastroianni⁵, G. De Sanctis⁶, M. Paoloni⁷, M. Marignani⁸, C. Pasquazzi⁸, N. Iapadre⁹, T. Mari¹⁰, G. Parruti¹¹, S. Romano¹², M. Visca¹², A. Moretti¹³, I. Vecchiet¹⁴, L. Sarmati⁴, M. Andreoni⁴, G. Cappiello¹², A. Spanò¹², S. Grelli^{1,3}, M. Angelico¹⁵, C.F. Perno¹, V. Svircher¹

¹Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy, ²National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ³Tor Vergata University Hospital, Microbiology and Virology Unit, Rome, Italy, ⁴Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, ⁵"Sapienza" University, Department of Public Health and Infectious Disease, Rome, Italy, ⁶"Umberto I" University Hospital, Rome, Italy, ⁷"S.S. Filippo e Nicola" Hospital, Infectious Disease Unit, Avezzano, Italy, ⁸"S. Andrea Hospital", Department of Gastroenterology, Rome, Italy, ⁹San Salvatore Hospital", L'Aquila, Italy, ¹⁰"Nuovo Regina Margherita" Hospital, Rome, Italy, ¹¹Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ¹²Microbiology and Virology Unit, "S. Pertini" Hospital, Rome, Italy, ¹³Gastroenterology Unit, "San Filippo Nevi" Hospital, Rome, Italy, ¹⁴Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy, ¹⁵Tor Vergata University Hospital, Hepatology Unit, Rome, Italy

OC 48 09.30-09.37 Extended duration of treatment with pegylated interferon alfa-2a in patients with active chronic hepatitis B, HBeAg-negative and E genotype: a retrospective analysis

L. Boglione, S. Mornese Pinna, J. Cusato, G. Cariti, A. D'Avolio, G. Di Perri
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy



OC 49 09.40-09.47 The degree of genetic variability in HBsAg C-terminus profoundly influence HBsAg levels in HBeAg-negative chronic HBV genotype D infection

R. Salpini¹, A. Battisti¹, L. Carioti¹, D. Di Carlo¹, O. Anastasiou², U.S. Gill³, L. Colagrossi¹, A. Bertoli¹, L. Fabeni¹, V. Fini¹, L. Piermatteo¹, A. Iuvare⁴, V. Malagnino⁵, C. Cerva⁵, M. Lichtner⁶, C. Mastroianni⁶, G. De Sanctis⁷, M. Paoloni⁸, M. Marignani⁹, C. Pasquazzi⁹, N. Iapadre¹⁰, T. Mari¹¹, G. Parruti¹², I. Vecchie¹³, L. Sarmati¹³, M. Andreoni¹³, M. Angelico¹⁴, S. Grelli¹⁴, P.T.F. Kennedy³, J. Verheyen³, C.F. Perno¹, V. Svicher¹
¹Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy, ²Institute of Virology, University-Hospital, University Duisburg-Essen, Essen, Germany, ³Hepatology, Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine & Dentistry, QMUL, London, UK, ⁴Tor Vergata University Hospital, Microbiology and Virology Unit, Rome, Italy, ⁵Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, ⁶"Sapienza" University, Department of Public Health and Infectious Disease, Rome, Italy, ⁷"Umberto I" University Hospital, Rome, Italy, ⁸"S.S. Filippo e Nicola" Hospital, Infectious Disease Unit, Avezzano, Italy, ⁹"S.Andrea Hospital", Department of Gastroenterology, Rome, Italy, ¹⁰"San Salvatore Hospital", L'Aquila, Italy, ¹¹"Nuovo Regina Margherita" Hospital, Rome, Italy, ¹²Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ¹³Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy, ¹⁴Tor Vergata University Hospital, Hepatology Unit, Rome, Italy

OC 50 09.50-09.57 Peripheral and intrahepatic virological characterization in HBeAg negative Chronic Hepatitis B to evaluate risk of disease progression and HCC in the "grey-zone" viral load cohort

R. Salpini¹, L. Colagrossi¹, A. Battisti¹, D. Di Carlo¹, N. Hansi², C.F. Perno¹, U.S. Gill², P.T.F. Kennedy², V. Svicher¹
¹Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy, ²Hepatology, Centre for Immunobiology, Blizard Institute, Barts and The London SMD, QMUL, London, United Kingdom

OC 51 10.00-10.07 Clinical usefulness of accurate HCV genotype and subtype assignment by HCV sequencing in more genomic regions in the era of new direct acting antiviral agents

M. Aragri¹, V.C. Di Maio¹, C. Pillinini¹, M.C. Bellocchi¹, L. Carioti¹, E. Teti², C. Masetti³, F. Antenucci³, L. Gianserra⁴, A. Pieri⁵, V. Pace Palitti⁶, S. Barbaliscia¹, A. Bertoli¹, K. Yu La Rosa¹, R. Campoli¹, I. Lenci³, S. Francioso³, P. Cacciatore⁵, E. Polilli⁵, S. Landonio⁷, M. Melis⁸, M. Paoloni⁹, V. Micheli¹⁰, L.A. Nicolini¹¹, S. Marengo¹², L. Lambiase⁴, M. Milana³, I. Maida⁸, L. Sarmati², A. Pellicelli¹³, L. Nosotti¹⁴, E. Biliotti¹⁵, M. Marignani¹⁶, F. Sozio⁵, C. Minichini¹⁷, D. Romagnoli¹⁸, B. Bruzzone¹⁹, M. Siciliano²⁰, G. D'Ettore²¹, M. Lichtner²², C. Sarrecchia², A. Grieco²³, F. Morisco²⁴, C. Mastroianni²², J. Vecchie²⁵, M. Puoti²⁶, N. Caporaso²⁴, S. Bruno²⁷, A. Craxi²⁸, P. Tarquini²⁹, C. Magni⁷, S. Babudieri⁸, G. Taliani¹⁵, V. Vullo²¹, A. Picciotto¹², C. Pasquazzi⁴, G. Parruti⁵, M. Angelico³, M. Andreoni², V. Cento¹, C.F. Perno¹, F. Ceccherini-Silberstein¹

¹Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, ²Infectious Disease, University Hospital of Rome Tor Vergata, Rome, Italy, ³Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ⁴Infectious Diseases, Sant'Andrea Hospital - "La Sapienza" University, Rome, Italy, ⁵Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ⁶Hepatology Unit, Pescara General Hospital, Pescara, Italy, ⁷Division of Infectious Disease, Hospital Sacco of Milan, Milan, Italy, ⁸Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Italy, ⁹Infectious Disease Unit, Avezzano General Hospital, Avezzano, Italy, ¹⁰Unit of Microbiology, Hospital Sacco of Milan, Milan, Italy, ¹¹Infectious Diseases, AOU IRCCS San Martino-IST, Genova, Italy, ¹²Hepatology Unit, AOU IRCCS San Martino-IST, Genova, Italy, ¹³Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, ¹⁴Hepatology Unit, National Institute of Health, Migration and Poverty, Rome, Italy, ¹⁵Infectious and Tropical Diseases Unit, Department of Clinical Medicine, "La Sapienza" University, Rome, Italy, ¹⁶Gastroenterology and Hepatology, AO S.Andrea "La Sapienza" University, Rome, Italy, ¹⁷Infectious Diseases and Viral Hepatitis Unit, Second University of Naples, Naples, Italy, ¹⁸Department of Biomedical, Metabolic and Neural Sciences, NOCSAE Baggiovara, Italy, ¹⁹Hygiene Unit, AOU IRCCS San Martino-IST, Genova, Italy, ²⁰Gastroenterology, Catholic University of Rome, Rome, Italy, ²¹Infectious Diseases, "La Sapienza" University, Rome, Italy, ²²Infectious Diseases, "La Sapienza" University, Latina, Italy, ²³Liver Transplant Unit, Catholic University of Rome, Rome, Italy, ²⁴Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Naples, Italy, ²⁵Infectious Disease Clinic, Hospital Ss. Annunziata, Chieti, Italy, ²⁶Hospital Niguarda Ca'Granda, Milan, Italy, ²⁷Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy, ²⁸Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, ²⁹Infectious Disease, Hospital of Teramo, Teramo, Italy

OC 52 10.10-10.17 Meaning and correlates of detectable HCV residual viremia in HIV/HCV coinfecting and HCV monoinfected patients

I. Mastroiosa¹, U. Visco Comandini¹, P. Lorenzini¹, G. Fabbri¹, A.R. Garbuglia², M.R. Capobianchi², G. D'Offizi¹, R. Lionetti¹, F. Lupi¹, A. Giannetti¹, A. Ammassari¹, A. Antinori¹, M. Zaccarelli¹

¹Clinical Department and ²Laboratory of Virology, National Institute for Infectious Diseases, IRCCS, L. Spallanzani, Rome

OC 53 10.20-10.27 NS5A-resistance may reduce NS5A-based retreatment efficacy after DAA-failure: a real-life experience

V. Cento¹, V.C. Di Maio¹, S. Barbaliscia¹, C. Masetti², C. Minichini³, B. Rossetti⁴, S. Marengo⁵, Y. Troshina⁶, C. Baiguera⁷, M. Zazz⁸, C. Dentone⁹, S. Landonio¹⁰, L.A. Nicolini¹¹, C. Cauda⁸, M. Melis¹², M. Schiavini¹⁰, B. Bruzzone¹³, V. Calvaruso¹⁴, V. Micheli¹⁵, S. Paolucci¹⁶, M. Aragri¹, A. Bertoli¹, I. Lenci³, T. Ruggiero¹⁷, V. Messina¹⁸, L. Boglione¹⁹, A.R. Buonomo²⁰, R. Cozzolongo²¹, F. Morisco²², G. Barbarini²³, A. Craxi¹⁴, S. Babudieri¹², M. Puoti⁷, A. Ciancio⁶, G. Rizzardini¹⁰, A. De Luca⁴, N. Coppola³, M. Angelico², C.F. Perno¹, and F. Ceccherini-Silberstein¹, on behalf of HCV Virology Italian Resistance Network (VIRONET-C)

¹Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, ²Hepatology Unit, Policlinic Foundation of Rome Tor Vergata, Rome, Italy, ³Infectious Diseases, Department of Mental and Physical Health and Preventive Medicine, Second University of Naples, Naples, Italy, ⁴Infectious Diseases, Siena University Hospital, Siena, Italy, ⁵Division of Hepatology, University of Genoa-AOU IRCCS San Martino-IST, Genova, Italy, ⁶Gastroepatology, Department of Medical Sciences, City of Health and Science of Turin, University of Turin, Turin, Italy, ⁷Infectious Diseases, Hospital Niguarda Ca'Granda, Milan, Italy, ⁸Virology, Siena University Hospital, Siena, Italy, ⁹Infectious Diseases, Sanremo Hospital, Italy, ¹⁰1st Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan Italy, ¹¹Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa-AOU IRCCS San Martino-IST, Genova, Italy, ¹²Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Italy, ¹³Hygiene Unit, University of Genoa-AOU IRCCS San Martino-IST, Genova, Italy, ¹⁴Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, ¹⁵Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, Milan Italy, ¹⁶Molecular Virology, Policlinic Foundation San Matteo, Pavia, Italy, ¹⁷Infectious Diseases, "Amedeo di Savoia" Hospital, Turin, Italy, ¹⁸Infectious Diseases Unit, A.O. S. Anna e S. Sebastiano, Caserta, ¹⁹Unit of Infectious Diseases, University of Turin, Turin, Italy, ²⁰Infectious Diseases, University «Federico II», Naples, Italy, ²¹Department of Gastroenterology, Scientific Institute for Digestive Disease "Saverio de Bellis" Hospital, Castellana Grotte, Bari, Italy, ²²Gastroenterology, University «Federico II», Naples, Italy, ²³Division of Infectious and Tropical Diseases, Policlinic Foundation San Matteo, Pavia, Italy

ORAL COMMUNICATIONS 09.05-10.30

AULA 2

HIV Epidemiology and Prevention

Chairs: S. Babudieri (Sassari), P. Pezzotti (Roma), G. Rezza (Roma)

OC 54 09.05-09.12 Dynamics of HIV-1 Transmission Clusters In Newly Diagnosed Individuals Between 2004-2016 In Italy

L. Fabeni¹, C. Alteri², G. Berno¹, R. Scutari², D. Di Carlo², C. Gori¹, A. Bertoli², S. Carta¹, N. Orchi¹, S. Cicalini¹, C. Pinnetti¹, L. Mazzuti³, O. Turriziani³, A. Latini⁴, V. Borghi⁵, F. Montella⁶, A. Pennica⁷, C.M. Mastroianni⁸, C. Mussini⁵, M. Colafigli⁴, E. Girardi¹, M. Andreoni⁹, A. Antinori¹, F. Ceccherini-Silberstein², C.F. Perno¹, M.M. Santoro²

¹National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy, ²University of Rome Tor Vergata, Rome, Italy, ³Sapienza University, Rome, Italy, ⁴San Gallicano-IRCCS, Rome, Italy, ⁵Modena University Hospital, Modena, Italy, ⁶S. Giovanni Addolorata Hospital, Rome, Italy, ⁷S. Andrea Hospital, Sapienza University of Rome, Rome, Italy, ⁸Sapienza University, Polo Pontino, Latina, Italy, ⁹University Hospital Tor Vergata, Rome, Italy

OC 55 09.15-09.22 Evolution of transmitted HIV-1 drug resistance in Italy from 2006 to 2016

B. Rossetti^{1,2}, S. Di Giambenedetto², C. Torti³, M.C. Postorino³, G. Punzi⁴, F. Saladini⁵, W. Gennari⁶, V. Borghi⁷, L. Monno⁸, A.R. Pignataro⁹, E. Polilli¹⁰, M. Colafigli², A. Poggi¹¹, S. Tini¹², M. Zazzi⁵, A. De Luca^{1,5}

¹Infectious Diseases Unit, AOU Senese, Siena Italy, ²Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ³Infectious Diseases Unit, Catanzaro, Italy, ⁴Virology, Bari Hospital, Bari, Italy, ⁵Biotechnologies Department, Siena University, Siena, Italy, ⁶Virology, Modena Hospital, Modena, Italy, ⁷Infectious Diseases Unit, Modena Hospital, Modena, Italy, ⁸Infectious Diseases Unit, Bari Hospital, Bari, Italy, ⁹Humanitas San Raffaele, Milano, Italy, ¹⁰Virology, Pescara Hospital, Pescara, Italy, ¹¹Infectious Diseases Unit, S. Maria Annunziata Hospital, Firenze, Italy, ¹²Medicine Department, Città di Castello, Italy

OC 56 09.25-09.32 A multi-dimensional evaluation of PrEP adoption: the Italian perspective

L. Ferrario¹, E. Foglia¹, E. Garagiola¹, G. Cenderello², A. Di Biagio³, G. Rizzardini^{4,5}, M. Errico⁶, R. Iardino⁷, D. Croce^{1,8} on behalf of the PREPA-RAHTHI Study

¹Centre for Research on Health Economics, Social and Health Care Management, LIUC-Università Cattaneo, Castellanza, Italy, ²Galliera Hospital, Department of Infectious Diseases, Genova, Italy, ³IRCCS San Martino IST Hospital, Unit of Infectious Diseases, Genova, Italy, ⁴Fatebenefratelli Sacco Hospital, Department of Infectious Diseases, Milan, Italy, ⁵School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa, ⁶President of the NPS - Network Persone Sieropositive, Italy, ⁷President of the Bridge Foundation, Milan, Italy, ⁸School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

OC 57 09.35-09.42 Pre-exposure prophylaxis knowledge and attitudes among sexually active men who have sex with men in Italy - Italian results of "Flash! PrEP in Europe", an European community-based study

M.L. Cosmaro¹, M. Oldrini¹, G.M. Corbelli², A. Bernier³, R. Stranz⁴, V. Schlegel⁴, R. Delabre⁴, K. Jonas⁵

¹Fondazione ILLA Milano, ²Plus Onlus, Bologna, ³Coalition Internationale Sida, France, ⁴AIDES, France, ⁵Maastricht University, Netherlands

OC 58 09.45-09.52 "Let's do it Fast": an outreach program of HIV rapid testing for general population in Rome by Anlaids Lazio and INMI Spallanzani

R. Galipò¹, P. Narciso¹, P. Ferri¹, G.V. Calvino³, A. Navarra², N. Orchi²

¹Anlaids Lazio Onlus, ²Infectious Disease Epidemiology Unit - AIDS Reference Centre, National Institute for Infectious Disease "L. Spallanzani" - IRCCS, ³Anlaids Onlus

OC 59 09.55-10.02 Adverse effects and associated treatment discontinuation of antiretroviral regimens used in HIV Post-Exposure Prophylaxis

G. De Carli¹, E. Schifano¹, A. Agresta¹, L. Signorini², F. Niero³, A. Franco⁴, V. Puro¹, the IRAPEP Collaborative Group

¹Centro di Riferimento AIDS, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, ²AO Spedali Riuniti, Brescia, Italy, ³AO L. Sacco, Milan, Italy, ⁴AORN Ospedali dei Colli, Naples, Italy

OC 60 10.05-10.12 Gender differences in HCV exposure, active replication and genotypes in HIV patients entering care in Italy


B. Rossetti^{1,2}, P. Lorenzini³, A. Cingolani², A. Tavelli⁴, M. Puoti⁵, G. Cassola⁶, G. Angarano⁷, G. Taliani⁸, E. Girardi⁹, A. Antinori³, A. d'Arminio Monforte¹⁰, A. De Luca^{1,11}

¹Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ²Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ³Infectious Diseases Department, INMI "Lazzaro Spallanzani", Rome, Italy, ⁴ICONA Foundation, Milan, Italy, ⁵Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ⁶Infectious Diseases, Ente Ospedaliero Ospedali Galliera, Genoa, Italy, ⁷Clinic of Infectious Diseases, University of Bari, Italy, ⁸Infectious and Tropical Diseases Unit, Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy, ⁹Epidemiology Department, INMI "Lazzaro Spallanzani", Rome, Italy, ¹⁰ASST Santi Paolo e Carlo, University of Milan, Clinic of Infectious and Tropical Diseases, Department of Health Sciences, Milan, Italy, ¹¹Department of Medical Biotechnologies, University of Siena, Italy

OC 61 10.15-10.22 HCV and HCV/HIV coinfecting patients known to Tuscan Regional Health Service in 2016

C. Stasi^{1,2}, M. Puglia¹, S. Bartolacci¹, F. Voller¹, C. Silvestri¹

¹Observatory of Epidemiology, Regional Health Agency of Tuscany - Florence, Italy, ²Department of Experimental and Clinical Medicine, University of Florence - Florence, Italy

**SYMPOSIUM ICAR-SIMIT-AISF** 10.30-11.50**AUDITORIUM****HCV: new waves, new horizons?**

Chairs: A. Craxi (Palermo), T. Santantonio (Foggia), G. Taliani (Roma)

In the last years, the treatment of patients with chronic HCV infection has undergone remarkable evolution at different waves with the introduction of direct acting antiviral drugs (DAAs), first combined with interferon and ribavirin, and then in all-oral therapy with the use of ribavirin, to date in many cases in ribavirin-free treatments. The aim of this symposium is the meeting among specialists to provide a scientific update, reflections on specific HCV cases and tools for evaluating those aspects that today have the greatest criticisms in managing patients with chronic hepatitis C. We will talk about virological DAA-failures and their management, as well as the linkages of the virus with hepatocellular carcinoma, and therefore the role of DAAs in the clinical management of patients with (or at risk) of developing hepatocellular carcinoma, the meaning of healing a person from the virus over the liver disease, and finally the relationship between clinical and social aspects and the value of therapeutic HCV clearance in the single patient.

10.30-10.45	Virological and clinical network for the management of DAA failures in Italy	Francesca Ceccherini-Silberstein (Roma)
10.45-11.00	HCV and HCC: the role of DAA in clinical management	Erica Villa (Modena)
11.00-11.15	HCV beyond the liver	Giovanni Battista Gaeta (Napoli)
11.15-11.30	What is the value of therapeutic HCV clearance in the individual patient?	Gloria Taliani (Roma)
11.30-11.50	Discussion	

ORAL COMMUNICATIONS 10.35-11.55**AULA 1****Comorbidities**

Chairs: P. Cinque (Milano), C.M. Mastroianni (Latina)

10.35 - 10.50	CSF biomarkers for research and clinical purpose in HIV	Magnus Gisslén (Göteborg, S)
---------------	--	------------------------------

OC 62 10.50-10.57 **24 months follow-up of PROJECT STOP Smoking in HIV patients (STOPS HIV)**

G.V. De Socio¹, C. Gabrielli¹, S. Cardaci¹, G. Angeli¹, E. Schiaroli¹, M.B. Pasticci¹, D. Francisci¹, M. Dell'Omo², F. Baldelli¹

¹Clinica delle Malattie infettive e ²Centro anti fumo di Medicina del Lavoro, Azienda Ospedaliero-Universitaria di Perugia

OC 63 11.00-11.07 **Predicted HIV-1 tropism on plasma and cerebrospinal fluid is associated with neurocognitive disorders**

L. Motta¹, E. Scarvaglieri¹, T. Alice², D. Vai³, M. Trunfio¹, A. Palazzo¹, D. Imperiale³, V. Pirriatore¹, V. Ghisetti², S. Bonora¹, G. Di Perri¹, A. Calcagno¹

¹Unit of Infectious Diseases, Department of Medical Sciences, University of Study of Torino, Torino, Italy, ²Laboratory of Microbiology and Molecular Biology, Ospedale Amedeo di Savoia, Torino, Italy, ³Unit of Neurology, Ospedale Maria Vittoria, Torino, Italy

OC 64 11.10-11.17 **Dolutegravir trough concentration and neuropsychiatric symptoms in a cohort of HIV-infected patients on stable antiretroviral therapy**

A. Borghetti¹, S. Belmonti¹, M. Colafigli², F. Lombardi¹, A. Brita¹, De Nicolò³, R. De Marco¹, A. D'Avolio³, N. Ciccarelli¹, A. Ariaudo³, E. Visconti¹, A. Latini², A. Cingolani¹, E. Tamburrini¹, S. Bonora³, A. De Luca⁴, S. Di Giambenedetto¹

¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ²Infectious Dermatology, IFO S. Galliciano, Rome, Italy, ³Unit of Infectious Diseases, Department of Infectious Diseases, University of Torino, ⁴Infectious Diseases Unit, Siena University Hospital, Siena

OC 65 11.20-11.27 **HIV, complications and comorbidities: economic evidence from the field**

D. Croce^{1,2}, E. Garagiola¹, E. Foglia¹, L. Ferrario¹, P. Meraviglia³, T. Quirino⁴, B. Menzaghi⁴, C. Atzori³, G. Rizzardini^{3,5}

¹Centre for Research on Health Economics, Social and Health Care Management, LIUC—Università Cattaneo, Castellanza, Italy, ²School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³Fatebenefratelli Sacco Hospital, Milan, Italy, ⁴Valle Olona Hospital, Busto Arsizio, Italy, ⁵School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg

OC 66 11.30-11.37 **Hyperbilirubinemia is associated with a decreased risk of carotid atherosclerosis in HIV-infected patients with virological suppression**

C. Muccini^{1,2}, A. Carbone¹, L. Galli¹, A. Poli¹, M. Maillard¹, M. Cernuschi¹, V. Spagnuolo², A. Bigoloni¹, M. Guffanti¹, N. Gianotti¹, A. Lazzarin^{1,2}, A. Castagna^{1,2}

¹Infectious Diseases, IRCCS San Raffaele, Milano, Milano, Italy, ²Università Vita-Salute San Raffaele, Milano, Milano, Italy

OC 67 11.40-11.47 **How many and which HIV patients with fatty liver are at risk of progressive liver disease?**

M. Menozzi¹, A. Malagoli¹, A. Santoro¹, F. Nascimbeni², V. Borghi¹, S. Zona¹, F. Schepis³, A. Lonardo¹, C. Mussini¹, G. Guaraldi¹

¹Malattie Infettive, Università degli studi di Modena e Reggio Emilia, ²Medicina Metabolica, Università degli studi di Modena e Reggio Emilia, ³Gastroenterologia, Università degli studi di Modena e Reggio Emilia

ORAL COMMUNICATIONS 10.35-11.55

AULA 2

HIV: Walking along the continuum of care

Chairs: M. Farinella (Roma), M. Oldrini (Como), F. von Schloesser (Roma)

OC 68 10.35-10.42 **Anlaids Lazio inside chat lines: prevention and counseling through mobile apps**

R. Galipò, J. Doria Pamphilj, P. Ferri, P. Narciso, A. Palummieri, M. Ghenzer
Anlaids Lazio

OC 69 10.45-10.52 **HIV self-testing in Italy**

S. Pittalis¹, N. Orchi², G. De Carlis², A. Navarra¹, V. Puro², E. Girardi¹

¹Clinical Epidemiology Unit, National Institute for Infectious Disease "L. Spallanzani" - IRCCS, ²Infectious Disease Epidemiology Unit - AIDS Reference Centre, National Institute for Infectious Disease "L. Spallanzani" - IRCCS, Rome

OC 70 10.55-11.02 **Testing MSM in cruising venues**

D. Zagato¹, D. Deserti², S. Aliverti², A. Bianchi¹, L. Colombo², A. Costa², F.M. Esposito¹, M. Lanza¹, P. Liebenberg², S. Loli¹, M. Maggi², F. Malasoma², M. Manfredini¹, G. Mones², R. Muzzetta², V. Nicotera¹, A. Pezzotti¹, M. Pierini¹, M. Pivi², F. Raffaele², F. Rossi¹, R. Sanvito², F. Seghi², M. Scarzella¹, M. Vismara², L. Zingarelli², M. Zoia¹, M. Cernuschi¹

¹Istituto ASA - Associazione Solidarietà AIDS, ²Istituto CIG Arcigay Milano

OC 71 11.05-11.12 **Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for HIV infected people**

A. Saracino¹, M. Zaccarelli², P. Lorenzini², A. Bandera³, G. Marchetti⁴, F. Castelli⁵, A. Gori³, E. Girardi⁶, C. Mussini⁷, P. Bonfanti⁸, A. Ammassari², A. d'Arminio Monforte⁴, for the Icona Foundation Study Group

¹Clinic of Infectious Diseases, University of Bari, Italy, ²Clinical Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy, ³Clinic of Infectious Diseases, 'San Gerardo' Hospital - University of Milano-Bicocca, Monza, Italy, ⁴Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy, ⁵University Division of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy, ⁶Department of Epidemiology, National Institute for Infectious Diseases "L. Spallanzani," IRCCS, Rome, Italy, ⁷Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, ⁸Unit of Infectious Diseases, ASST Lecco, "A. Manzoni" Hospital, Lecco, Italy

OC 72 11.15-11.22 **Perceptions of barriers for optimal Retention in Care in people with HIV: a national survey**

P. Piselli¹, G. Chiaradia¹, M. Breviglieri², A. Camposeragna³, M. Errico⁴, C. Falanga⁵, M. Farinella⁶, G. Gaiera⁷, S. Marcotullio⁸, M. Oldrini⁹, L. Rancilio¹⁰, M. Stagnitta³, C. Cimaglia¹, P. Scognamiglio¹, G. Ippolito¹, E. Girardi¹

¹Istituto Nazionale Malattie Infettive "L. Spallanzani", IRCCS, Roma, ²Arcigay, ³CNCA, ⁴NPS, ⁵ANLAIDS, ⁶Circolo Mario Mieli, ⁷CICA, ⁸NADIR, ⁹Lila, ¹⁰Caritas

OC 73 11.25-11.32 **Social media and people with HIV: work in progress. Results from an Italian survey**

A. Donti¹, M. Boni¹, M.M. Daglio¹, A.P. Cavazzuti¹, G. Fattori²

¹Marketing Sociale Onlus, ²Social Marketing, Compass, University of Bologna

OC 74 11.35-11.42 **Causes of switch of antiretroviral treatment in a cohort of HIV+ subjects. Analysis of ten years registered trends (2007-2016)**

B.M. Celesia, G.E. Recchia, M. Gussio, M. Maresca, M.E. Locatelli, R. Fontana del Vecchio, G. Lupo, R. Bruno, L. Vinci, C. Coco, S. Piacenti, L. La Ferla, B. Cacopardo

Unit of Infectious Diseases, University of Catania. ARNAS Garibaldi Catania

SATELLITE SYMPOSIUM 12.00-12.45

AUDITORIUM

Unrestricted educational grant of Bristol-Myers Squibb

HCV and Post-Hoc in real life experience in Italy

Chairs: M. Brunetto (Pisa), G.B. Gaeta (Napoli)

The availability of highly effective and well-tolerated DAAs has changed the approach to treating chronic HCV infection (CHC). Data from real life reflect and in some cases exceed those reported in the pivotal trials and today we are able to cure infection and halt liver disease progression reducing both liver-related and overall mortality. Moreover data accumulated in the last few years from real life were useful to improve patient's outcomes in terms of efficacy and safety. The Symposium will focus on the Italian experience with DAAs in real life practice and on open issues in treatment optimization of antiviral therapy in specific settings of CHC patients.


12.00-12.15 **Can we do better than phase 3 trials in real life practice? Lessons from genotype 2 and 3**

Antonio Craxi (Palermo)

12.15-12.30 **Retreatment optimization and baseline features influencing HCV treatment choice**

Francesca Ceccherini-Silberstein (Roma)

12.30-12.45 **Discussion**

**SATELLITE SYMPOSIUM** 12.00-12.45**AULA 1**

Unrestricted educational grant of Janssen

PIs consolidated experience from the randomized studies to real world evidence

Chair: A. Antinori (Roma)

PIs are an antiretroviral class whose efficacy is well known due to randomized studies and real world experience. Nowadays the challenge is to offer new therapeutic options to confirm the effectiveness and improving at the same time the patients quality of life. The new booster responds to these challenges and meeting patient needs through flexibility and versatility providing more personalized combinations.

- | | | |
|-------------|--|---------------------------|
| 12.00-12.15 | Darunavir/Cobicistat: the first results from the European real world experience | Andrea Gori (Monza) |
| 12.15-12.30 | What kind of future for new therapeutic options? | Adriano Lazzarin (Milano) |
| 12.30-12.45 | Discussion | |

SATELLITE SYMPOSIUM 13.00-13.45**AUDITORIUM**

Unrestricted educational grant of Gilead Sciences

Sofosbuvir-based STRs: the answer to HCV infection

Chair: M. Andreoni (Roma)

Thanks to an extraordinary progress in the development of antiviral drugs for oral use that has created conditions for simple, short, highly effective and highly tolerable therapies, the Scientific Community has now the possibility to modify the natural history of the HCV-related disease. Concomitant administration of direct antiviral agents with different mechanism of action, could increase effectiveness in clinical practice. The appropriate selection of anti-HCV treatment is meaningful to achieve clinical responses. For this reason, clinicians need to be informed about distinctive patterns of therapeutic options with particular attention to their genetic barriers to RASs and to maintain high adherence standards. HIV/HCV disease management is complicated by the co-existing HIV infection, concomitant antiretroviral therapies, co-morbidities due to ageing and HIV infection duration. In particular, PK/PD considerations and DDIs should be taken into account before HCV treatment initiation in this sub-population.

- | | | |
|-------------|--|---------------------------|
| 13.00-13.15 | Sofosbuvir-based STR: state of the art | Gianpiero D'Offizi (Roma) |
| 13.15-13.30 | Drug-to-Drug Interactions and PK/PD profile in HIV/HCV patient management | Stefano Bonora (Torino) |
| 13.30-13.45 | Discussion | |

SATELLITE SYMPOSIUM 13.00-13.45**AULA 1**

Unrestricted educational grant of Bristol-Myers Squibb

Heart comes first

Chairs: R. Cauda (Roma), A. d'Arminio Monforte (Milano)

In the recent years the HIV+ population has aged. Data from Spanish VACH cohort as well as from the main Italian cohorts show how currently, the HIV+ patients aged 50 years or more represent almost half of the population in care. Findings from the EuroSIDA cohort indicate that in this population the prevalence of the most important CVD risk factors (dyslipidemia, hypertension, obesity, CKD, smoking) is increasing. As a consequence today, and even more in the future, the infectious disease specialist must pay and increasing attention to primary and secondary prevention of comorbidities while caring for older HIV+ patients. The symposium aims to share new scientific evidences that support clinicians in the management of the ageing HIV+ population, with a special focus on antiretroviral treatment optimization.

- | | | |
|-------------|--|--------------------------------|
| 13.00-13.15 | Heart and antiretroviral therapy: guidelines and hard endpoints | Cristina Mussini (Modena) |
| 13.15-13.30 | Do we need triple therapy for heart prevention? | Simona Di Giambenedetto (Roma) |
| 13.30-13.45 | Discussion | |



SYMPOSIUM 13.55-15.25

AUDITORIUM

PrEPing today: critical issues and challenges

Chairs: G.M. Corbelli (Bologna), C. Mussini (Modena), V. Puro (Roma)

The major international health agencies recommend PrEP as a strategy for reducing new HIV infections in selected populations. The Symposium addresses the issue by highlighting the current challenges, the emerging national models of implementation in Europe and the new tools for promoting/applying the strategy through new web media.

13.55-14.10	Women and PrEP: evidences and perspectives	Laura Sighinolfi (Ferrara)
14.10-14.25	Implementing PrEP in clinical practice: The Paris experience	Alexandre Aslan (Paris, F)
14.25-14.40	PrEP & AIDES: l'expérience de la première association française de lutte contre le VIH/sida	Francesca Belli (Paris, F)
14.40-14.55	How information technology could help in implementing PrEP	Silvia Nozza (Milano)
14.55-15.25	Discussion	

ORAL COMMUNICATIONS 14.00-15.30

AULA 1

Hepatitis: epidemiology and basic research

Chairs: A. Calcagno (Torino), S. Di Giambenedetto (Roma), M. Lichtner (Latina)

OC 75 14.00-14.07 An outbreak of acute hepatitis A among young adult men in Rome: the experience of a large teaching hospital

A. Ciccullo¹, G. Baldin¹, R. Gagliardini¹, A. Borghetti¹, A. Emiliozzi¹, D. Faliero¹, D. Moschese¹, E. Treccarichi¹, D. Speziale², K. De Gaetano Donati¹, E. Visconti¹, R. Cauda¹, S. Di Giambenedetto¹, F. Pallavicini¹

¹Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, ²Dipartimento di Microbiologia, Università Cattolica del Sacro Cuore, Roma, Italy

OC 76 14.10-14.17 Huge decrease of hepatocellular apoptosis in both HIV/HCV co-infected and HCV mono-infected patients undergoing IFN free therapy despite persistence of inflammation


P. Zuccalà¹, C. Mascia¹, M. Lichtner², S. Vita¹, R. Marocco², S. Savinelli¹, F. Mengoni¹, T. Tieghi², I. Pozzetto², G. d'Ettorre¹, F. Paoletti¹, C.M. Mastroianni², V. Vullo¹

¹Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy, ²Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Polo Pontino, Latina, Italy

OC 77 14.20-14.27 HCV genotype 3 resistance profile characterization in DAA-naïve and DAA-failed patients in Italy

S. Barbaliscia¹, V.C. Di Maio¹, E. Teti², I. Lenci³, M. Aragri¹, C. Masetti³, E. Polilli⁴, L. Gianserra⁵, V. Pace Palitti⁶, B. Bruzzone⁷, S. Paolucci⁸, N. Coppola⁹, T. Ruggiero¹⁰, T. Pollicino¹¹, C.F. Magni¹², V. Micheli¹³, A. Di Biagio¹⁴, F.P. Antonucci¹, A. Bertoli¹, K. Yu La Rosa¹, R. Campoli¹, L. Sticchi⁷, M. Melis¹⁵, S. Francioso³, L. Foroghi², C. Sarrecchia², S. Landonio¹², V. Calvaruso¹⁶, F. Morisco¹⁷, I. Maida¹⁸, S. Marengo¹⁸, A. Lleo¹⁹, V. Ghisetti¹⁰, A. Ciancio²⁰, P. Sacchi²¹, S. Novati²², G. Brancaccio⁹, A. Pieri⁴, M. Puoti²³, P. Toniutto²⁴, V. Vullo²⁵, A. Aghemo²⁶, G. Di Perri²⁷, S. Babudieri¹⁵, G. Rizzardini¹², S. Bruno¹⁹, A. Pellicelli²⁸, G. Taliani²⁹, G. Raimondo¹¹, F. Baldanti⁸, G.B. Gaeta⁹, A. Craxi¹⁶, C. Pasquazzi⁵, L. Sarmati⁴, G. Parruti⁴, M. Angelico³, M. Andreoni², V. Cento¹, C.F. Perno¹, F. Ceccherini-Silberstein¹ on behalf of HCV Virology Italian Resistance Network (VIRONET-C)

¹Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, ²Infectious Diseases, University Hospital of Rome Tor Vergata, Rome, Italy, ³Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ⁴Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ⁵Infectious Diseases, Sant'Andrea Hospital – "La Sapienza" University, Rome, Italy, ⁶Hepatology Unit, Pescara General Hospital, Pescara, Italy, ⁷Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ⁸Molecular Virology, IRCCS Policlinic Foundation San Matteo, Pavia, Italy, ⁹Infectious Diseases and Viral Hepatitis Unit, Second University of Naples, Naples, Italy, ¹⁰Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy, ¹¹Department of Internal Medicine, University Hospital of Messina, Messina, Italy, ¹²Division of Infectious Disease, ASST Fatebenefratelli Sacco, Milan, Italy, ¹³Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, Milan, Italy, ¹⁴Infectious Disease, IRCCS AOU San Martino - IST, Genoa, Italy, ¹⁵Infectious Diseases Unit, University of Sassari, Sassari, Italy, ¹⁶Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, ¹⁷Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Naples, Italy, ¹⁸Division of Hepatology, IRCCS San Martino, IST Genova, Genoa, Italy, ¹⁹Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy, ²⁰Unit of Gastroenterology, University of Turin, Department of Medical Sciences, City of Health and Science of Molinette Turin Hospital, Turin, Italy, ²¹Division of Infectious and Tropical Diseases, IRCCS Policlinic Foundation San Matteo, Pavia, Italy, ²²Institute of Infectious Diseases, University of Pavia, Pavia, Italy, ²³Department of Infectious Diseases, Hospital Niguarda Ca'Granda, Milan, Italy, ²⁴Department of Medical Sciences Experimental and Clinical, Medical Liver Transplant Section, Udine, Italy, ²⁵Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ²⁶Unit of Gastroenterology and Hepatology, IRCCS Foundation "Ca' Granda-Ospedale Maggiore Policlinico", Milan, Italy, ²⁷Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Turin, Italy, ²⁸Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, ²⁹Infectious and Tropical Diseases Unit, Department of Clinical Medicine, "La Sapienza" University of Rome, Rome, Italy



OC 78 14.30-14.37 Complex and frequent multiclass HCV resistance in almost all HCV genotypes at DAA failure: what chances for second-line regimens?

V.C. Di Maio¹, V. Cento¹, I. Lenci², M. Aragri¹, S. Barbaliscia¹, C. Masetti², S. Paolucci³, T. Pollicino⁴, N. Coppola⁵, M. Melis⁶, F. Niero⁷, V. Micheli⁸, V. Calvaruso⁹, S. Francioso², B. Bruzzone¹⁰, T. Ruggiero¹¹, M. Bolis⁷, M. Starace⁵, A. Bertoli¹, K. Yu La Rosa¹, R. Campoli¹, F.P. Antonucci¹, C. D'Ambrosio¹², F. Morisco¹³, M. Zazzi¹⁴, B. Rossetti¹⁵, A. De Luca¹⁵, L. Lambiase¹⁶, I. Maida⁶, S. Marengo¹⁷, G. Brancaccio⁵, L.A. Nicolini¹⁸, A. Di Biagio¹⁸, L. Sticchi¹⁰, V. Ghisetti¹¹, R. Cozzolongo¹⁹, M. Rendina²⁰, A. Ciaccio²¹, V. Boccaccio²², A. Grieco²³, M. Brunetto²⁴, P. Colombatto²⁴, G. D'Etorre²⁵, E. Meregalli²¹, S. Galli²⁶, G.B. Gaeta⁵, A. Ciancio²⁷, L. Marinaro¹¹, E. Polilli²⁸, P. Cacciatore²⁸, P. Andreone²⁹, G. Barbarini³⁰, R. Gulminetti³¹, W. Gennari³², V. Borghi³³, R. Maserati³¹, V. Pace Palitti³⁴, P. Tarquini³⁵, M. Puoti³⁶, V. Sangiovanni³⁷, A. Giorgini³⁸, M. Paoloni³⁹, M. Lichtner⁴⁰, M.L. Ponti⁴¹, N. Caporaso¹³, S. Babudieri⁷, G. Gubertini⁷, S. Bruno²², V. Vullo²⁵, G. Rizzardini⁷, A. Pellicelli¹², C. Pasquazzi¹⁶, G. Parruti²⁸, G. Raimondo⁴, F. Baldanti³, A. Craxi⁹, M. Angelico², M. Andreoni⁴², C.F. Perno¹, F. Ceccherini-Silberstein¹ on behalf of HCV Virology Italian Resistance Network (VIRONET-C)

¹Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, ²Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ³Molecular Virology, Policlinic Foundation San Matteo, Pavia, Italy, ⁴Department of Internal Medicine, University Hospital of Messina, Messina, Italy, ⁵Infectious Diseases and Viral Hepatitis Unit, Second University of Naples, Naples, Italy, ⁶Infectious Diseases Unit, University of Sassari, Sassari, Italy, ⁷Division of Infectious Disease, ASST Fatebenefratelli Sacco, Milan, Italy, ⁸Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, Milan, Italy, ⁹Gastroenterology, "P.Giaccone" University Hospital, Palermo, Italy, ¹⁰Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ¹¹Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy, ¹²Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, ¹³Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Naples, Italy, ¹⁴Virology, Siena University Hospital, Siena, Italy, ¹⁵Infectious Diseases, Siena University Hospital, Siena, Italy, ¹⁶Infectious Diseases, Sant'Andrea Hospital – "La Sapienza" University, Rome, Italy, ¹⁷Division of Hepatology, University of Genoa-AOU IRCCS San Martino-IST, Genoa, Italy, ¹⁸Infectious Disease, IRCCS AOU San Martino - IST, Genoa, Italy, ¹⁹Department of Gastroenterology, Scientific Institute for Digestive Disease "Saverio de Bellis" Hospital, Castellana Grotte, Bari, Italy, ²⁰Department of Emergency and Organ Transplantation, Section of Gastroenterology, University Hospital, Bari, Italy, ²¹Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy, ²²Department of Biomedical Sciences, Humanities University, Rozzano, Milan, Italy, ²³Liver Transplant Unit, Catholic University of Rome, Rome, Italy, ²⁴Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses - University Hospital of Pisa, Italy, ²⁵Department of Public Health and Infectious Diseases, "La Sapienza" University of Rome, Rome, Italy, ²⁶Microbiology and Virology Unit, Sant'Orsola-Malpighi Hospital-Bologna, Italy, ²⁷Gastroepatology, Department of Medical Sciences, City of Health and Science of Turin, University of Turin, Turin, Italy, ²⁸Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ²⁹Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, ³⁰Division of Infectious and Tropical Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ³¹Institute of Infectious Diseases, University of Pavia, Pavia, Italy, ³²Microbiology Laboratory, University Hospital, Modena, Italy, ³³Infectious Diseases Clinic, University Hospital, Modena, Italy, ³⁴Hepatology Unit, Pescara General Hospital, Pescara, Italy, ³⁵Infectious Disease, Hospital "G. Mazzini", Teramo, Italy, ³⁶Department of Infectious Diseases, Hospital Niguarda Ca'Granda, Milan, Italy, ³⁷Hospital Cotugno, Naples, Italy, ³⁸General Medicine Unit, SST Santi Paolo e Carlo, Milan, Italy, ³⁹Infectious Disease Unit, Avezzano General Hospital, Avezzano, Italy, ⁴⁰Infectious Diseases, "La Sapienza" University, Latina, Italy, ⁴¹Hepatology Unit, Brotzu Hospital, Cagliari, Italy, ⁴²Infectious Diseases, University Hospital of Rome Tor Vergata, Rome, Italy

OC 79 14.40-14.47 Positively charged mutations in HBsAg C-terminus are tightly correlated with HBV-induced hepatocellular carcinoma and profoundly hamper the structural folding of this domain

R. Salpini¹, L. Carioti¹, M. Aragri¹, D. Di Carlo¹, L. Colagrossi¹, A. Battisti¹, L. Piermatteo¹, A. Bertoli¹, L. Fabeni², A. Ricciardi³, R. Longo⁴, S. Romano⁴, G. Cappiello⁴, A. Spanò⁴, P. Trimoulet⁵, H. Fleury⁵, J. Vecchie⁶, N. Iapadre⁷, A. Barlattani⁸, T. Mari⁹, C. Pasquazzi¹⁰, I. Lenci¹¹, S. Francioso¹¹, G. Parruti¹², L. Sarmati¹³, M. Andreoni¹³, M. Angelico¹¹, F. Ceccherini-Silberstein¹, C.F. Perno¹, V. Svicher¹

¹Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy, ²National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy, ³Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, ⁴Microbiology and Virology Unit, "S. Pertiini" Hospital, Rome, Italy, ⁵Hôpital Pellegrin tripode, Laboratoire de Virologie, Bordeaux, France, ⁶Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy, ⁷San Salvatore Hospital", L'Aquila, Italy, ⁸Hepatology Unit, "S. Giacomo" Hospital, Rome, Italy, ⁹Nuovo Regina Margherita Hospital, Rome, Italy, ¹⁰S. Andrea Hospital", Department of Gastroenterology, Rome, Italy, ¹¹Tor Vergata University Hospital, Hepatology Unit, Rome, Italy, ¹²Infectious Disease Unit, Ospedale Civile, Pescara, Italy

OC 80 14.50-14.57 An extensive degree of genetic variability characterizes Hepatitis Delta Antigen and correlates with elevated serum HDV-RNA levels

L. Colagrossi¹, R. Salpini¹, R. Scutari¹, A. Battisti¹, L. Piermatteo¹, A. Bertoli¹, L. Fabeni², C. Minichini³, P. Trimoulet⁴, H. Fleury⁴, E. Nebuloso⁵, M. De Cristofaro⁵, G. Cappiello⁵, A. Spanò⁵, V. Malagnino⁶, T. Mari⁷, A. Barlattani⁷, N. Iapadre⁸, M. Lichtner⁹, C. Mastroianni⁹, I. Lenci¹⁰, C. Pasquazzi¹¹, G.M. De Sanctis¹², A. Galeota Lanza¹³, M. Stanzone¹⁴, G. Stornaiuolo¹⁴, M. Marignani¹¹, L. Sarmati¹⁵, M. Andreoni¹⁵, M. Angelico¹⁰, C.F. Perno¹, N. Coppola³, V. Svicher¹

¹Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy, ²National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy, ³Second University of Naples, Department of Mental Health and Public Medicine, Section of Infectious Diseases, Naples, Italy, ⁴Hôpital Pellegrin tripode, Laboratoire de Virologie, Bordeaux, France, ⁵Sandro Pertini Hospital, Rome, Italy, ⁶Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, ⁷Nuovo Regina Margherita Hospital, Rome, Italy, ⁸San Salvatore Hospital, L'Aquila, Italy, ⁹Sapienza University, Department of Public Health and Infectious Diseases, Rome, Italy, ¹⁰Tor Vergata University Hospital, Hepatology Unit, Rome, Italy, ¹¹S. Andrea Hospital, Department of Gastroenterology, Rome, Italy, ¹²Umberto I Hospital, Rome, Italy, ¹³AO Cardarelli, Gastroenterology Unit, Naples, Italy, ¹⁴Second University of Naples, Viral Unit, Naples, Italy

OC 81 15.00-15.07 Irreversible circulating Mucosal associated invariant T cells (MAITs) loss despite successful interferon-free therapy in chronically HIV/HCV co-infected patients

E.S. Cannizzo¹, M. Cerrone¹, E. Merlini¹, B. van Wilgenburg², L. Swadling², C. Tincati¹, A. De Bona¹, A. d'Arminio Monforte¹, P. Klenerman², G. Marchetti¹

¹Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, ²Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK

OC 82 15.10-15.17 HCV-genotype 3h: is a difficult-to-diagnose and to-treat HCV sub-genotype in the DAA' era?

C. Minichini¹, M. Starace¹, S. De Pascalis¹, M. Macera¹, L. Occhiello¹, M. Caroprese¹, M. Vitrone², V. Iovinella³, B. Guerrera⁴, M. Masarone⁵, N. Coppola¹

¹Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania, L. Vanvitelli, Naples, Italy, ²Internal Medicine, University of Campania & AORN Ospedali dei Colli-Monaldi Hospital, Naples, ³Infectious Diseases, ASL Napoli 1, Naples, ⁴Internal Medicine, University of Campania, L. Vanvitelli, Naples, Italy, ⁵Gastroenterology Unit, University of Salerno, Italy

OC 83 15.20-15.27 Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV-HCV co-infected individuals

D.F. Bavaro¹, G. Bruno¹, L. Scudeller², D. Fiordelisi¹, N. Ladisa¹, L. Monno¹, A. Saracino¹, G. Angarano¹

¹University of Bari "Aldo Moro", Clinic of Infectious Diseases, Bari, Italy, ²Scientific Direction, Clinical Epidemiology Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy


ORAL COMMUNICATIONS 14.00-15.30

AULA 2

Basic science and clinical virology

Chairs: M. Clementi (Milano), M.C. Re (Bologna), S. Rusconi (Milano)

- OC 84** 14.00-14.07 **HIV-1 B subtype underwent a deep genetic evolution that impacted its pathogenic potential over the years 2003-2016**
C. Alteri¹, L. Fabeni², R. Scutari¹, G. Berno², D. Di Carlo¹, C. Gori², A. Bertoli¹, V. Fedele², S. Carta², A. Vergori², I. Mastroianni², R. Bellagamba², M. Colafigli³, C. Mussini⁴, F. Montella⁵, A. Pennica⁶, C.M. Mastroianni⁷, E. Girardi², M. Andreoni⁸, A. Antinori², F. Ceccherini-Silberstein¹, V. Svicher¹, C.F. Perno^{1,2}, M.M. Santoro¹
¹University of Rome Tor Vergata, Italy, ²National Institute for Infectious Diseases L. Spallanzani-IRCC, Rome, Italy, ³San Gallicano Hospital, Rome, Italy, ⁴University Hospital of Modena, Italy, ⁵San Giovanni Hospital, Rome, Italy, ⁶San'Andrea Hospital, Rome, Italy, ⁷Sapienza University, Polo Pontino, Latina, Italy, ⁸University Hospital of Rome Tor Vergata
- OC 85** 14.10-14.17 **Very low level residual viremia do correlate with HIV-DNA load in successfully suppressed individuals on cART**
A. Callegaro^{1,2}, M. Arosio^{1,2}, A. Carobbio^{1,2}, E. Di Filippo³, L. Comi³, D. Valenti³, F. Maggiolo³
¹Microbiology and Virology Laboratory, ²Biobank Laboratory, ³USC Infectious Diseases, ASST-PG23, Bergamo
- OC 86** 14.20-14.27 **HIV-1 tropism evolution is reduced in presence of Integrase Inhibitors based regimens**
C. Alteri¹, R. Scutari¹, A. Bertoli¹, D. Armenia¹, C. Gori², G. Fabbri², C. Cerva³, C.M. Mastroianni⁴, A. Cristaudo⁵, M. Andreoni³, A. Antinori², V. Svicher¹, F. Ceccherini-Silberstein¹, C.F. Perno^{1,2}, M.M. Santoro¹
¹University of Rome Tor Vergata, Italy, ²Lazzaro Spallanzani Hospital IRCCS, Rome, Italy, ³University Hospital of Rome Tor Vergata, ⁴Sapienza University, Polo Pontino, Latina, Italy, ⁵San Gallicano Hospital, Rome, Italy
- OC 87** 14.30-14.37 **HIV-1 non-R5 tropism correlates with higher residual viral replication and a larger size of the cellular viral reservoir in patients under suppressive ART**
E. Lombardi¹, S. Belmonti¹, L. Rapone¹, A. Borghetti¹, R. Gagliardini¹, G. Baldin¹, A. Emiliozzi¹, D. Faliero¹, A. Ciccullo¹, A. De Luca^{2,3}, R. Cauda¹, S. Di Giambenedetto¹
¹Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³University Division of Infectious Diseases, Hospital Department of Specialized and Internal Medicine, Siena, Italy
- OC 88** 14.40-14.47 **Long-term Impact of Monotherapy on HIV-1 Reservoir, Immune Activation and Epstein-Barr Virus Co-infection**
M.R. Petrara¹, A.M. Cattelan², L. Sasset³, R. Freguja¹, F. Carmona⁴, S. Sanavia⁴, M. Zanchetta⁴, P. Del Bianco⁴, A. De Rossi^{1,4}
¹Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, AIDS Reference Centre, University of Padova, Italy, ²Division of Infectious and Tropical Diseases, Azienda Ospedaliera and University of Padova, Italy, ³Division of Infectious Disease, Azienda Ospedaliera di Rovigo, Italy, ⁴Istituto Oncologico Veneto-IRCCS, Padova, Italy
- OC 89** 14.50-14.57 **Variability of sumoylation sites in HIV-1 integrase correlates with viro-immunological parameters and integrase resistance**
D. Armenia¹, C. Gori², A. Bertoli¹, F. Forbici², V. Fedele², D. Pizzi², W. Gennari³, L. Monno⁴, F. Saladini⁵, D. Francisci⁶, M. Zaccarelli², A. Vergori², I. Mastroianni², A. Latini⁷, C. Stingone⁸, C.M. Mastroianni⁹, F. Montella¹⁰, C. Mussini³, M. Andreoni⁸, F. Ceccherini-Silberstein¹, M. Zazzi⁵, A. Antinori², C.F. Perno², M.M. Santoro¹
¹University of Rome Tor Vergata, Rome, Italy, ²INMI L. Spallanzani Hospital, Rome, Italy, ³University of Modena, Modena, Italy, ⁴University of Bari, Italy, ⁵University of Siena, Italy, ⁶Azienda Ospedaliera S.Maria di Terni, Terni, Italy, ⁷San Gallicano Dermatological Institute, IRCCS, Rome, Italy, ⁸University Hospital Tor Vergata, Rome, Italy, ⁹La Sapienza University Polo Pontino, Latina, Italy, ¹⁰San Giovanni Addolorata Hospital, Rome, Italy
- OC 90** 15.00-15.07 **HIV transmitted drug resistance in patients recently diagnosed with HIV from 2011 to 2016 in ASST GOM Niguarda**
P. Tau¹, A. Nava², S. Torri², R. Rossotti¹, G.L. Chianura¹, D. Motta¹, D. Fanti², M.C. Maioli¹, M. Puoti¹
¹S.C. Malattie Infettive - ASST Grande Ospedale Metropolitano Niguarda, ²S.C. Analisi Chimico Cliniche e Microbiologia - ASST Grande Ospedale Metropolitano Niguarda, Milano
- OC 91** 15.10-15.17 **Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integraseinhibitor (INSTI)**
C. Spertilli Raffaelli¹, L. Paglicci¹, B. Rossetti^{2,3}, M. Colafigli³, G. Punzi⁴, V. Borghi⁵, M. Pecorari⁶, C.F. Perno⁷, G. Penca⁸, A. Antinori⁹, M. Zazzi¹, A. De Luca^{1,2}, G. Zanelli^{1,2}
¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Infectious Diseases Unit, AOU Senese, Siena, Italy, ³Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ⁴Virology, Bari Hospital, Bari, Italy, ⁵Infectious Diseases Unit, Modena Hospital, Modena, Italy, ⁶Microbiology and Virology Unit, University Hospital, Modena, Italy, ⁷Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, ⁸Infectious Diseases Department, Ente Ospedaliero Ospedali Galliera, Genoa, Italy, ⁹Infectious Diseases Department, INMI "Lazzaro Spallanzani", Rome, Italy
- OC 92** 15.20-15.27 **Prevalence of resistance mutations to Integrase Inhibitors in INSTI-experienced HIV-1 infected patients in a large Italian cohort**
S. Modica¹, B. Rossetti^{1,2}, F. Lombardi³, F. Lagi⁴, M. Maffeo¹, R. D'Autilia⁵, M. Pecorari⁶, I. Vicenti⁷, B. Bruzzone⁸, G. Magnani⁹, S. Paolucci¹⁰, D. Francisci¹¹, G. Penca¹², D. Sacchini¹³, M. Zazzi¹, A. De Luca¹, A. Di Biagio¹⁴
¹Infectious Diseases Clinic, University of Siena, Siena, Italy, ²Clinic of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, ³Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, ⁴Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁵Department of Mathematics, University of Roma Tre, Rome, Italy, ⁶Unit of Microbiology and Virology, Modena University Hospital, Modena, Italy, ⁷Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁸Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ⁹Department of Infectious Diseases, S. Maria Nuova IRCCS Hospital, Reggio Emilia, Italy, ¹⁰Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ¹¹Infectious Diseases Clinic, Perugia University Hospital, Perugia, Italy, ¹²Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, ¹³Clinic of Infectious Diseases, "Guglielmo da Saliceto" Hospital, Piacenza, Italy, ¹⁴Infectious Diseases Clinic, IRCCS AOU San Martino-IST, Genoa, Italy



AUDITORIUM

15.30-16.00

ICAR Special Awards

Chairs: A. Antinori (Roma), A. De Luca (Siena), M. Zazzi (Siena)

■ **Best Poster Award**

Andrea Antinori (Roma), Andrea De Luca (Siena), Maurizio Zazzi (Siena)

■ **SIMIT Awards to best Oral Communications selected among:
Clinical HIV, Clinical HCV, Virology and Immunopathogenesis**

Antonio Chirianni (Napoli), Massimo Galli (Milano)

16.00-16.30

Closing remarks

A. Antinori (Roma), A. De Luca (Siena), M. Zazzi (Siena)



9° CONGRESSO
NAZIONALE

12-14
GIUGNO 2017

Italian Conference on
AIDS and Antiviral Research



POSTER EXHIBITION



Indicates posters selected for
"ICAR 2017 Best Poster Awards"
see pages 81



CLINICAL HEPATITIS

- P 1 Treatment with ledipasvir/sofosbuvir for 8 weeks in naïve patients with chronic hepatitis C and genotype 1: a preliminary analysis**
S. Mornese Pinna, L. Boggione, J. Cusato, A. De Nicolò, G. Cariti, A. D'Avolio, G. Di Perri
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
- P 2 Response-guided treatment in the era of DAAs: is it actually a farewell?**
G. Bruno, A. Procopio, C. Fabrizio, E. Milano, L. Monno, M. Milella, A. Saracino, G. Angarano
Clinic of Infectious Diseases, University of Bari
- P 3 Evolution of renal function abnormalities in a cohort of HCV and HCV/HIV co-infected patients treated with DAA**
L. Montanari¹, L.A. Nicolini¹, F. Bovis², L. Taramasso¹, C. Saffioti¹, P. Tatarelli¹, E. Balletto¹, F. De Puente¹, C. Viscoli¹, A. Di Biagio¹
¹Infectious Diseases-Department of Health Sciences (DISSAL), University of Genoa, IRCCS San Martino-IST, Genoa, ²Section of Biostatistics, Department of Health Sciences (DISSAL), University of Genoa
- P 4 High efficacy and tolerability of DAA therapy for HCV in HIV-infected patients from the real practice: the complete experience of Tuscany**
B. Valoriani¹, E. Salomoni², M. Pozzi², S. Sani³, R. Cinelli³, B. Rossetti¹, A. Gonnelli⁴, R. Iapoco⁵, S. Fabiani⁵, D. Tacconi⁶, L. Bernini⁶, P. Blanc⁷, P. Pierotti⁷, C. Nencioni⁸, A. Nerli⁹, S. Luchi¹⁰, M. De Gennaro¹⁰, A. De Luca¹, D. Bartolozzi²
On behalf of SIMIT TOSCANA and EPATOLOGI TOSCANI
¹UOC Malattie Infettive Universitarie, AOU Senese, Siena, ²Malattie Infettive e Tropicali, AOU Careggi, Firenze, ³Malattie Infettive Spedali Riuniti di Livorno, Livorno, ⁴UOC Malattie Infettive Ospedaliere ed Epatologia, AOU Senese, Siena, ⁵Malattie Infettive AOU Pisana, Pisa, ⁶Malattie Infettive Ospedale San Donato, Arezzo, ⁷Malattie Infettive e Tropicali, Ospedale Santa Maria Annunziata, Firenze, ⁸Malattie Infettive Ospedale Misericordia, Grosseto, ⁹Malattie Infettive Ospedale di Prato, Prato, ¹⁰Malattie Infettive e Epatologia, Ospedale San Luca, Lucca
- P 5 Second Generation of Direct Antiviral Agents: an analysis of the European Pharmacovigilance Database**
M. De Fina
Chair of Pharmacology, Department Science of Health, University of Catanzaro, Catanzaro, Italy
- P 6 Direct antiviral agents: an analysis of the European pharmacovigilance database**
M. De Fina
Chair of Pharmacology, Department Science of Health, University of Catanzaro, Catanzaro, Italy
- P 7 Influence of HBV genotypes on the clinical presentation of HBV chronic infection: a study on immigrant populations living in Southern Italy**
E. Sagnelli¹, L. Alessio², C. Sagnelli^{1,3}, L. Gualdieri⁴, M. Pisaturo⁵, C. Minichini¹, G. Di Caprio^{1,2}, M. Starace¹, L. Onorato^{1,2}, M. Macera¹, G. Scotti⁶, N. Coppola¹
¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Italy, ²Medical Center, Centro Sociale ex Canapificio, Caserta, ³Medical center, Centro Suore Missionarie della Carità, Naples, Italy, ⁴Medical Center, Centro per la Tutela della Salute degli Immigrati, Naples, Italy, ⁵Medical Center, Centro di Accoglienza "La tenda di Abramo", Caserta, Italy; Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ⁶Infectious Diseases Unit, Foggia
- P 8 Correlation between the hepatic expression of human microRNA hsa-miR-125a-5p and the progression of fibrosis in patients with overt and occult HBV infection**
L. Onorato¹, G. de Stefano², C. Minichini¹, V. Messina⁴, M. Starace¹, M. Panella³, P. Filippini⁴, N. Mosca³, L. Alessio⁴, N. Farella², N. Potenza³, E. Sagnelli¹, N. Coppola¹, A. Russo³
¹Department of Mental Health and Public Medicine, University of Campania Luigi Vanvitelli, Naples, ²IX Interventional Ultrasound Unit for Infectious Diseases, AORN dei Colli, P.O. Cotugno, Naples, ³Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania Luigi Vanvitelli, Caserta, ⁴Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta
- P 9 Assessment of Non Alcoholic Fatty Liver Disease (NAFLD) in a cohort of HIV monoinfected patients**
P. Columpsi¹, V. Zuccaro¹, L. Maiocchi², G. Ferraioli², L. Sacchi³, P. Sacchi¹, C. Filice², R. Bruno^{1,2}
¹Department of Infectious and Tropical Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, ²Department of Medical, Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, ³Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia
- P 10 Efficacy and tolerability of treatment with the new direct acting antivirals (DAAs) in thalassemic patients with chronic Hepatitis C**
S. Onali¹, I. Maida², C. Balestrieri³, F. Arcadu⁴, E. Urru¹, F. Pes¹, D. Porcu¹, G. Serra³, G. Flore², E. Dore², C. Satta⁴, P.P. Bitti⁵, M.G. Sanna⁵, L. Serusi⁵, M. Conti², M. Casale¹, F. Figorilli¹, M.C. Pasetto¹, L. Chessa^{1,2}
¹Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy, ²Department of Experimental and Clinic Medicine, University of Sassari, Sassari, Italy, ³Liver Unit, Department of Internal Medicine, Azienda Ospedaliera-Universitaria di Cagliari, Cagliari, Italy, ⁴Internal Medicine and Gastroenterology, San Francesco Hospital, ASL 3, Nuoro, Italy, ⁵Immunohematology and Transfusional Medicine, San Francesco Hospital, ASL 3, Nuoro, Italy
- P 11 DAA-based regimens in HBsAg /anti-HCV positive patients: the need to control HBV replication to avoid HBV reactivation**
M. Macera¹, M. Stanzione¹, V. Messina², G. D'Adamo³, V. Sangiovanni⁴, L. Miogioresi⁵, L. Fontanella⁶, S. De Pascalis¹, G. Stornaiuolo¹, A. Galeota Lanza⁷, T. Ascione⁸, G.B. Gaeta¹, I. Gentile⁹, G. Piai⁵, N. Coppola¹
¹Department of Mental Health and Public Medicine, University of Campania, Naples, Italy, ²Infectious Disease, A.O. Caserta, Caserta, Italy, ³Internal Medicine Unit, A.O. Nocera, Nocera (Salerno), Italy, ⁴Third Infectious Disease Unit, AO Cotugno, Naples, Italy, ⁵Gastroenterology Unit, A.O. Caserta, Caserta, Italy, ⁶Gastroenterology Unit, A.O. Fatebenefratelli, Naples, Italy, ⁷Hepatology Unit, AO Cardarelli, Naples, Italy, ⁸IX Infectious Diseases Unit, AO Cotugno, Naples, Italy, ⁹Infectious diseases Unit, Federico II University, Naples, Italy

- P 12 Liver steatosis in HIV-infected patients: cross-sectional analysis of prevalence, risk factors and management**
R. Rossotti, M. Merli, C. Baiguera, L.J. Garcia-Fraile Fraile, M. Puoti
 Niguarda Hepatitis Center, Division of Infectious Diseases, Milan
- P 13 Changes in liver stiffness assessment in chronic hepatitis C patients treated with direct-acting antivirals: monocentric experience between 2015 and 2016**
F. Barbaro, S. Cavinato, E.M. Erne, A. Cattelan
 Unità Operativa Complessa Malattie Infettive, Azienda Ospedaliera Università di Padova, Padova, Italy
- P 14 Drug Addicts Adherence to new DAAs in real-life: is HCV cure possible in this key population?**
E. Teti¹, L. Foroghi¹, V. Cento², C. Stingone¹, M. Compagno¹, G. Malerba¹, A. Cavasio¹, E. Rossi³, D. Masci³, P. Sammarco³, R. Sista³, S. Capasso³, B. Coladarce³, G. Rodoquino³, M. Patti³, F. Patrino³, M. Pellegrino⁴, C. Sarrecchia¹, C.F. Perno², L. Sarmati¹, M. Barra³, M. Andreoni¹
¹Clinical Infectious Diseases, Tor Vergata University, Rome, Italy, ²Virology Unit, Tor Vergata University, Rome, Italy, ³Villa Maraini Foundation ONLUS, Rome, Italy, ⁴SerT Casilina 1368, Rome, Italy
- P 15 Hepatocellular carcinoma risk in HCV patients undergoing Direct-Acting Antivirals in field-practice**
M. Schiavini¹, C. Magni¹, S. Landonio¹, F. Niero¹, M. Passerini¹, M. Crespi², R. Giorgi¹, A. Mainini¹, R. Bianco³, L. Pennacchi², S. Passerini¹, G. Gubertini¹, E. Angeli¹, G. Rizzardini¹
¹Department of Infectious Disease - ASST-FBF-Sacco, Milan, Italy, ²Department of Oncology, Gastroenterology and Surgery- ASST-FBF-Sacco, Milan, Italy, ³Emergency Department -UOC Diagnostic Radiology, ASST-FBF-Sacco, Milan, Italy
- P 16 Impact of concomitant medication on efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin: analysis of phase III trials**
M. Puoti¹, J. Petrovic², F. Marra³, D. Back³, T. Welzel⁴, S. Christensen⁵, M. Buti⁶, F. Zoulim⁷, G. Dore⁸
¹Department of Infectious Diseases, AO Niguarda Ca' Granda, Milano, Italy, ²AbbVie Inc., North Chicago, IL, USA, ³Department of Molecular and Clinical Pharmacology, University of Liverpool, UK, ⁴Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe University, Frankfurt, Germany, ⁵CIM Infectious diseases, Muenster, Germany; ⁶Hepatology, Hospital Vall de Hebron, Barcelona, Spain, ⁷Hepatology, Hôpital de la Croix-Rousses Hospices Civils de Lyon, Lyon, France, ⁸Kirby Institute, UNSW Australia (University of New South Wales), Sydney, NSW, Australia
- P 17 Stiffness and fibrosis scores improvement in HIV/HCV coinfecting patients after DAA**
G. Fabbri, M. Zaccarelli, I. Mastrososa, L. Timelli, A. Vergori, S. Cicalini, R. Bellagamba, M.M. Plazzi, A. Antinori, A. Ammassari
 UOC Immunodeficienze Virali, Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani", IRCCS, Rome
- P 18 Pros and cons of an 18-month lamivudine prophylaxis of HBV reactivation in anti-HBc-positive/HBsAg-negative patients with hematological malignancies**
N. Capoluongo¹, A. Marrone², C. D'Amore², M. Pisaturo¹, M. Esposito³, S. Guastafierro⁴, I. Siniscalchi², M. Macera¹, A. Boemio², L. Onorato¹, L. Rinaldi², C. Minichini¹, L.E. Adinolfi², E. Sagnelli¹, L. Mastrullo³, N. Coppola¹
¹Department of Mental health and public medicine, University of Campania, Luigi Vanvitelli, Naples, Italy, ²Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, ³Hematology Unit, Ascalesi Hospital, Naples, Italy, ⁴Hematology Unit, University of Campania, Luigi Vanvitelli, Naples, Italy
- P 19 Mitochondrial toxicity and body shape changes during first generation Nucleos(t)ide Analogues long term administration in HBVinfected patients**
V. Fiore¹, G. Madeddu¹, M. Melis¹, F. Mannu⁵, A.A. Muredda¹, G. Garrucciu², F. Bandiera³, S. Zaru⁴, P. Bagella¹, S. Ortu¹, S. Babudieri¹
¹Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Italy, ²Internal Medicine Unit, University Hospital of Sassari, Italy, ³General Medicine Unit, SS. Annunziata Hospital, Sassari, Italy, ⁴Gastroenterology Unit, SS. Annunziata Hospital, Sassari, Italy, ⁵Nurexibiotec, Sassari, Italy
- P 20 Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in co-infected HIV-HCV patients treated with the new direct acting antivirals (DAAs)**
F. Pes¹, S. Onali¹, C. Balestrieri², F. Figorilli¹, G. Serra², C. Pasetto¹, L. Chessa^{1,2}
¹Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy, ²Liver Unit, Department of Internal Medicine, Azienda Ospedaliera-Universitaria di Cagliari, Cagliari, Italy
- P 21 Clinical findings of HCV chronic infection in undocumented immigrants and low-income refugees in three areas of Southern Italy**
E. Sagnelli¹, L. Alessio², C. Sagnelli^{1,2,4}, L. Gualdieri⁵, M. Pisaturo^{4,2,3}, C. Minichini¹, G. Di Caprio², M. Starace¹, Lorenzo Onorato^{1,2}, G. Scotto⁶, M. Macera^{1,2}, N. Coppola¹
¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Italy, ²Medical Center, Centro Sociale ex Canapificio, Caserta; Medical Center, Centro di Accoglienza "La tenda di Abramo", Caserta, Italy, ³Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ⁴Medical center, Centro Suore Missionarie della Carità, Naples, Italy, ⁵Medical Center, Centro per la Tutela della Salute degli Immigrati, Naples, Italy, ⁶Infectious Diseases Unit, Foggia
- P 22 Age, genotype 3 and liver stiffness > 18 KPa are related with sustained virological response (SVR12) in cirrhotic patients with hepatitis C treated with direct acting antivirals (DAAs)**
P. Nasta, S. Odolini, S. Casari, A. Spinetti, S. Zaltron, L. Urbinati, P. Lanza, C. Quirico, A. Bonito, E. Festa, E. Pollastri, E. Chiari, F. Castelli
 University Division of Infectious Diseases, Spedali Civili General Hospital, Brescia
- P 23 Direct-acting antivirals efficacy in hepatitis C-infected and HIV/HCV co-infected patients: a real life experience**
P. Lanza, S. Odolini, S. Casari, E. Bigoloni, A. Spinetti, S. Zaltron, P. Nasta, L. Urbinati, E. Festa, E. Pollastri, A. Bonito, F. Castelli
 University Division of Infectious and Tropical Diseases, University of Brescia and Brescia Spedali Civili General Hospital, Brescia, Italy



- P 24 Clinical and virologic outcome in a cohort of HCV+ women undergoing DAA**
R. Marocco, I. Pozzetto, T. Tieghi, B. Kertusha, C. Del Borgo, V.S. Mercurio, M. Lichtner, C.M. Mastroianni
Infectious Disease Unit, Sapienza University, Latina, Italy
- P 25 Impact of treatment length (12 vs 24 weeks) on efficacy of DCV/SOF/RBV treatment in HCV-infected patients with genotype 3 and advanced liver fibrosis or compensated cirrhosis**
L. Campana¹, A.L. Tortora², E. Visconti¹, E. Tamburrini¹, M. Pompili², A. Cingolani¹, M. Siciliano²
¹Institute of Infectious Disease, ²Gastroenterology, Catholic University, Foundation Hospital "A. Gemelli", Roma, Italy
- P 26 Lymphoproliferative disease with mixed cryoglobulinemia and hyperviscosity syndrome in an HIV-infected patient: HCV is the only culprit**
P. Zanotti¹, I. Izzo¹, S. Casari¹, C. Cattaneo², S. Zaltron¹, A. Spinetti¹, S. Odolini¹, C. Chirico¹, C. Grecchi¹, E. Festa¹, F. Castelli¹
¹University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy, ²University Department of Hematology, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
- P 27 Is Rapid Virological Response at Week 4 a good Predictor of Treatment Outcome (SVR) in Patients with Chronic Hepatitis C in Direct acting antivirals (DAAs) era?**
A. Bonito, S. Odolini, S. Casari, E. Bigoloni, A. Spinetti, S. Zaltron, P. Nasta, L. Urbinati, P. Lanza, E. Pollastri, C. Chirico, E. Festa, F. Castelli
University Division of Infectious and Tropical Diseases, University of Brescia and Brescia Spedali Civili General Hospital, Brescia, Italy
- P 28 Spontaneous HCV clearance after trauma and splenectomy: a case-report**
S. Dal Zoppo, S. Lorenzotti, C. Fornabaio, F. Zacchi, A. Zoncada, N. Brianese, A. Pan
Infectious Diseases Unit - Hospital of Cremona
- P 29 IFN-free treatment in genotype 4 HCV patients**
C. Taibi¹, E. Giombini², M. Selleri², B. Bartolini², C. Minozze², S. Cerilli¹, L. Loiacono¹, M.R. Capobianchi², G. D'Offizi¹, A.R. Garbuglia²
¹Hepatology and Infectious Diseases Unit, National Institute for Infectious Diseases "L. Spallanzani" I.R.C.C.S., Rome, Italy, ²Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani" I.R.C.C.S., Rome, Italy
- P 30 Safety of Direct Acting Antivirals for treatment of chronic HCV: a Case series of adverse drug reactions in course of treatment with DAAs**
T. Kamal Eldin, F. De Zottis, B. Pinchera, A. Spera, A.E. Maraolo, R. Scotto, E. Borgogno, E. Zappulo, M.G. Nerilli, G. Tosone, F. Minervini, G. Bonadies, I. Gentile, G. Borgia
Department of Clinical Medicine and Surgery . University of Naples Federico II
- P 31 Sixty weeks of undetectability HCV RNA after two weeks of combination therapy with ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in a compensated cirrhosis mono-infected patient**
C. Imburgia¹, C. Iaria¹, E.R. Dalle Nogare¹, T. Prestileo¹, A. Sanfilippo¹, F. Di Lorenzo¹, A. Ficalora¹, C. Buscemi¹, S. Marra¹, S. Corrao^{1,2}
¹Infectious Diseases Unit, Department of Medicine, National Relevance and High Specialization Hospital Trust (ARNAS) Civico - Di Cristina - Benfratelli, Palermo, Italy, ²Head of Internal Medicine Department, National Relevance and High Specialization Hospital Trust (ARNAS) Civico - Di Cristina - Benfratelli, Palermo, Italy
- P 32 Assessment of cytokines profile in HCV-positive patients receiving DAAs**
A. Occhionero¹, L. Caiazza¹, C. Catena¹, M. Reale², F. Vignale¹, C. Ucciferri¹, K. Falasca¹, J. Vecchiei¹
¹Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, ²Unit of Immunodiagnostic and Molecular Pathology, Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy
- P 33 Acute HBV reactivation (rHBV) following successful DDA treatment of HCV in a cirrhotic HIV infected patient**
E. Barchi¹, A. Zerbini², N. Solomita¹, M. Massari¹
¹UO Malattie Infettive ²Laboratorio di Autoimmunità, Allergologia e Biotecnologie Innovative - Ospedale e IRCCS S.Maria Nuova Reggio Emilia
- P 34 Evaluation of estimated glomerular filtration rate in hepatitis C virus positive patients treated with interferon free regimens with directly acting antivirals**
A. Strazzulla¹, G. Coppolino², G.S. Barreca³, I. Gentile⁴, L. Rivoli⁵, M.C. Postorino¹, M. Mazzitelli¹, G. Greco¹, C. Costa¹, V. Pisani¹, N. Marascio³, A. Focà³, G. Fuiano³, E. Gulletta⁴, C. Torti¹
¹Infectious and Tropical Diseases Unit, Department of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, Italy, ²Nephrology and Dialysis Unit, "Pugliese-Ciaccio" Hospital, Catanzaro, Italy, ³Microbiology Unit, Department of Health Sciences, "Magna Graecia" University, Catanzaro, Italy, ⁴Clinical Pathology Unit, Department of Health Sciences, "Magna Graecia" University, Catanzaro, Italy, ⁵Nephrology Unit, Department of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, Italy
- P 35 Evolution of estimated glomerular filtration rate and plasmatic neutrophil gelatinase-associated lipocalin in hepatitis C virus positive patients treated with directly acting antivirals**
A. Strazzulla¹, G. Coppolino², G.S. Barreca³, I. Gentile⁴, L. Rivoli⁵, M.C. Postorino¹, M. Mazzitelli¹, G. Greco¹, C. Costa¹, V. Pisani¹, M.A. Simeoni³, D. Foti⁴, N. Marascio³, A. Focà³, G. Fuiano³, E. Gulletta⁴, C. Torti¹
¹Infectious and Tropical Diseases Unit, Department of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, Italy, ²Nephrology and Dialysis Unit, "Pugliese-Ciaccio" Hospital, Catanzaro, Italy, ³Microbiology Unit, Department of Health Sciences, "Magna Graecia" University, Catanzaro, Italy, ⁴Clinical Pathology Unit, Department of Health Sciences, "Magna Graecia" University, Catanzaro, Italy, ⁵Nephrology Unit, Department of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, Italy



- P 36 Regression of liver fibrosis and stability of steatosis in HIV/HCV co-infected patients treated with DAAs**
F. Patti, A. Barco, L. Marinaro, C. Montrucchio, C. Alcantarini, C. Costa, S. Scabini, M. Milesi, M. Ferrara, M. Tettoni, A. D'Avolio, G. Di Perri, S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy
- P 37 Direct-Acting Antivirals (DAAs) for the treatment of HCV infection in HIV/HCV-coinfected patients: a real life experience**
C. Valeriani^{1,4}, A. Costantini^{2,4}, A. Giacometti^{1,4}, O. Cirioni^{1,4}, B. Canovari³, M. Balducci³, S. Castelletti^{1,4}, Z. Pasquini⁴, M. Bora^{1,3,4}, F. Barchiesi⁴
¹Clinica Malattie Infettive Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, ²Immunologia Clinica e Tipizzazione Tessutale Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, ³Malattie Infettive, Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro, ⁴Dipartimento di scienze biomediche e sanità pubblica Università Politecnica delle Marche Ancona

CLINICAL HIV

- P 38 Changes in lipid profile and MDRD after simplification to DRV/c mono and dual-therapy based regimens: data from a large Italian cohort**
A. Vergori¹, A. Ammassari¹, F. Di Sora², A. Giannetti¹, A. Latini³, D. Francisci⁴, R. Bellagamba¹, I. Mezzaroma⁵, S. Cicalini¹, G. D'Ettore⁵, R. Maddaluno¹, R. Monarca⁶, M. Lichtner⁷, E. Schiaroli⁸, S. Di Giambenedetto⁹, G. Maffongelli¹⁰, A. Antinori¹, M. Zaccarelli¹
¹Area Dipartimentale HIV/AIDS, Istituto Nazionale per le Malattie Infettive, IRCCS L. Spallanzani, Roma, ²Unità Operativa AIDS, Ospedale San Giovanni, Roma, ³Unità di Dermatologia infettiva, IFO-Istituto San Gallicano, Roma, ⁴Clinica Malattie infettive, Azienda Ospedaliera S. Maria, Terni, ⁵Clinica Malattie Infettive Università La Sapienza, Roma, ⁶Unità Operativa Medicina Penitenziaria, Azienda Ospedaliera Viterbo, ⁷Università "La Sapienza di Roma", Polo Pontino, ⁸Divisione Malattie Infettive Ospedale di Perugia, ⁹Istituto di Clinica Malattie Infettive, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Roma, ¹⁰UOC Malattie Infettive, Policlinico Tor Vergata, Roma
- P 39 Trends and causes of hospitalization during 1998-2016 in HIV-infected persons entered specialized care in an Italian hospital**
A. Borghetti¹, F. Lombardi¹, I. Fanti¹, L. Camoni², S. Bellino², A. Ciccullo¹, G. Baldin¹, R. Gagliardini¹, A. De Luca³, R. Cauda¹, P. Pezzotti², S. Di Giambenedetto¹
¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy, ²National Institute of Health (Istituto Superiore di Sanità), Department of Infectious Diseases, Rome, Italy, ³Division of Infectious Diseases, Siena University Hospital, Siena, Italy Department of Medical Biotechnologies, University of Siena, Siena, Italy
- P 40 Evolution of inflammation, monocyte activation and coagulation markers in the ATLAS-M randomized trial**
S. Belmonti¹, F. Lombardi¹, S. Lamonica¹, A. Ciccullo¹, G. Baldin¹, R. Gagliardini¹, A. Borghetti¹, M. Fabbiani², R. Cauda¹, A. De Luca^{3,4}, S. Di Giambenedetto¹
¹Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, ³Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁴University Division of Infectious Diseases, Hospital Department of Specialized and Internal Medicine, Siena, Italy
- P 41 Compassionate use of tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: an Italian experience**
G. Maffongelli¹, C. Cerva¹, C. Stingone¹, M.M. Plazzi², G. Fabbrì², A. Vergori², P. Vitiello³, T. Quirino³, R. Rossotti⁴, E. Danieli⁴, P. Tau⁴, M. Puoti⁴, L. Gazzola⁵, A. D'Arminio⁵, P. Lanza⁶, F. Castelli⁶, M. Trizzino⁷, A. Cascio⁷, P. Costenaro⁸, V. Manfrin⁸, R. Ferretto⁸, M. Colafigli⁹, A. Latini⁹, C. Cristaudo⁹, R. Valentinotti¹⁰, R. Luzzati¹⁰, S. Salpietro¹¹, E. Carini¹¹, A. Castagna¹¹, A. Lazzarin¹¹, A. Di Biagi¹², L. Gianserra¹³, A. Pennica¹³, B. Rossetti¹⁴, S. Modica¹⁴, A. de Luca¹⁴, P. Vittozzi¹⁵, P. Pavone¹⁵, G. Dettorre¹⁵, G. Palmiero¹⁵, G. Borgia¹⁶, G. Nardini¹⁷, G. Guaraldi¹⁷, C. Mussini¹⁷, E. Schiaroli¹⁸, F. Baldelli¹⁸, G. Lapadula¹⁹, V. Pastore¹⁹, A. Gori¹⁹, S. La Monica²⁰, R. Cauda²⁰, L. Badia²¹, P. Viale²¹, R. Marino²², F. Sozio²³, G. Parruti²³, R. Corsini²⁴, G. Magnani²⁴, M.A. Carleo²⁵, G. Pellicano²⁶, G. Nunnari²⁶, S. Marinello²⁷, A.M. Cattelan²⁷, A. Trentalange²⁸, L. Marinaro²⁸, S. Bonora²⁸, S. Ferrara²⁹, T. Santantonio²⁹, A. Chirianni²⁵, A. Antinori², L. Sarmati¹, M. Andreoni¹ con il patrocinio della Società Italiana Malattie Infettive (SIMIT)
¹Policlinico Tor Vergata Roma - UOC Malattie Infettive, ²NMI Lazzaro Spallanzani, Roma - Day Service, ³ASST Valle Olona - Presidio di Busto Arsizio - UO Malattie infettive, ⁴ASST Grande Ospedale Metropolitano Niguarda, Milano - SC Malattie Infettive, ⁵Ospedale San Paolo, Milano - Clinica Malattie Infettive e Tropicali, ⁶Spedali Civili, Brescia - UO Malattie Infettive 2, ⁷AOU Policlinico "P. Giaccone", Palermo - UOC Malattie Infettive, ⁸Ospedale Alto Vicentino Az ULSS n. 4 "Alto Vicentino" - UO Malattie Infettive, ⁹IFO - Ist Dermatologico San Gallicano Roma - Dermatologia Infettiva, ¹⁰Azienda Ospedaliero-Universitaria "Ospedali Riuniti di Trieste", ¹¹Malattie Infettive IRCCS Ospedale San Raffaele, Milano - Malattie infettive, ¹²IRCCS AOU San Martino Genova, Istituto Malattie Infettive, ¹³Azienda Ospedaliera Sant'Andrea, Roma - UOC Malattie infettive, ¹⁴Azienda Ospedaliera Universitaria Senese, Siena - UOC Malattie Infettive Universitarie, ¹⁵Policlinico Umberto I Sapienza, Roma - Malattie infettive, ¹⁶AOU Federico II, Napoli - Malattie infettive, ¹⁷A.O.U. Policlinico di Modena - Clinica delle Malattie Infettive e Tropicali, ¹⁸Ospedale SM Misericordia, Perugia - Clinica delle malattie infettive - Medicina, ¹⁹Ospedale San Gerardo, Monza - UO Malattie Infettive, ²⁰Policlinico Agostino Gemelli Istituto di Clinica Malattie Infettive, ²¹UO Malattie Infettive, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna, ²²P.O. "G. Jazolino", Vibo Valentia - UO Malattie infettive, ²³Ospedale Civile Spirito Santo Pescara, UO Malattie Infettive, ²⁴Arcispedale S. Maria Nuova di Reggio Emilia - UO Malattie Infettive, ²⁵Azienda Ospedaliera dei Colli - Ospedale D. Cotugno III Divisione, ²⁶Azienda Ospedaliera Universitaria G. Martino UOC Malattie Infettive, ²⁷Azienda Ospedaliera Università di Padova UO Malattie Infettive, ²⁸Ospedale Amedeo di Savoia Clinica Universitaria di Malattie infettive, ²⁹UO Malattie Infettive Ospedali Riuniti di Foggia
- P 42 Optimal viro-immunological response among patients starting antiretroviral therapy (ART) during primary HIV-1 infection (PHI)**
A. Mondì¹, C. Pinnetti¹, I. Abbate², G. Rozera², M.M. Plazzi¹, I. Mastroianni¹, R. Libertone¹, P. Lorenzini¹, M.R. Capobianchi², A. Antinori¹, A. Ammassari¹
¹Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy



- P 43 High-dose rosuvastatin significantly increases serum vitamin D concentration in HIV-infected patients on combination antiretroviral therapy**
L. Calza¹, E. Magistrelli¹, V. Colangeli¹, M. Borderi¹, E. Rosselli Del Turco¹, L. Bussini¹, I. Bon², M.C. Re², P. Viale¹
¹Clinics of Infectious Diseases, ²Unit of Microbiology, S.Orsola-Malpighi Hospital, University of Bologna
- P 44 Statin treatment plus vitamin D supplementation significantly decrease serum levels of inflammation and coagulation markers in HIV-infected patients on combination antiretroviral therapy**
L. Calza, E. Magistrelli, V. Colangeli, R. Manfredi, E. Rosselli Del Turco, L. Bussini, P. Viale
Clinic of Infectious Diseases, S.Orsola-Malpighi Hospital, University of Bologna
- P 45 Bloodstream infections in patients living with HIV infection in the recent cART era: did something change?**
L. Taramasso¹, F. Liggieri¹, G. Cenderello², F. Bovis³, A. Mesini¹, B. Giannini⁴, M. Giacomini⁴, G. Cassola², C. Viscoli¹, A. Di Biagio⁵
¹University of Genova, Infectious Disease Clinic, IRCCS San Martino-IST, Genova, ²Unit of Infectious Diseases, Ente Ospedaliero Ospedali Galliera, Genova, ³Biostatistics Unit, Department of Health Sciences, University of Genova, Genova, ⁴Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genova, Genova, ⁵Infectious Disease Clinic, IRCCS San Martino-IST, Genova
- P 46 A Randomized, Crossover Study to Evaluate the Efficacy of Maraviroc in Reducing the Cardiovascular Risk in HIV viro-suppressed Patients. A Pilot, Explorative, Study**
F. Baldelli¹, M. Pirro¹, E. Schiaroli¹, A. Alunno¹, F. Bagaglia¹, S. Bastianelli¹, V. Bianconi¹, O. Bistoni¹, S. Cipriani¹, V. De Angelis², E. Falcinelli¹, S. Pierucci¹, S. Gerli¹, P. Gresele¹, D. Francisci¹
¹Medicine Department - University of Perugia, ²Medicine Oncology - S. Maria della Misericordia Hospital of Perugia
- P 47 Age at acquisition of HIV affects the risk of comorbidities after 25 years of infection exposure**
N. Riva¹, A. Malagoli¹, I. Franconi¹, A. Bianchi¹, P. Sorin², A. Streinu-Cercel², E. Rossi³, M. De Rosa³, C. Mussini¹, G. Guaraldi¹
¹Department of infectious disease, Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Modena, Italy, ²National Institute for Infectious Diseases "Prof. Dr. Matei Balș", Bucharest, Romania, ³Consorzio interuniversitario per il calcolo automatico (CINECA), Bologna, Italy
- P 48 Durability of raltegravir plus abacavir/lamivudine regimens in HIV-1-infected patients: the ORASWIRAL Study**
L. Galli¹, A. Poli¹, C. Muccini^{1,2}, N. Galizzi^{1,2}, A. Danise¹, V. Spagnuolo², S. Salpietro¹, N. Gianotti¹, E. Carini¹, A. Lazzarin^{1,2}, A. Castagna^{1,2}
¹Infectious Diseases, IRCCS San Raffaele, Milano, Milano, Italy, ²Università Vita-Salute San Raffaele, Milano, Milano, Italy
- P 49 Maraviroc Pharmacokinetics in HCV/HIV co-infected patients treated with DAAs**
A. Barco¹, L. Marinaro¹, F. Patti¹, M. Merli², O. Bargiacchi³, C. Montrucchio¹, C. Alcantarini¹, F. Favata¹, A. Ariaudo¹, C. Costa¹, M. Tettoni¹, H. Hasson², A. D'Avolio¹, C. Uberti-Foppa², G. Di Perri¹, S. Bonora¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ²Infectious Diseases Clinic, IRCCS, San Raffaele Hospital, Milan, Italy, ³Infectious Diseases Section, Maggiore della Carità Hospital, Novara, Italy
- P 50 Virological Response and Resistance Profile in HIV-1 Infected Patients Starting a First-Line Regimen Containing a Protease Inhibitor or an Integrase Inhibitor in Clinical Practice**
D. Redi¹, C. Spertilli Raffaelli¹, A. D'Avino², M.C. Postorino³, A. Bezenchek⁴, R. Scutari⁵, A. Emiliozzi², M. Di Gaetano⁶, S. Barbaliscia⁵, I. Fantì², D. Di Carlo⁵, S. Di Giambenedetto², V. Borghi⁶, M. Zazzi⁷, M.M. Santoro⁵
¹Infectious Diseases Clinic, University of Siena, Italy, ²Institute of Clinical Infectious Diseases Catholic University of Sacred Heart Rome, Italy, ³Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, Italy, ⁴IPRO - InformaPRO S.r.l., Rome, Italy, ⁵Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy, ⁶Infectious Diseases Clinic, AOU of Modena, Modena, Italy, ⁷Laboratory of Virology, University of Siena, Siena, Italy
- P 51 Incidence and predictors of drug changes in first-line cART show stability of regimens including integrase inhibitors notwithstanding complexity of factors and increased propensity to change over calendar years: results from the MASTER Cohort Study**
E. Focà¹, M. Proserpi², F. Castelli¹, S. Casari¹, F. Maggiolo³, E. Di Filippo³, S. Di Giambenedetto⁴, F. Baragli⁵, N. Ladisa⁶, A. Gori⁷, L. Sighinolfi⁸, A. Pan⁹, C. Torti¹⁰ on behalf of MASTER Cohort Study Group
¹University Division of Infectious and Tropical Disease, University of Brescia and Spedali Civili General Hospital, Brescia, ²Department of Epidemiology, College of Public Health and Health Professions & College of Medicine, University of Florida, Gainesville, FL, ³Clinic of Infectious Diseases, Ospedali Riuniti Bergamo, ⁴Institute of Infectious Diseases, Catholic University of Sacred Heart Rome, ⁵Clinic of Infectious Diseases, S. M. Annunziata Hospital Florence, ⁶Institute of Infectious Diseases, Policlinico di Bari, ⁷Clinic of Infectious Diseases, Ospedale S. Gerardo Monza, ⁸Clinic of Infectious Disease, S. Anna Hospital Ferrara, ⁹Clinic of Infectious Diseases, Istituti Ospitalieri Cremona, ¹⁰Clinic of Infectious Diseases University Magna Graecia Catanzaro
- P 52 Cerebrospinal Fluid EBV Replication is Associated with Compartmental Inflammation and Pleocytosis in HIV-positive naïve and Treated Individuals**
T. Lupia¹, M.G. Milia², C. Atzori¹, S. Audagnotto¹, D. Imperiale³, A. Romito¹, S. Scabini¹, G. Gregori², F. Lipani¹, S. Bonora¹, G. Di Perri¹, A. Calcagno¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, ²Laboratory of Microbiology and Molecular Biology, Ospedale Amedeo di Savoia, ASLTO2, ³Unit of neurology, Maria Vittoria Hospital, ASLTO2



- P 53 Outcome of HIV-associated Non Hodgkin Lymphomas presenting at HIV diagnosis or under antiretroviral treatment- Results from MULTICENTRIC STUDY of HIV Associated Lymphomas (MUSTHAL study)**
A. Bandera¹, L. Verga², I. De Benedetto¹, E. Colella¹, E. Doni², A. Muscatello¹, N. Bianchetti², F. Crippa³, D. Dalu⁴, O. Giglio⁵, M. Menà⁶, D. Santoro⁵, E. Suardi³, P. Vitiello⁷, C. Zeroli⁷, A. Gori¹
¹Infectious Diseases Unit, S. Gerardo Hospital, Monza, University of Milan-Bicocca, ²Haematology Unit, S. Gerardo Hospital, Monza, University of Milan-Bicocca, ³San Paolo Hospital, Institute of Infectious and Tropical Diseases, Dep. Health and Sciences, University of Milan, ⁴Department of Oncology, Luigi Sacco Hospital, Milan, ⁵Infectious Diseases Unit, Sant'Anna Hospital, Como, ⁶Department of Infectious Diseases, Ospedale Civile di Legnano, Legnano, ⁷Infectious Diseases Unit, Ospedale di Circolo di Busto Arsizio
- P 54 Alternate-day TDF/FTC/EFV single tablet regimen as maintenance therapy in virologically suppressed HIV individuals: results of the Day-On Day-Off (DODO) pilot study**
C. Tontini¹, S. Agolini¹, M. Cognigni¹, A. Corsi¹, A. Marchionni¹, M. Martini¹, M. Rocchi¹, L. Butini², A. Costantini^{1,2}
Servizio Regionale di Immunologia Clinica e Tipizzazione Tessutale: ¹Università Politecnica delle Marche - Ancona, ²Azienda Ospedaliero Universitaria Ospedali Riuniti - Ancona
- P 55 Efficacy and safety of switching to dolutegravir (DTG) plus tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or elvitegravir (EVG)/cobicistat (COBI)/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) in virologically suppressed (VS) HIV-infected patients in clinical practice: results from a multicenter, observational study**
G. Baldin¹, A. Ciccullo¹, A. Borghetti¹, S. Lamonica¹, A. Capetti², M.V. Cossu², S. Rusconi³, L. Oreni³, G. Sterrantino⁴, F. Lagi⁴, A. Latini⁵, M. Colafigli⁵, A. Giacometti⁶, J. Vecchief⁷, G. Carvana⁸, S. Di Giambenedetto¹ and G. Madeddu⁹
¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy, ²Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, ³Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, ⁴Division of Tropical and Infectious Diseases, 'Careggi' Hospital, Florence, Italy, ⁵Infectious Dermatology and Allergology Unit, IFO S. Galliciano Institute (IRCCS), Rome, Italy, ⁶Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy, ⁷Infectious Diseases Clinic, University of Chieti, Chieti, Italy, ⁸Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
- P 56 Optimization strategies in a multicenter cohort of HIV1-infected, virologically suppressed patients: dual therapy (lamivudine + dolutegravir) vs Single Tablet Regimen (abacavir/lamivudine/dolutegravir)**
G. Baldin¹, A. Ciccullo¹, A. Capetti², S. Rusconi³, G. Sterrantino⁴, G. Madeddu⁵, M.V. Cossu², T. Formenti³, F. Lagi⁴, M. Colafigli⁵, A. Freedman⁷, A. De Luca⁸, S. Di Giambenedetto¹
¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy, ²Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, ³Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, ⁴Division of Tropical and Infectious Diseases, 'Careggi' Hospital, Florence, Italy, ⁵Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ⁶Infectious Dermatology and Allergology Unit, IFO S. Galliciano Institute (IRCCS), Rome, Italy, ⁷Department of Infectious Diseases, University Hospital of Wales, Cardiff, UK, ⁸University Division of Infectious Diseases, Siena University Hospital, Siena, Italy
- P 57 Efficacy and Tolerability of dual therapy based on dolutegravir (DTG) and atazanavir/ritonavir (ATV/r) in the clinical setting**
C. Alcantarini, M. Ferrara, L. Marinaro, B. Granozzi, M.C. Tettoni, C. Montrucchio, M. Milesi, A. Barco, C. Costa, G. Di Perri, S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy
- P 58 Integrase strand-transfer inhibitors mutations in ART-naive patients with acute/recent HIV-1 infection: exploring an evolving scenario**
L. Lepore, C. Fabrizio, A. Leone, A. Lagioia, G. Punzi, A. Saracino, G. Angarano, L. Monno
Clinica Malattie Infettive, Università di Bari
- P 59 Dual unboosted atazanavir-lamivudine combination as maintenance treatment in virologically suppressed HIV-1-infected patients**
F. Rigo¹, G. Cucchetto¹, M. Lanzafame¹, S. Nicolè¹, E. Lattuada¹, E. Concia¹, S. Vento^{2,3}
¹Infectious Diseases Unit, "G.B. Rossi" University Hospital, Verona, Italy, ²Department of Medicine, School of Medicine, Nazarbayev University, ³University Medical Center, Astana, Kazakhstan
- P 60 Elevated serum uric acid levels impair endothelial function in HIV patients receiving antiretroviral therapy**
D. Francisci¹, V. Bianconi², E. Schiaroli¹, M.R. Mannarino², F. Bagaglia², A. Sahebkar³, T. Merriman⁴, F. Baldelli¹, M. Pirro²
¹Unit of Infectious Diseases, Department of Medicine, University of Perugia, ²Unit of Internal Medicine, Department of Medicine, University of Perugia, ³Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran, ⁴Department of Biochemistry, University of Otago, New Zealand
- P 61 Effect of Switching to Dolutegravir on HIV-DNA Levels and Residual Viremia in Patients with Suppressed HIV-RNA**
F. Lombardi¹, S. Belmonti¹, R. Ricci², D. Speciale², E. Visconti¹, D. Moschese¹, A. Borghetti¹, R. Gagliardini¹, G. Baldin¹, A. De Luca^{3,4}, R. Cauda¹, S. Di Giambenedetto¹
¹Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, ²Department of Diagnostic and Laboratory Medicine, Institute of Microbiology, Catholic University of Sacred Heart, Rome, Italy, ³Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁴University Division of Infectious Diseases, Hospital Department of Specialized and Internal Medicine, Siena, Italy
- P 62 The disease burden associated with HIV associated chronic pulmonary disease exceed COPD diagnosis**
A. Santoro¹, A. Malagoli¹, L. Wallace², M. Menozzi¹, M. Digaetano¹, N. Riva¹, I. Franconi¹, A. Raimondi¹, A. Bianchi¹, C. Mussini¹, G. Guaraldi¹
¹Infectious Disease Department, University of Modena and Reggio Emilia, Italy, ²Geriatric Medicine Research Unit Dalhousie University/Nova Scotia Health Authority



- P 63 Metabolic, renal and liver events related to EVG/COBI/FTC/TDF use in SCOLTA project: a real life experience**
N. Squillace¹, E. Ricci², T. Quirino³, A. Gori¹, L. Carezzi², G.V. De Socio⁴, G. Orofino⁵, C. Martinelli⁶, F. Peruzzo⁷, S. Rusconi⁸, P. Maggi⁹, B.M. Celesia¹⁰, L. Cordier², F. Vichi¹¹, L. Calza¹², K. Falasca¹³, A. Di Biagio¹⁴, G.F. Pellicano¹⁵, P. Bonfanti¹⁶
¹Infectious Diseases Clinic, Azienda Socio Sanitaria Territoriale di MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy, ²Department of Infectious Diseases, Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco-Milano, Italy, ³Unit of Infectious Diseases, Azienda Socio Sanitaria Territoriale della Valle Olona - Busto Arsizio (VA), Italy, ⁴Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ⁵Unit of Infectious Diseases, Amedeo di Savoia Hospital, Torino, Italy, ⁶Unit of Infectious Diseases, Careggi Hospital, Firenze, Italy, ⁷Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ⁸Infectious Diseases, Department of Biomedical and Clinical Science Luigi Sacco, University of Milan, Milan, Italy, ⁹Infectious Disease Clinic, University of Bari, Italy, ¹⁰Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, ¹¹Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Firenze, Italy, ¹²Department of Infectious Diseases, S.Orsola Malpighi Hospital, Bologna, Italy, ¹³Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G.d'Annunzio" Chieti-Pescara, Chieti, Italy, ¹⁴Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy, ¹⁵Infectious Diseases, G. Martino Hospital -University of Messina, Messina, Italy, ¹⁶Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy
- P 64 Efficacy and safety of the switch to dolutegravir-based dual therapy in HIV positive experienced patients**
M. Giralda¹, E. Quiros², G. Parainfo², F. Maggiolo³, E. De Filippo³, S. Digiambenedetto⁴, A. Gori⁵, N. Ladisa⁶, M. Di Pietro⁷, L. Sighinolfi⁸, A. Pan⁹, F. Castelnuovo¹⁰, N. Mazzini¹, G. Carosi¹ and the MaSTER study group
¹M.I.S.I Foundation, ²University Division of Infectious and Tropical Disease, University of Brescia, Brescia, Italy, ³Clinic of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy, ⁴Institute of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ⁵Clinic of Infectious Diseases, Ospedale S. Gerardo, Monza, Italy, ⁶Institute of Infectious Diseases Policlinico di Bari, Italy, ⁷Clinic of Infectious Diseases, S. M. Annunziata Hospital, Florence, Italy, ⁸Clinic of Infectious Disease, S. Anna Hospital, Ferrara, Italy, ⁹Clinic of Infectious Diseases, Istituti Ospitalieri, Cremona, Italy, ¹⁰Clinic of Infectious Disease, ASST Spedali Civili di Brescia, Brescia, Italy
- P 65 Atazanavir-based dual antiretroviral regimens in routine clinical practice**
M. Colafigli¹, A. Borghetti², I. Fanti², G. d'Etorre³, F. Di Sora⁴, G. Maffongelli⁵, E. Anzalone⁶, R. Marocco⁷, A. Pennica⁸, M. Scuderi⁹, M. Lichtner⁷, A. Cristaudo¹, C.M. Mastroianni⁷, M. Andreoni¹⁵, V. Vullo³, R. Cauda², A. Latini¹, S. Di Giambenedetto²
¹UOSD Dermatologia MST, ambientale, Tropicale e Immigrazione, IFO- San Gallicano, Roma, ²Istituto di Clinica delle Malattie Infettive, Università Cattolica del S. Cuore, Roma, ³Policlinico Umberto I Università La Sapienza, Roma- Malattie Infettive, ⁴AO San Giovanni Addolorata UOS Immunologia Clinica, ⁵UOC Malattie Infettive, Policlinico Tor Vergata, Roma, ⁶UOC Malattie Infettive, Ospedale F. Spaziani di Frosinone, ⁷UOC Malattie Infettive, Università Sapienza di Roma, Ospedale Santa Maria Goretti, Latina, ⁸UOC Malattie Infettive, AO Sant'Andrea, Roma, ⁹UOSD Malattie Infettive AO "S. Camillo de Lellis" Rieti
- P 66 Unmet needs of patients infected by HIV with HCV/HBV co-infections over a decade in Italy: results of the Italian MaSTER cohort**
C. Torti¹, M. Prosperi², M. Giralda³, P. Nasta⁴, E. Quiros-Roldan⁴, F. Maggiolo⁵, S. Di Giambenedetto⁶, A. Saracino⁷, M. di Pietro⁸, L. Sighinolfi⁹, A. Gori¹⁰, S. Lorenzotti¹¹, M.C. Postorino¹, G. Carosi²
¹Infectious and Tropical Diseases Unit, University "Magna Graecia", Catanzaro, Italy, ²Department of Epidemiology, College of Public Health and Health Professions & College of Medicine, University of Florida, Gainesville, FL, ³Infectious Diseases and International Health Foundation, Brescia, Italy, ⁴Infectious and Tropical Diseases, University of Brescia, Brescia, Italy, ⁵Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo, Italy, ⁶Infectious Diseases, Policlinico A. Gemelli - Catholic University, Roma, Italy, ⁷Infectious Diseases, Policlinico di Bari, Italy, ⁸Infectious Diseases, S.M. Annunziata Hospital, Firenze, Italy, ⁹Infectious Diseases, Nuovo Polo Ospedaliero di Cona, Ferrara, Italy, ¹⁰Infectious Diseases, San Gerardo Hospital, Monza, Italy, ¹¹Infectious Diseases, Istituti Ospitalieri, Cremona, Italy
- P 67 The effect of switching to Darunavir/r + Maraviroc dual therapy in virologically suppressed patients on the progression of liver fibrosis: findings from a randomized study**
B. Rossetti^{1,2}, R. Gagliardini², G. Sterrantino³, V. Colangeli⁴, A. Latini⁵, M. Colafigli⁵, Vignale⁶, S. Rusconi⁷, A. Di Biagio⁸, G. Orofino⁹, I. Mezzaroma¹⁰, V. Vullo¹¹, D. Francisci¹², C. Mastroianni¹³, M. Trezzi¹⁴, B. Canovari¹⁵, A. D'Arminio Monforte¹⁶, S. Lamonica², D. Faliero², S. Di Giambenedetto², A. De Luca^{1,7} for GUSTA trial study group
¹Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ²Clinic of Infectious Diseases, Catholic University of Sacred Heart, Roma, Italy, ³Clinic of Infectious Diseases, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy, ⁴Clinic of Infectious Diseases, Azienda Ospedaliera Universitaria S.Orsola Malpighi, Bologna, Italy, ⁵Infectious Dermatology and Allergy IRCCS IFO, Roma, Italy, ⁶Clinic of Infectious Diseases, G. D'Annunzio University, Chieti, Italy, ⁷Infectious and Tropical Diseases Unit, DIBIC L. Sacco Hospital, University of Milano, Italy, ⁸Infectious Diseases Unit, IRCCS S. Martino-IST, Genova, Italy, ⁹Infectious Diseases Unit A, Amedeo di Savoia Hospital, Torino, Italy, ¹⁰Department of Clinical Medicine, Sapienza University of Rome, Roma, Italy, ¹¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Roma, Italy, ¹²Clinic of Infectious Diseases, University of Perugia, Italy, ¹³Infectious Disease Unit, SM Goretti Hospital, Department of Public Health and Infectious Diseases, Sapienza University, Latina, Italy, ¹⁴Infectious Diseases Unit, Pistoia Hospital, Italy, ¹⁵Infectious Diseases Unit, Pesaro Hospital, Italy, ¹⁶Infectious and Tropical Diseases Institute, Department of Health Sciences, University of Milan, San Paolo Hospital, Milan, Italy, ¹⁷Department of Medical Biotechnologies, University of Siena, Italy
- P 68 Prevalence of fragility vertebral fractures in a population of HIV-infected patients**
S. Duranti¹, A. Londero¹, F. Vescini², N. Castaldo¹, F. Grimaldi², M. Bassetti¹
¹Clinica di Malattie Infettive, Azienda Sanitaria Universitaria Integrata di Udine, ²Endocrinologia e Malattie del Metabolismo, Azienda Sanitaria Universitaria Integrata di Udine
- P 69 Use of Integrase Strand Transfer Inhibitors (INSTIs) is not associated to Neurocognitive Impairment (NCI) in HIV positive persons**
C. Pinnetti, I. Mastroianni, P. Lorenzini, P. Balestra, M. Ricottini, A. Mondì, V. Mazzotta, G. Fabbri, S. Cicalini, M. Zaccarelli, A. Ammassari, A. Antinori
 National Institute for Infectious Diseases, IRCCS, L. Spallanzani, HIV/AIDS Department, Rome
- P 70 Dolutegravir plus rilpivirine dual regimen as a switch option in HIV-infected, cART-experienced subjects**
A.F. Capetti¹, G.V. De Socio², M.V. Cossu¹, G. Sterrantino³, G. Barbarini⁴, S. Di Giambenedetto⁵, G.C. Orofino⁶, A. Di Biagio⁷, B.M. Celesia⁸, B. Argentero¹, G. Rizzardini^{1,9}
¹1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy, ²Infectious Diseases Clinic, Azienda Ospedaliera-Universitaria di Perugia, Perugia, Italy, ³Division of Infectious Diseases, "Careggi" Hospital, Firenze, Italy, ⁴2nd Division of Infectious Diseases, "Policlinico San Matteo" Hospital, Pavia, Italy, ⁵2nd Division of Infectious Diseases, "Policlinico Universitario Agostino Gemelli" Hospital, Roma, Italy, ⁶Division of Infectious Diseases, "Amedeo di Savoia" Hospital, Torino, Italy, ⁷Infectious Diseases Clinic, "San Martino" Hospital, Genova, Italy, ⁸Infectious Diseases Unit, University of Catania, ARNAS (Azienda Ospedaliera di Rilevato Nazionale e di Alta Specializzazione) Garibaldi, Catania, Italy, ⁹Whitwaterstrand University, Johannesburg, South Africa
- P 71 Diabetes and insulin resistance in HIV infected adults**
F. Maggiolo¹, R. Teocchi², E. Di Filippo¹, L. Comi¹, A. Callegaro³, D. Valenti¹, M. Rizzi¹
¹USC of Infectious Diseases, ²Informatic Department, ³Laboratory of Microbiology and Virology, ASST Papa Giovanni XXIII, Bergamo



- P 72 Correlates of neurocognitive impairment among chronically HIV-suppressed patients under treatment with tenofovir/emtricitabine/efavirenz: screening results from the SWEAR (Switch from Efavirenz/Atripla to Rilpivirine) Study**
G. Lapadula¹, P. Tatarelli², E. Focà³, F. Bai⁴, S. Bonora⁵, A. Bandera¹, M. Bani⁶, M. Valsecchi⁶, M. Fabbiani¹, G. Di Perri⁴, A. Di Biagio², F. Castelli³, A. d'Arminio-Monforte⁴, F. Conti⁶, M. Tosato², B. Saccani³, S. Compostella³ and A. Gori for the SWEAR study group^{1,6}
¹UO Malattie Infettive, Ospedale San Gerardo, ASST Monza, Monza, ²Clinica Malattie Infettive, IRCCS AOU San Martino-IST, Genova, ³Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia, Brescia, ⁴UO Malattie Infettive, Ospedale San Paolo, ASST Santi Carlo e Paolo, Università degli Studi di Milano, ⁵Clinica di Malattie Infettive, Università degli Studi di Torino, Torino, ⁶Università di Milano-Bicocca, Milano, Italy
- P 73 Raltegravir plus lamivudine as "maintenance" therapy in suppressed HIV-1 infected patients in real life settings**
G. Cucchetto¹, M. Lanzafame¹, S. Nicolè¹, E. Lattuada¹, L. Calza², E. Concia¹
¹Infectious Disease Unit, G.B. Rossi University Hospital, Verona, Italy, ²Clinic of Infectious Diseases, University of Bologna at S. Orsola-Malpighi Hospital in Bologna, Italy
- P 74 Long-term Immune Response to 13-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine In HIV-1 Infected Adults**
F. Lombardi¹, S. Belmonti¹, B. Rossetti^{1,2}, S. Modica³, L. Paglicci³, S. Lamonica¹, R. Cauda¹, A. De Luca^{2,3}, F. Montagnani^{2,3}
¹Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, ²University Division of Infectious Diseases, Hospital Department of Specialized and Internal Medicine, Siena, Italy, ³Department of Medical Biotechnologies, University of Siena, Italy
- P 75 Virological and Immunological efficacy of Maraviroc-based regimens in experienced patients with undetectable HIV viral load**
D. Redi¹, B. Rossetti^{1,13}, L.I. Bellazzi², I. Vicenti³, G. Colao⁴, G. Sterrantino⁵, L. Monno⁶, G. Punzi⁷, V. Borghi⁸, M. Pecorari⁹, S. Paolucci¹⁰, P. Meraviglia¹¹, V. Micheli¹², S. Di Giambenedetto^{1,3}, M. Zazzi³, A. De Luca^{1,13}
¹Infectious Diseases Clinic, University of Siena, Italy, ²Infectious Diseases Clinic, S. Matteo Hospital, Pavia, Italy, ³Laboratory of Virology, University of Siena, Italy, ⁴Laboratory of Virology, Careggi Hospital, Florence, Italy, ⁵Infectious Diseases Clinic, Careggi Hospital, Florence, Italy, ⁶Infectious Diseases Clinic, University of Bari, Italy, ⁷Laboratory of Virology, Bari, Italy, ⁸Infectious Diseases Clinic, Modena, Italy, ⁹Laboratory of Virology, Modena, Italy, ¹⁰Laboratory of Virology, S. Matteo Hospital, Pavia, Italy, ¹¹Second Division of Infectious Diseases Clinic, L. Sacco Hospital, Milan, Italy, ¹²Laboratory of Microbiology of Second Division of Infectious Diseases Clinic, L. Sacco Hospital, Milan, Italy, ¹³Clinic of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
- P 76 Durability and virological response to Dual and Mono Antiretroviral therapy in 45 HIV+ patients: a 5-years experience at Santa Maria Annunziata Hospital, Florence Area, 2012-2016**
F.M. Fusco¹, F. Vichi¹, A. Poggi¹, M.C. Burla², L. Rabatti², F. Baragli¹, A. Gabbuti¹, A. Degli Esposti¹, P. Pierotti¹, C. Blè, L. Mecocci¹, M. Di Pietro³, P. Blanc¹
¹SOC Malattie Infettive 1, Azienda USL Toscana Centro, Ospedale S. Maria Annunziata, Bagno a Ripoli (FI), ²Servizio di Farmacia Ospedaliera, Ospedale S. Maria Annunziata, USL Toscana Centro, Bagno a Ripoli (FI), ³SOC Malattie Infettive 2, Azienda USL Toscana Centro, Ospedale San Jacopo, Pistoia
- P 77 Durable viral control by boosted atazanavir or darunavir plus maraviroc (MVC) in poorly adherent subjects in view of long-acting regimens**
A.F. Capetti¹, M.V. Cossu¹, N. Astuti¹, S. Landonio¹, F. Niero¹, S. Vimercati², G. Rizzardini^{1,3}
¹1st Division of Infectious Diseases, Luigi Sacco Hospital, Milano, Italy, ²Pharmacy Unit, Luigi Sacco Hospital, Milano, Italy, ³Whitwaterstrand University, Johannesburg, South Africa
- P 78 Darunavir/cobicistat monotherapy in experienced HIV-1 positive subjects**
G. Sterrantino, P. Rogasi, M. Trotta, A. Bartoloni
Azienda Ospedaliero-Universitaria Careggi, Sod Malattie Infettive e Tropicali, Firenze
- P 79 Different Cell Cycle Modulation in SKOV-3 Ovarian Cancer Cell Line by Anti-HIV Drugs**
M.A. Carleo¹, V. Sangiovanni¹, V. Iodice¹, A. De Luca², V. Esposito³, A. Chirianni¹
¹III Divisione Infezioni sistemiche e dell'Immunodepresso - AO Ospedali dei Colli - O. "D. Cotugno" - Napoli, ²Dipartimento di Salute Mentale e Fisica e Medicina Preventiva - Sezione di Anatomia Umana - Università degli Studi della Campania "L. Vanvitelli", ³IV Divisione Immunodeficienze e Malattie Infettive di genere - AO Ospedali dei Colli - O. "D. Cotugno" - Napoli
- P 80 Internet illiteracy as a barrier to web- based health promotion resource among elderly HIV patients**
A. Caselgrandi¹, A. Malagoli¹, M. Mancini¹, V. Masi¹, E. Bardi¹, M. Corni¹, M. Menozzi¹, S. Zona¹, F. Carli¹, C. Mussini¹, L. Wallace², G. Guaraldi¹
¹Clinica delle Malattie Infettive e Tropicali, Università di Modena e Reggio Emilia, ²Department of Medicine Dalhousie University, Halifax, Canada
- P 81 HIV Genotypic Drug Resistance test (GRT) for Integrase Strand Transfer Inhibitors (INSTIs) at low level viremia: light and shadow in the clinical practice**
D. Mileto¹, D. Cattaneo², A. Mancon¹, A. Tamoni¹, L. Fiori¹, P. Meraviglia³, S. Rusconi⁴, M. Gismondo¹, V. Micheli¹
¹Clinical Laboratory of Microbiology, Virology and Biomengencies, ASST FBF-Sacco, L. Sacco University Hospital, ²Unit of Clinical Pharmacology, ASST FBF-Sacco, L. Sacco University Hospital, ³Department Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, ⁴3rd Division of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan
- P 82 Changes of lipid profile after switching to E/C/F/TAF: data from the Italian Compassionate Use Program**
A. Vergori¹, G. Fabbri¹, P. Lorenzini¹, M. Plazzi¹, G. Maffongelli², C. Cerva², P. Vitiello³, T. Quirino³, R. Rossotti⁴, E. Danieli⁴, P. Tau⁴, M. Puoti⁴, P. Lanza⁵, F. Castelli⁵, M. Trizzino⁶, A. Cascio⁶, P. Costenaro⁷, V. Manfrin⁷, R. Ferretto⁷, M. Colafigli⁸, A. Latin⁹, C. Cristaudo⁸, L. Gianserra⁹, A. Pennica⁹, B. Rossetti¹⁰, S. Modica¹⁰, A. de Luca¹⁰, G. Nardini¹¹, G. Guaraldi¹¹, C. Mussini¹¹, E. Schiaroli¹², F. Baldelli¹², G. Lapadula¹³, V. Pastore¹³, A. Gori¹³, S. La Monica¹⁴, R. Cauda¹⁴, L. Badia¹⁵, P. Viale¹⁵, R. Corsini¹⁶, G. Magnani¹⁶, M.A. Carleo¹⁷, G. Pellicano¹⁸, G. Nunna-ri¹⁸, A. Chirianni¹⁷, M. Andreoni², A. Antinori¹ con il patrocinio della Società Italiana di Malattie Infettive e Medicina Tropicale
¹Area Dipartimentale HIV/AIDS, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS, Roma, ²UOC Malattie Infettive-Policlinico Tor Vergata, Roma, ³UO Malattie infettive, ASST Valle Olona, Presidio di Busto Arsizio, ⁴SC Malattie Infettive ASST Grande Ospedale Metropolitano Niguarda, Milano, ⁵UO Malattie Infettive 2, Spedali Civili, Brescia, ⁶UOC Malattie Infettive, AOU Policlinico P. Giaccone, Palermo, ⁷UO Malattie Infettive, Ospedale Alto Vicentino Az ULSS n. 4 "Alto Vicentino", ⁸Dermatologia Infettiva, IFO - Ist Dermatologico San Gallicano, Roma, ⁹UOC Malattie infettive, Azienda Ospedaliera Sant' Andrea, Roma, ¹⁰UOC Malattie Infettive Universitarie, Azienda Ospedaliera Universitaria Senese, Siena, ¹¹Clinica delle Malattie Infettive e Tropicali, AOU Policlinico, Modena, ¹²Clinica delle malattie infettive - Medicina, Ospedale SM Misericordia, Perugia, ¹³UO Malattie Infettive, Ospedale San Gerardo, Monza, ¹⁴Istituto di Clinica Malattie Infettive, Policlinico Agostino Gemelli, Roma, ¹⁵UO Malattie Infettive, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna, ¹⁶UO Malattie Infettive, Arcispedale S. Maria Nuova, Reggio Emilia, ¹⁷III Divisione, Azienda Ospedaliera dei Colli - Ospedale D. Cotugno, Napoli, ¹⁸UOC Malattie Infettive, Azienda Ospedaliera Universitaria G. Martino, Messina



- P 83 NRTI-sparing regimens: renal safety**
P. Colletti¹, A. Cervo¹, G. Mazzola¹, M. Trizzino¹, M. Mineo¹, L. Adamoli¹, P. Di Carlo¹, D. Matranga², A. Cascio¹
¹UOC di Malattie Infettive e Centro Regionale di Riferimento AIDS – Policlinico Palermo, ²Dipartimento PROSAMI – Università di Palermo
- P 84 Management of diabetes mellitus among HIV-infected patients in an Italian cohort**
F. Castelnuovo, A. Bergamasco
¹° Division of Infectious Diseases, Spedali Civili di Brescia
- P 85 Characteristics and viro-immunological outcomes of HIV-infected patients aged >65 years: a retrospective monocentric study**
A. Emiliozzi, R. Gagliardini, A. Borghetti, G. Baldin, D. Moschese, D. Faliero, A. Ciccullo, S. Lamonica, R. De Marco, A. Brita, S. Belmonti, F. Lombardi, R. Cauda, S. Di Giambenedetto
Department of Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
- P 86 Retrospective observational study on efficacy of TDF/FTC+DTG as a first-line therapy versus other recommended first line therapies in clinical practice**
F. Del Puente, P. Tatarelli, E. Balleto, N. Riccardi, F. Magnè, A. Di Biagio
IRCCS San Martino, Infectious Disease Department, Genova
- P 87 Trimethylamine-N-oxide Serum Concentrations in HIV-positive Treated Patients**
C. Costa, C. Montrucchio, D. Pensi, S. Sbrulati, C. Alcantarini, A. Barco, M. Ferrara, M. Milesi, A. Trentalange, M.C. Tettoni, A. D'Avolio, S. Bonora, G. Di Perri, A. Calcagno
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino
- P 88 Patients with sub-adherence to HAART: how to identify them to prevent therapy failures?**
G. Orofin¹, M. Guastavigna², C. Carcieri¹, S. Bertini³, D. Piccioni³, S. Carosella², M. Farenga², G. Cinnirella³, P. Caramello²
¹Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy, ²Division A of Infectious Diseases, Amedeo di Savoia Hospital, Turin, Italy, ³Pharmacy Department, Amedeo di Savoia Hospital, Turin, Italy
- P 89 Statin need and protease inhibitors: harm or a clinical opportunity?**
S. Zona, F. Carli, M. Menozzi, B. Beghetto, G. Nardini, A. Santoro, C. Mussini, G. Guaraldi
Infectious Diseases Unit, Policlinico di Modena
- P 90 Antiretroviral dual regimens sparing agents from boosted (RTV or Cobi)-protease inhibitor class and integrase strand transfer inhibitors (ISTIs) class**
A. Mastroianni¹, E. Briganti¹, F. Allegrini¹, C. Grosso¹, S. Brighi¹, S. Di Cesare¹, G.F. Ravaglia², F. Pieraccini², C. Cancellieri¹
¹U.O. Malattie Infettive, P.O. "G.B. Morgagni – L.Pierantoni", Forlì, ²Farmacia, P.O. "G.B. Morgagni – L.Pierantoni", Forlì
- P 91 Boosted darunavir plus dolutegravir as salvage or simplification of salvage therapy: 48 weeks' data**
A.F. Capetti¹, G. Orofino², G. Sterrantino³, A. Soria⁴, G. Cenderello⁵, M.V. Cossu¹, A.M. Cattelan⁶, G.V. De Socio⁷, S. Rusconi⁸, N. Riccardi⁹, G.M. Baldin⁹, G. Barbarini¹⁰, F.P. Niero¹, G. Rizzardini^{1,12}
¹1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy, ²1st Division of Infectious Diseases, Amedeo di Savoia Hospital, Torino, Italy, ³Division of Infectious Diseases, "Careggi", Hospital, Firenze, Italy, ⁴Infectious Diseases Clinic, "San Gerardo de' Tintoni" University Hospital, Monza, Italy, ⁵Division of Infectious Diseases, Ospedali Galliera, Genova, Italy, ⁶Division of Infectious and Tropical Diseases, Azienda Ospedaliera-Universitaria di Padova, Padova, Italy, ⁷Infectious Diseases Clinic, Azienda Ospedaliera-Universitaria di Perugia, Perugia, Italy, ⁸Infectious Diseases Clinic, ASST Fatebenefratelli-Sacco, Milano, Italy, ⁹Infectious Diseases Clinic, "San Martino" Hospital, Genova, Italy, ¹⁰2nd Division of Infectious Diseases, Università Cattolica del Sacro Cuore, Roma, Italy, ¹¹2nd Division of Infectious Diseases, "Policlinico San Matteo" Hospital, Pavia, Italy, ¹²Whitwaterstrand University, Johannesburg, South Africa
- P 92 CCR5 inhibitor based antiretroviral therapy and liver fibrosis progression in HIV positive patients (MAICOL study final and posthoc analysis)**
P. Nasta¹, E. Chiari¹, F. Gatti², M. Giralda³, F. Pasotti⁴, D. Ricotta⁴, G. Carosi³, F. Castelli¹
¹University Division of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy, ²"La Memoria" Hospital, Emergency Room, Gavardo, Brescia, Italy, ³MISI Foundation-Infectious Diseases and International Health, ⁴Department of Biomedical Sciences and Technologies, University of Brescia, Italy
- P 93 Management and prevention of dolutegravir-related insomnia**
A.F. Capetti¹, I. De Benedetto², G.M. Baldin³, A. Latini⁴, G. Sterrantino⁵, S. Landonio¹, M.V. Cossu¹, F.P. Niero¹, N. Astuti¹, L. Valsecchi¹, P. Meraviglia¹, S. Di Giambenedetto³, A. Gori², G. Rizzardini^{1,6}
¹1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy, ²Infectious Diseases Clinic, "San Gerardo de' Tintoni" University Hospital, Monza, Italy, ³2nd Division of Infectious Diseases, Università Cattolica del Sacro Cuore, Roma, Italy, ⁴Infectious Dermatology Unit, IFO – Istituto Dermatologico San Gallicano, Roma, Italy, ⁵Division of Infectious Diseases, "Careggi", Hospital, Firenze, Italy, ⁶Whitwaterstrand University, Johannesburg, South Africa
- P 94 Hypophosphatemia is not a predictive marker of impaired bone mineral density: a cross sectional study**
M. Maritati¹, V. Guardigni^{2,3}, D. Segala³, L. Sghinolfi³
¹Section of Infectious Diseases, Department of Medical Sciences, University of Ferrara, Italy, ²Department of Medical and Surgical Sciences, University of Bologna, Italy, ³Infectious Diseases Unit, Sant'Anna Hospital, Ferrara, Italy
- P 95 Prevalence and correlates of transaminitis in HIV-1 infected patients in the absence of HCV and HBV infection**
C. Resnati¹, V. Morena¹, E. Gervasi¹, S. Limonta¹, L. Oreni¹, A. Riva²
¹Infectious Diseases Unit, L. Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy, ²III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy

- P 96 How maraviroc was prescribed in routine clinical practice and what impact of fibrosis or inflammation markers?**
P.M. Concetta¹, C. Torti¹, P. Nasta², E. Quiros-Roldan², F. Maggiolo³, S. Di Giambenedetto⁴, A. Saracino⁵, M. Pietro⁶, L. Sighinolfi⁷, A. Gori⁸, S. Lorenzotti⁹, G. Carosi¹⁰
¹Infectious and Tropical Diseases Unit, University "Magna Graecia", Catanzaro, Italy, ²Infectious and Tropical Diseases, University of Brescia, Brescia, Italy, ³Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo, Italy, ⁴Infectious Diseases, Policlinico A. Gemelli – Catholic University, Roma, Italy, ⁵Infectious Diseases, Policlinico di Bari, Italy, ⁶Infectious Diseases, S.M. Annunziata Hospital, Firenze, Italy, ⁷Infectious Diseases, Nuovo Polo Ospedaliero di Cona, Ferrara, Italy, ⁸Infectious Diseases, San Gerardo Hospital, Monza, Italy, ⁹Infectious Diseases, Istituti Ospitalieri, Cremona, Italy, ¹⁰Infectious Diseases and International Health Foundation, Brescia, Italy
- P 97 A comparison of 2-year durability of efavirenz and rilpivirine based regimens in clinical practice: data from the ICONA Foundation cohort**
A. Di Biagio¹, L. Taramasso², A. Cozzi-Lepri³, F. Maggiolo⁴, A. Tavelli⁵, S. Lo Caputo⁶, S. Bonora⁷, M. Zaccarelli⁸, P. Caramello⁹, A. Costantini¹⁰, C. Viscoli², A. d'Arminio Monforte¹¹
¹Infectious Disease Clinic, IRCCS San Martino-IST, Genova, Italy, ²University of Genova, Infectious Disease Clinic, IRCCS San Martino-IST, Genova, Italy, ³University College London, London, United Kingdom, ⁴Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, ⁵ICONA foundation, ⁶Infectious Diseases Clinic, Policlinico Hospital Giovanni XXIII, Bari, Italy, ⁷Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ⁸National Institute of Infectious Diseases Lazzaro Spallanzani, Rome, Italy, ⁹Department of Infectious Diseases, Amedeo di Savoia Hospital, Torino, Italy, ¹⁰Department of Health Sciences, University of Ancona, Ancona, Italy, ¹¹Clinic of Infectious and Tropical Diseases, Department of Health Sciences, S Paolo Hospital, University of Milan, Milan, Italy
- P 98 Assessment of appropriateness of first-line combined antiretroviral treatment (cART): the preliminary results of Liguria experience V.E.L.A. study**
G. Cenderello¹, A. Di Biagio², F. Artom¹, C. Dentone³, V. Bartolacci⁴, P. De Leo⁵, M. Anselmo⁵, M. Guerra⁶, B. Giannini⁷, P. Orcamo⁸, S. Artioli⁶, G. Ferrea³, G. Riccio⁴, M. Anselmo⁵, M. Giacomini⁷, G. Cassola¹, C. Viscoli²
¹SC Malattie Infettive, EO Ospedali Galliera, ²SC Clinica Malattie Infettive, IRCCS AOU San Martino-IST, ³SC Malattie Infettive, ASL-1, ⁴SC Malattie Infettive, ASL-2, Albenga, ⁵SC Malattie Infettive ASL-2, Savona, ⁶SC Malattie Infettive ASL-5, ⁷Dipartimento Informatica, Bioingegneria, Robotica e Ingegneria dei Sistemi, Università di Genova, ⁸Dipartimento Salute e Servizi Sociali Regione Liguria
- P 99 Pure red cells aplasia due to parvovirus-B19 chronic infection in HIV-HCV co-infected patients. Report of two cases**
F. Sabbatini, I. De Benedetto, M. Fabbiani, A. Soria, S. Trovati, A.M. Peri, A. Dolara, L. Bisi, A. Cappelletti, E. Colella, A. Bandera, A. Gori
 Infectious Diseases Clinic, San Gerardo Hospital, Monza, Italy
- P 100 Darunavir/ritonavir at reduced dosage of 600mg/100 mg once daily in a short numbers of heavily experienced HIV-1 positive patients**
E. Lattuada, M. Lanzafame, S. Nicolè, F. Rigo, G. Cucchetto, E. Concia
 Azienda Ospedaliera Universitaria Integrata, Unità Operativa di Malattie Infettive, Verona
- P 101 Low dose of unboosted atazanavir plus dolutegravir as simplification strategy for HIV-infected patients receiving antiretroviral therapy**
E. Pontali, A. Torresin, G. Cenderello, M. Feasi, M.P. Crisalli, G. Penco, N. Bobbio, G. Cassola
 S.C. Malattie Infettive – E.O. Ospedali Galliera, Genoa
- P 102 Management of comorbidities in HIV-infected population: results of a multicenter survey in Italy**
A. Borghetti¹, M. Colafigli², N. Coppola³, A. Costantini⁴, O. Cirioni⁵, Di Biagio⁶, F. Di Sora⁷, M. Fabbiani⁸, S. Ferrara⁹, A. Giacometti⁵, A. Latini², A. Maddaloni¹⁰, M. Maritati¹¹, M. Martini⁴, G. Orofino¹², A. Pennica¹³, D. Penoncelli¹², C. Resnati¹⁴, S. Rusconi¹⁴, L. Sighinolfi¹¹, G. Sterrantino¹⁵, L. Taramasso⁶, M. Zazzi¹⁶, S. Di Giambenedetto¹, A. De Luca¹⁷ for the Ecco Group
¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy, ²Infectious Dermatology, IFO San Gallicano, Rome, Italy, ³Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy, ⁴Clinical Immunology, Università Politecnica delle Marche, Ancona, Italy, ⁵Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy, ⁶Infectious Diseases, San Martino Hospital, University of Genova, Genova, Italy, ⁷Azienda ospedaliera San Giovanni Addolorata, Rome, Italy, ⁸Department of Infectious and Tropical Diseases, University of Brescia and Brescia Spedali Civili General Hospital, Brescia, Italy, ⁹University Hospital "Ospedali Riuniti" di Foggia, Foggia, Italy, ¹⁰A.O. Dei Colli - Hospital for Infectious Diseases D. Cotugno, Naples, Italy, ¹¹Hospital Infectious Diseases, Azienda ospedaliera universitaria di Ferrara, Ferrara, Italy, ¹²Unit of Infectious Diseases, "Divisione A", Ospedale Amedeo di Savoia, Torino, Italy, ¹³Infectious Diseases, Faculty of Medicine and Psychology, University of Rome "La Sapienza", Rome, Italy, ¹⁴Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, ¹⁵Division of Tropical and Infectious Diseases, "Careggi" Hospital, Florence, Italy, ¹⁶Department of Molecular Biology, University of Siena, Siena, Italy, ¹⁷University Division of Infectious Diseases, Siena University Hospital, Siena, Italy
- P 103 Dolutegravir monotherapy in HIV-infected naive patients with <100,000 copies/ml HIV-RNA load: a long-term follow-up**
M. Lanzafame^{1,3}, S. Nicolè³, D. Gibellini², E. Lattuada³, G. Cucchetto³, F. Rigo³, E. Diani², E. Concia³, S. Vento^{4,5}
¹"Diagnosis and Therapy of HIV Infection" Unit, G.B. Rossi University Hospital, Verona, Italy, ²Microbiology Unit, G.B. Rossi University Hospital, Verona, Italy, ³Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy, ⁴Department of Medicine, School of Medicine, Nazarbayev University and ⁵Nazarbayev University Medical Center, Astana, Kazakhstan
- P 104 Efficacy and safety of lipid-lowering therapy in the treatment of patients with HIV disease and hypercholesterolemia: A 20 YEARS single-centre retrospective study**
A. Mastroianni, F. Allegrini, E. Briganti, S. Di Cesare, C. Grosso, C. Antonini, S. Brighi
 U.O. Malattie Infettive, Dipartimento di Medicina Specialistica, P.O. "G.B. Morgagni - L. Pierantoni", Forlì
- P 105 An uncommon localization of non-Hodgkin lymphoma in a HIV patient under successful antiretroviral therapy: a case report of an endobronchial cancer**
O. Tambara¹, G. Bonadies¹, A.E. Maraola¹, G. Palmiero¹, F. Borrelli¹, G. di Filippo¹, U. Caterino², G. Borgia¹
¹Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", Naples, Italy, ²Thoracic Endoscopic V Unit, AORN Monaldi Hospital, Naples, Italy
- P 106 Tuberculosis-related IRIS masking cerebral cryptococcoma. A case report**
S. Coladonato, F. Volpato, A. Cascavilla, E. Magistrelli, M. Tadolini, S. Ianniruberto, R. Pascale, L. Marconi, G. Virgili, N. Rossi, P. Viale
 Infectious Disease Unit, S.Orsola-Malpighi Hospital, University of Bologna



- P 107 Evaluation of cardiovascular risk in HIV positive patients under HAART**
S. Lardo, K. De Gaetano Donati, V. Mazzotta, V. Mazzocato, M. Olivieri, S. Costanzo, A. De Curtis, L. Iacoviello, E. Tamburrini, R. Cauda
¹Infectious Diseases Department, Catholic University, Roma, ²Environmental and Genetic Epidemiology, Cellular Biology Laboratory and Statistical Methods in Epidemiology Unit, IRCCS Neuromed, Pozzilli, Isernia
- P 108 "High" antiretroviral deintensification: a case series**
M. Lanzafame^{1,3}, R. Gottardo², S. Nicolè³, E. Lattuada³, G. Cucchetto³, F. Rigo³, E. Concia³, F. Tagliaro², S. Vento^{4,5}
¹"Diagnosis and Therapy of HIV Infection" Unit, G.B. Rossi University Hospital, Verona, Italy, ²Forensic Medicine Unit, G.B. Rossi University Hospital, Verona, Italy, ³Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy, ⁴Department of Medicine, School of Medicine, Nazarbayev University, ⁵Nazarbayev University Medical Center, Astana, Kazakhstan
- P 109 Evaluation of HIV-RNA decay, HIV-DNA and inflammation markers modification in a cohort of twenty HIV-1 infected naive patients treated with ABC/3TC/DTG**
S. Nicolè¹, M. Lanzafame¹, E. Lattuada¹, R. Mazzi¹, F. Rigo¹, G. Cucchetto¹, D. Gibellini², E. Diani², E. Concia¹
¹Infectious and Tropical Diseases Unit, G.B. Rossi University Hospital, Verona, Italy, ²Microbiology Unit, G.B. Rossi University Hospital, Verona, Italy
- P 110 Monitoring requirements in antiretroviral-naïve patients: the experience of INMI Spallanzani in Rome**
F. Ferrara, M. Rizzica, S. Murachelli, A. Antinori, A. Ascani, G. Zaccaro, B. Moreno, L. Chiroso, M. Carli
INMI "L.Spallanzani" IRCCS, Rome, Italy
- P 111 Pharmacokinetics of darunavir/cobicistat in an Italian observational, multicenter, prospective study (The START Of ReZolsta "ST.O.RE" study - TMC114FD1HTX4003)**
A. Gori¹, E. Focà², A. Antinori³, A. Vergori³, R. Maserati⁴, S. Rusconi⁵, V. Di Cristo⁵, A. Uglietti⁶, R. Termini⁶, D. Mancusi⁶
¹Department of Infectious Diseases, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, ²Unit of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy, ³HIV/AIDS Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy, ⁴Infectious Diseases, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁵Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, ⁶Janssen-Cilag SpA, Medical Affairs Department, Infectious Diseases, Cologno Monzese (MI) - Italy
- P 112 Cardiovascular risk in HIV+ patients: 2006 - 2016 Vasto Infectious Diseases experience**
S. Antonelli, M.P. Sciotti
UO Infectious Diseases - Hospital "San Pio da Pietrelcina", Vasto (CH)
- P 113 Efficacy and safety of Dolutegravir-based combination antiretroviral therapy in clinical practice in naive HIV-infected patients: results from a multicenter study**
G. Caruana¹, G. Madeddu¹, P. Bagella¹, F. Clark², G. Nunnari³, G. Pellicano³, G. Angioni⁴, M. Sedda⁵, A. De Vito⁶, S. Babudieri¹, A. Freedman⁷
¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Italy, ²University Hospital of Wales Pharmacy, Cardiff, UK, ³Unit of Infectious Diseases, G. Martino University Hospital, University of Messina, Italy, ⁴Department of Infectious Diseases, Santissima Trinità Hospital, ASL Cagliari, Italy, ⁵University of Cagliari, Cagliari, Italy, ⁶University of Sassari, Sassari, Italy, ⁷Department of Infectious Diseases, University Hospital of Wales, Cardiff, UK
- P 114 Hepatic safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in patients with pre-existing hepatic comorbidities**
E. Francalanci¹, L. Badia^{1,2}, V. Guardigni^{1,2}, L. Bussini¹, P. Viale¹, G. Verucchi^{1,2}
¹UO Malattie Infettive, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna, ²Centro di Ricerca per lo Studio delle Epatiti, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna

COINFECTIONS/SEXUALLY TRANSMITTED INFECTIONS

- P 115 Prevalence of quadrivalent and nonavalent Human Papillomavirus vaccine genotypes among HIV-infected men who have sex with men in Rome, Italy**
M.G. Donà¹, A. Latini¹, M. Colafigli¹, M. Benevolo², F. Rollo², M. Zaccarelli³, D. Moretto⁴, A. Giglio⁴, A. Cristaudo¹, M. Giuliani¹
¹HIV/STI UNIT, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy, ²Pathology Department, Regina Elena National Cancer Institute, Rome, Italy, ³National Institute for Infectious Diseases, Lazzaro Spallanzani, (IRCCS), Rome, Italy, ⁴Clinical Pathology and Microbiology Department, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy
- P 116 Effect of HCV eradication on specific CMV response in HCV+ and HCV/HIV subjects undergoing DAAs**
S. Vita¹, C. Mascia¹, P. Zuccalà¹, O. Turriziani¹, R. Marocco², I. Pozzetto², C. Ajassa¹, M. Lichtner², C.M. Mastroianni², V. Vullo¹
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome ²Infectious Disease Unit, ²Sapienza University, Latina, Italy
- P 117 High/Low Risk HPV genotype distribution and persistence in HIV positive and negative patients**
M. Statzu¹, I. Scianora¹, I. Tino¹, C. Bitossi¹, G. De Girolamo², I. Schietroma², E.N. Cavallari², M. Gentile¹, G. Antonelli¹, C. Scagnolari¹, A. Pierangeli¹, G. d'Ettorre²
¹Department of Molecular Medicine, Laboratory of Virology affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognietti, Sapienza University, Rome, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy
- P 118 Abnormal anal cytology among HIV-infected men who have sex with men: prevalence and predictors**
M.G. Donà¹, M. Benevolo², A. Latini¹, M. Colafigli¹, M. Zaccarelli³, F. Rollo², A. Giglio⁴, D. Moretto⁴, A. Cristaudo¹, M. Giuliani¹
¹HIV/STI UNIT, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy, ²Pathology Department, Regina Elena National Cancer Institute, Rome, Italy, ³National Institute for Infectious Diseases, Lazzaro Spallanzani, (IRCCS), Rome, Italy, ⁴Clinical Pathology and Microbiology Department, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy



- P 119 European outbreak of Hepatitis A in MSM population: our experience in Padua General Hospital**
G. Marini, A. Celotti, D. Coletto, S. Marinello, A. Cattelan
 Infectious Diseases Department of Padua University Hospital
- P 120 Outbreak of Hepatitis A among men who have sex with men in Umbria**
L.M. Saraca¹, C. Di Giuli², A.R. Ciccaglione^{3}, G. Priante⁴, B. Tiri⁵, D. Francisci⁶*
¹Infectious Diseases Clinic, "S.Maria" Hospital, Terni, ^{2*}National Institute of Health, Rome
- P 121 Screening of papillomavirus infection (HPV) and anal cancer in MSM HIV positive in Sanremo Hospital**
I. De Macina¹, C. Dentone¹, P. Quilici², P. Secondo³, A. Dusi⁴, G. Ferrea¹
¹Infectious Diseases Unit, Sanremo Hospital, ²Pathology Unit, Sanremo Hospital, ³Surgical Department, Sanremo hospital, ⁴Microbiology Unit, Sanremo Hospital
- P 122 Prevalence and sociodemographic correlates of hepatitis B and C coinfection and triple infection among People Living with HIV: a seven year retrospective data review of rural HIV Clinic in Northern Nigeria**
V. Adepoju, V. Okafor, C. Ogbudebe, C. Ekerete-Udofia
 KNCV Tuberculosis Foundation, Lagos, Nigeria
- P 123 Screening for HBV, HCV and Treponema pallidum infections in HIV-positive patients in North-West of Benin, Africa**
C. Ceriani¹, S. Cavallari¹, T. Cerulli¹, C. Debora¹, M. De Paschale¹, K. Diombo², J. Ndayake², P. Viganò³, P. Clerici¹
¹Microbiology Unit, ASST Ovest Milanese, Legnano (MI), Italy, ²Fatebenefratelli Saint Jean De Dieu Hospital, Taguiéta, Benin, ³Infectious Diseases Department, ASST Ovest Milanese, Legnano (MI), Italy

GENDER ISSUES

- P 124 Gender differences in retention in care in a prospective cohort of HIV-infected adults in Tigray, Ethiopia**
R. Bucciardini¹, P. Tatarelli², V. Fragola¹, T. Abegaz³, S. Lucattini¹, A. Halifom⁴, E. Tadesse³, M. Berhe³, K. Pugliese¹, P. De Castro¹, R. Terlizzi¹, L. Fucili¹, M. Di Gregorio¹, M. Mirra¹, T. Zegeye⁴, A. Giammarioli¹, S. Vella¹, L. Abraham³, H. Godefay, the CASA-project Health Facilities⁴
¹Istituto Superiore di Sanità, Rome, Italy, ²Division of Infectious Diseases, Department of Health Sciences (DISSAL), IRCCS AOU San Martino-IST, University of Genoa, Genoa, Italy, ³College of Health Sciences, Mekelle University, Mekelle, Ethiopia, ⁴Tigray Regional Health Bureau, Mekelle, Ethiopia
- P 125 Switch from PI/r based therapy to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir in a cohort of women with HIV infection and stable antiretroviral therapy: retrospective analysis of efficacy and tolerability after 48 weeks**
R. Pennone, A. Maddaloni, A. Busto, P. Rosario, M. D'Abbraccio, V. Esposito
 Division of Immunodeficiency and Gender-related Infectious Diseases, "D. Cotugno" Hospital, AORN "Dei Colli", Naples, Italy
- P 126 Non-filter love. Forms and causes of barebacking**
G. Fracca, A. Bianchi, M. Cernuschi, M. Lanza
 ASA - Associazione Solidarietà AIDS

HEPATITIS CLINICAL DIAGNOSTICS AND PATHOGENESIS

- P 127 Partial recovery of peripheral T cell homeostasis following successful treatment with direct antiviral agents (DAA) in HIV/HCV coinfecting patients**
M. Chiamenti, F. Bai, R. Curetti, A. De Bona, G. Marchetti, A. d'Arminio Monforte
 Clinic of Infectious Diseases, Department of Health Sciences, San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy
- P 128 Monitoring DAAs treatment for chronic hepatitis C by quantitative HCV RNA and HCV core Antigen assays**
S. Mercinelli¹, B. Rossetti^{1,2}, C. Gandolfo³, M. Pomi¹, R. Salviati¹, G. Lentini³, A. De Luca^{1,4}, M.G. Cusi³
¹Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ²Clinic of Infectious Diseases, Catholic University of Sacred Heart, Roma, Italy, ³Department of Medical Biotechnologies, Microbiology, University of Siena, Italy, ⁴Department of Medical Biotechnologies, University of Siena, Italy
- P 129 Urinary metabolites in patients with chronic hepatitis C virus infection as revealed by nuclear magnetic resonance-based metabolomics**
E. Biliotti¹, A. Tomassini², D. Palazzo¹, G. Capuani², F. Sciubba², R. Esvan¹, M. De Angelis¹, C. Franchi¹, G. Iaiani¹, P. Maida¹, M. Spaziante¹, A. Miccheli², G. Taliani¹
¹Department of Clinical Medicine, Sapienza University of Rome, Italy, ²Department of Chemistry, Sapienza University of Rome, Italy
- P 130 High rate of misclassification of advanced fibrosis using APRI and Fib-4 in a cohort of HIV/HCV patients**
L. Adamoli¹, G. Mazzola¹, V. Calvaruso², P. Colletti¹, A. Cervo¹, M. Trizzino¹, P. Di Carlo¹, S. Corrao³, F. Di Lorenzo³, T. Prestileo³, A. Sanfilippo³, V. Di Marco², A. Cascio¹
¹Department of Sciences for Health Promotion "G. D'Alessandro", University of Palermo, Palermo, Italy, ²Sezione di Gastroenterologia, Di.Bi.M.I.S., University of Palermo, Palermo, Italy, ³ARNAS, Civico-Benfratelli Hospital, Palermo, Italy





P 131 Marked Reduction of Adiponectin, Selenoprotein P and Fetuin A in HCV-infected Patients Treated with IFN-free Regimens

P. Pavone¹, G. d'Ettore¹, I. Schietroma¹, G. Corano-Scheri¹, S. Najafi-Fard¹, C. Pinacchio¹, C. Mascia¹, T. Tieghi², M. Lichtner², C. Mastroianni², V. Vullo¹

¹Sapienza Univ., Rome, Italy, ²Sapienza Univ., Polo Pontino, Latina, Italy

P 132 In Vitro Effect of Direct-Acting Antivirals (DAA) and Antiretroviral Drugs on Cell Toxicity and Matrix Metalloproteinase Inhibition in LX-2 Hepatic stellate Cells

I. Pati¹, T. Latronico¹, C. Mascia², F. Mengoni², A. Fasano¹, A. Zingaropoli², M. Lichtner^{2,3}, V. Vullo², C.M. Mastroianni^{2,3}, G.M. Liuzzi¹

¹Department of Biosciences, Biotechnology and Biofarmaceutics, University of Bari "A. Moro", Bari, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, ³Infectious Diseases Unit Sapienza University, Latina, Italy

HEPATITIS EPIDEMIOLOGY

P 133 Epidemiology and risk factors for HCV genotypes in a high prevalence region

R. Scotti¹, A.R. Buonomo¹, B. Pinchera¹, M. Crispo¹, C. Monari², M. Macera², S. De Pascalis², G. Di Filippo¹, F. Borrelli¹, N. Coppola², I. Gentile¹, G. Borgia¹

¹Department of Clinical Medicine and Surgery, Section of Infectious Diseases, AOU Federico II Naples, ²Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy

P 134 Acute HCV, HAV or HEV in HIV+ men having sex with men: a three years retrospective study in a single center of Emilia-Romagna

A. Mastroianni¹, F. Allegrini¹, E. Fiumana², P. Billi³, M. Della Strada³, S. Semprini³, V. Sambri³

¹U.O. Malattie Infettive, Dipartimento di Medicina Specialistica, P.O. "G.B. Morgagni – L. Pierantoni", Forlì, ²Servizio Igiene Pubblica - Area Igiene e Sanità Pubblica, Forlì, ³U.O. Microbiologia, Laboratorio Unico di Area Vasta Romagna Pievesestina, Cesena

P 135 Epidemiological and Phylogenetic study of HBV in Migrant People in the South of Italy (Calabria region)

F. Bulla, S. Lombardo, S. Ambrosio, G. Sirianni, N. Careri, L.A. Surace

Medicina del Viaggiatore e delle Migrazioni, A.S.P. Catanzaro

HIV CLINICAL DIAGNOSTICS AND PATHOGENESIS

P 136 Resistance detected in PBMC GRT predicts virological rebound in HIV-1 suppressed patients switching treatment

D. Armenia¹, M. Zaccarelli², V. Borghi³, W. Gennari³, D. Di Carlo¹, A. Giannetti², F. Forbici², A. Bertoli¹, C. Gori², L. Fabeni², C. Pinnetti², R. Marocco⁴, A. Latini⁵, F. Ceccherini Silberstein¹, C.M. Mastroianni⁴, C. Mussini³, A. Antinori², C.F. Perno², M.M. Santoro¹

¹University of Rome "Tor Vergata", Rome, Italy, ²National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ³Polyclinic of Modena, Modena, Italy, ⁴La Sapienza University Polo Pontino, Latina, Italy, ⁵San Gallicano Dermatological Institute, IRCCS, Rome, Italy

P 137 Effects of treatment with Maraviroc a CCR5 inhibitor on a human hepatic stellate cell line

S. Martini¹, A. Perna², A. Lucariello², M. Macera¹, M.A. Carleo³, G. Guerra⁴, V. Esposito⁵, A. De Luca², N. Coppola¹

¹Department of Mental Health and Preventive Medicine, section of Infectious Diseases, Second University of Naples, Italy, ²Department of Mental Health and Preventive Medicine, section of Human Anatomy, Second University of Naples, Italy, ³Department of Infectious Disease and Infectious Emergencies, Immunodepression and Systemic Infections Unit, P.O. Cotugno - A.O. Ospedali dei Colli, Naples, Italy, ⁴Department of Medicine and Health Sciences, University of Molise, Italy, ⁵Department of Infectious Disease and Infectious Emergencies, General Infectious Diseases Unit, P.O. Cotugno - A.O. Ospedali dei Colli, Naples, Italy

P 138 Calculation of the Avidity Index for anti-HIV antibodies on a cohort of Western blot (WB)-reactive samples

M. Aquilina¹, C. Colomba², D. Mililli², F. Bonura¹, G.M.E. Colomba¹, G.M. Giammanco¹, A. Cascio²

¹Section of Microbiology, ²Section of Infectious Diseases, Department of Sciences for Health Promotion and Mother and Child Care, University of Palermo, Italy

P 139 Performance of new end-to-end assay for HIV-1 Sanger sequencing

I. Bon, G. Musumeci, S. Longo, A. Bertoldi, V. D'Urbano, C. Fazio, C. Coppola, M.C. Re

Microbiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna, Bologna, Italy

P 140 Application of Sigma metrics for the assessment of precision in HIV viral load testing: an experience in the routine of a high throughput laboratory

A. Amendola¹, P. Piselli², M. Pisciotta¹, M. Paterno¹, M.R. Capobianchi¹

¹Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome Italy, ²Department of Epidemiology, National Institute for Infectious Diseases "L. Spallanzani", Rome Italy

P 141 Metabolic activity of lymphoid tissue evaluated using PET in acute HIV infection and long-term evolution of CD4/CD8 ratio

A. Bonazza¹, S. Zona¹, M. Menozzi¹, A. Santoro¹, M. Digaetano¹, A. Raimondi¹, V. Borghi¹, G. Guaraldi¹, N. Prandini², C. Mussini¹

¹Clinica di Malattie Infettive e Tropicali, Università degli studi di Modena e Reggio Emilia, ²Medicina Nucleare, AOU Policlinico di Modena

- P 142 Missed opportunities for earlier HIV diagnosis in late-presenting patients: a cohort study at an Italian HIV center during the period 2011-2016**
L. van den Bogaart, A. Ranzani, L. Oreni, G. Bozzi, C. Resnati, S. Antinori, M. Galli, A.L. Ridolfo
 Department of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy
- P 143 Comparison of genotypic and phenotypic drug susceptibility evaluation of a rare case of multidrug resistant HIV-1**
F. Saladini¹, A. Giannini¹, A. Martini¹, A. Poggi², F. Vichi², B. Del Pin², A. Boccutto¹, I. Vicenti¹, M. Di Pietro², M. Zazzi¹
¹Department of Medical Biotechnologies, University of Siena, ²Infectious Diseases Unit, S. Maria Annunziata Hospital Firenze
- P 144 Prevalence of cytological abnormalities and HPV infection in anal samples collected by anal swab among HIV-infected men who have sex with men referring to a large outpatient clinic**
E. Magistrelli¹, L. Calza¹, V. Colangeli¹, G. Policastro¹, E. Rosselli Del Turco¹, L. Bussini¹, N. Rossi¹, S. Venturoli², L. Prosperi³, P. Viale¹
 Department of Medical and Surgical Sciences, ²Clinics of Infectious Diseases, ³Unit of Microbiology, and ⁴Unit of Pathologic Anatomy, S.Orsola-Malpighi Hospital, University of Bologna
- P 145 TM6SF2 E167E variant is associated with higher serum cholesterol values and carotid intima-media thickness in patients with HIV infection**
G. Di Caprio¹, S. Martini¹, A. Cascone¹, C. Sagnelli², M. Starace³, N. Farella², G. De Stefano², C. Uberti Foppa⁵, H. Hasson⁵, G. Cirillo⁴, L. Alessio¹, E. Miraglia De Giudice⁴, A. Lazzarin⁵, N. Coppola^{1,3}
¹HIV Unit, Second University of Naples, Naples, Italy, ²IX Interventional Ultrasound Unit for Infectious Diseases - AORN dei Colli - P.O. Cotugno - Naples, Naples, Italy, ³Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy, ⁴Pediatric Unit, Second University of Naples, Naples, Italy, ⁵Department of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
- P 146 Role of FDG-PET/CT in patients with Kaposi sarcoma: a first retrospective analysis**
A. Borghetti¹, S. Annunziata², M. Camici¹, V. Rufini², S. Di Giambenedetto¹
¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy, ²Institute of Nuclear Medicine, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, Italy
- P 147 COPD screening program in a HIV outpatient clinic of Northern Italy**
E. Quiros-Roldan¹, M.C. Pezzoli¹, A. Ferraresi¹, E. Raffetti², N. Brianese¹, P. Lanza¹, E. Focà¹, A. Bonito¹, I. Izzo¹, C. Chirico¹, F. Castelli¹
¹University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy, ²Brescia University, Unit of Hygiene, Brescia, Italy
- P 148 Comparative evaluation of the Aptima® HIV-1 Quant Dx Assay and Roche CAP/CTM HIV-1 v2.0 for HIV-1 RNA Viral Load Detection and Quantitation in Plasma Samples of HIV-1-Infected Patients**
S. Longo, I. Bon, G. Musumeci, A. Bertoldi, V. D'Urbano, M.C. Re
 Microbiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna, Italy
- P 149 Evaluation of the new commercial Duplica-RealTime HLA-B*5701 EZ Type test for the HLA-B*5701 typing and the Italian HLA-B*5701 Network**
T. Allice¹, B. Bruzzone², M.G. Milia¹, E. Burdino¹, G. Gregori¹, T. Ruggiero¹, B. Simoncelli¹, N. Nigro², R. Barresi², M. Zazzi³ and V. Ghisetti¹
¹Laboratory of Microbiology and Virology, ASL Città di Torino, Torino, Italy, ²Hygiene Unit, IRCCS AOU San Martino-IST, Genova, Italy, ³Department of Medical Biotechnologies, University of Siena, Italy
- P 150 Evaluation of cardiovascular risk in HIV+ subjects following 3 different algorithms**
P. Vassalini¹, E.N. Cavallari¹, F. Vullo², M. Mancone³, S. Strano⁴, G. Ceccarelli⁵, G. d'Ettore¹, V. Vullo¹
¹Department of Public Health and Infectious Diseases "Sapienza" University of Rome, ²Department of Radiological Sciences, Oncology and Anatomical Pathology "Sapienza" University of Rome, ³Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences "Sapienza" University of Rome, ⁴Department of Heart and Great Vessels "Sapienza" University of Rome, ⁵Department of Infectious Diseases Policlinico Umberto I "Sapienza" University of Rome
- P 151 Switch to EVG/c/TAF/FTC in virologically-suppressed patients does not seem to have an effect on immune activation and T cell differentiation**
V. Bordoni¹, O. Forini¹, G. Fabbri¹, M.M. Plazzi¹, A. Vergori¹, G. Maffongelli², R. Bellagamba¹, M. Andreoni², A. Ammassari¹, A. Antinori¹, C. Agrati¹
¹INMI L Spallanzani, Rome, Italy, ²University of Tor Vergata, Rome, Italy

HIV EPIDEMIOLOGY AND PREVENTION

- P 152 Late presenters and young foreigners among heterosexuals with a new HIV diagnosis in Italy, 2010-2015**
*V. Regine¹, L. Pugliese¹, B. Suligo¹, and the Regional representatives of the National HIV Surveillance System**
¹Centro Operativo AIDS, Istituto Superiore di Sanità, Rome, Italy, *Regional representatives of the National HIV Surveillance System.
 Abruzzo: M. Di Giacomo, V. Faggioni, L. Scancella; Basilicata: F. Locuratolo, G. Cauzillo; Calabria: A.D. Mignoli, D.G. Chirico; Campania: G. Borgia; Emilia Romagna: E. Massimiliani; Friuli Venezia Giulia: T. Gallo, C. Braidà; Lazio: V. Puro, P. Scognamiglio, A. Mammone; Liguria: G. Icardi, P.L. Lai; Lombardia: M. Gramegna, L. Coppola, A. Piatti, A. Rosa, D. Cereda; Marche: F. Filippetti; Molise: A. Prozzo; Piemonte: C. Pasqualini; Provincia Autonoma di Bolzano: P. Mian, O. Moling, L. Pagani; Provincia Autonoma di Trento: P. Lanzafame, L. Collini, D. Bassetti; Puglia: M. Chironna; Sardegna: M.A. Palmas; Sicilia: G. Dardano; Toscana: F. Voller, M. Puglia, L. Pecori; Umbria: A. Tosti, R. Papili; Valle d'Aosta: M. Ruffier, M.G. Verardo, E.F. Echarlod, S. Amoroso; Veneto: F. Russo, F. da Re



- P 153 The Role of ART Simplification in Clinical Practice: Analysis of 143 Patients Followed at Two Italian Sites**
S. Mazzanti¹, Z. Pasquini¹, V. Barocci¹, F. Trave¹, O. Cirioni¹, A. Giacometti¹, M. Balducci², B. Canovari², F. Barchiesi³
¹Dipartimento di scienze biomediche e sanità pubblica, Università Politecnica delle Marche, Clinica Malattie Infettive Ospedali Riuniti di Ancona, ²Malattie Infettive Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro, ³Dipartimento di scienze biomediche e sanità pubblica, Università Politecnica delle Marche, Malattie Infettive Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro
- P 154 Correlation between higher incidence of comorbidities and more frequent recourse to dual antiretroviral regimens in a cohort of HIV aged patients compared to younger one: analysis of retrospective cross-sectional study**
S. Martini, N. Coppola, A. Cascone, P. Filippini
HIV Unit, University of Campania, L. Vanvitelli, Naples, Italy
- P 155 Low prevalence of transmitted HIV-1 drug resistance in north-west of Benin, Africa**
C. Ceriani¹, S. Cavallari¹, T. Cerulli¹, C. Debora¹, M. De Paschale¹, K. Diombo², J. Ndayake², P. Viganò³, P. Clerici¹
¹Microbiology Unit, ASST Ovest Milanese, Legnano (MI), Italy, ²Fatebenefratelli Saint Jean De Dieu Hospital, Taguiéta, Benin, ³Infectious Diseases Department, ASST Ovest Milanese, Legnano (MI), Italy
- P 156 AIDS home care service: past, present and future**
M. Trezzi, M. Giorgi, B. Menichini, S. Bonelli, M. Benvenuti, C. Fabbri, D. Messeri, M. Uberti, A. Vivarelli, F. Esperti, M. Di Pietro
S.O.C. Malattie infettive II - AUSL Toscana Centro - Pistoia
- P 157 PrEP as a preventive measure: what healthcare providers think about it. A qualitative research**
F. Debbia¹, L. Badia², P. Viale², M. Libanore³, L. Sighinolfi³, C. Mussini⁴, N. Assueri¹
¹Infermieristica preventiva e di comunità, Alma Mater Studiorum - Università degli Studi di Bologna, ²UO Malattie Infettive, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna, ³UO Malattie Infettive, Arcispedale S. Anna, Ferrara, ⁴Divisione di Malattie Infettive, Università degli Studi di Modena e Reggio Emilia
- P 158 Vaccination of HIV + patients: increase of adherence in a infectious diseases surgery**
V. Frumento², A. Beltrame¹, P. De Leo¹, E.N. Malfatto¹, M. Marturano¹, P. Briata², M. Anselmo¹
¹Infectious Diseases Department S. Paolo Hospital ASL 2 Liguria, ²Department of Prevention ASL 2 Liguria
- P 159 HIV Prevention in the Immigrants Day Hospital of Perugia**
G. Gamboni, M. Damiani, C. Sfara, B. Marchini
Anlaids Umbria A



IMMUNOLOGY

- P 160 HIV-1 reservoir is controlled control by transcriptionally unique NK cells and associates directly with their CD335 CD337 inducibility and IFN- γ production**
F. Marras^{1,2}, A. Casabianca⁴, F. Bozzano^{1,3}, M.L. Ascierio^{5,6}, C. Orlandi⁴, A. Di Biagio⁷, E. Pontali⁸, C. Dentone⁹, G. Orofino¹⁰, L. Nicolini^{7,11}, L. Taramasso¹¹, M. Magnani⁴, F.M. Marincola¹², E. Wang¹², L. Moretta¹³, A. De Maria^{1,7,11}
¹Center for Excellence in Biomedical Research, University of Genova, Italy, ²Istituto Giannina Gaslini, Genova, Italy, ³Department of Experimental Medicine, University of Genova, Italy, ⁴Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino (PU), Italy, ⁵Department of Oncology, Kimmel Cancer Center, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA, ⁶Clinica Malattie Infettive, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, ⁷U.O.C. Malattie Infettive, Ospedale Galliera, Genova, Italy, ⁸U.O.C. Malattie Infettive, Ospedale Sanremo, Sanremo (IM), Italy, ⁹U.O.C. Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy, ¹⁰Department of Health Sciences, DISSAL, University of Genova, Genova, Italy, ¹¹Sidra Medical and Research Centre, Doha, Qatar, ¹²Pediatric Hospital Bambino Gesù, Rome, Italy
- P 161 L/M and M/L blood RATIO in tuberculosis and HIV patients: comparative analysis, preliminary data**
P. Di Carlo¹, N.R. Caccamo², G. Guadagnino¹, A. Cascio¹
¹Department of Sciences for Health Promotion and Mother-Child Care "G. Alessandro". University of Palermo, ²Central Laboratory of Advanced Diagnosis and Biochemical Research (CLADIBIOR), University of Palermo
- P 162 Tryptophan metabolism in HIV-1 infected patients: the role of probiotics on gut-brain axis**
G. Corano Scheri¹, I. Schietroma¹, E. Nelson Cavallari¹, S. Najafi Fard¹, C. Pinacchio¹, G. De Girolamo¹, C. Selvaggi², G. Fanello³, L. Laghi⁴, G. Ceccarelli⁵, C. Scagnolari^{2,6}, V. Vullo¹, G. d'Ettore¹
¹Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Rome, Italy, ²Department of Molecular Medicine, Laboratory of Virology, University of Rome "Sapienza", Rome, Italy, ³Department of Emergency Surgery, Emergency Endoscopic Unit, Policlinico Umberto I, University of Rome "Sapienza", Rome, Italy, ⁴Department of Agro-Food Science and Technology, University of Bologna, Bologna, Italy, ⁵Department of Infectious Diseases, Policlinico Umberto I, University of Rome "Sapienza", Rome, Italy, ⁶Pasteur Institute Italy, Cenci-Bolognetti Foundation, Rome, Italy
- P 163 Vitamin D deficiency and gut inflammation in a cohort of HIV infected patients naive to Antiretroviral Therapy (ART)**
V. Cogliandro¹, L. Gazzola¹, G. Ancona¹, E. Borghi², F. Borgo², N. Iannotti¹, T. Bini¹, G. Marchetti¹, A. d'Arminio Monforte¹
¹Department of Health Sciences-University of Milan, Clinic of Infectious Diseases, San Paolo Hospital, ²Department of Health Sciences, University of Milan, Milan, Italy



NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS

- P 164 Control beliefs and anxiety are associated to HIV progression during successful ART**
N. Ciccarelli¹, R. Gagliardini¹, R. De Marco¹, A. Brita¹, S. Lamonica¹, E. Visconti¹, E. Tamburrini¹, A. Cingolani¹, A. De Luca^{1,2}, S. Di Giambenedetto¹
¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, ²Infectious Diseases Unit, Siena University Hospital, Siena
- P 165 Cerebrospinal fluid (CSF) biomarkers of immune activation and brain cell injury in HIV-infected patients with CSF viral escape syndrome**
V. De Zan, F. Ferretti, L. Passeri, D. Mennona, E. Tuveri, A. Lazzarin, P. Cinque
Department of Infectious Diseases San Raffaele Scientific Institute, Milano, Italy
- P 166 Clinical manifestations and outcomes in patients with neurosymptomatic cerebrospinal fluid viral escape syndrome**
F. Ferretti¹, V. De Zan¹, E. Tuveri¹, N. Gianotti¹, A. Boschini², A. Lazzarin¹, P. Cinque¹
¹Department of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy, ²San Patrignano Medical Center, Ospitaletto di Rimini, Rimini, Italy
- P 167 Blood Brain Barrier (BBB) damage is associated with an increased intratecal immune activation, but not with neuronal injury in HIV-infected patients**
C. Pinnetti, V. Fedele, S. Carta, M. Tempestilli, P. Lorenzini, I. Mastroiosa, A. Vergori, S. Grisetti, F. Baldini, C. Agrati, A. Ammassari, C.F. Perno, A. Antinori
National Institute for Infectious Diseases, IRCCS, L. Spallanzani HIV/AIDS Department, Rome
- P 168 CSF cytokine profile and blood brain barrier damage in HIV+ patients: role of HCV infection**
V. Bordoni¹, C. Pinnetti¹, V. Fedele¹, S. Carta¹, A. Sacchi¹, P. Lorenzini¹, A. Ammassari¹, C.F. Perno^{1,2}, C. Agrati¹, A. Antinori¹
¹INMI L.Spallanzani, Rome, Italy, ²University of Tor Vergata, Rome, Italy
- P 169 HIV Central Nervous System (CNS) escape/compartmentalization: correlation with plasma viral load and blood brain barrier damage**
D.F. Bavaro, A. Calamo, R. Dell'Acqua, M. Mariani, A. Saracino, L. Monno, G. Angarano
University of Bari "Aldo Moro", Clinic of Infectious Diseases, Bari, Italy
- P 170 Predictors of cognitive disorders in HIV-infected people: a 5-years follow-up study**
N. Ciccarelli¹, A. Borghetti¹, A. Brita¹, R. De Marco¹, M. Fabbiani², R. Gagliardini¹, A. Ciccullo¹, A. De Luca^{1,3}, R. Cauda¹, S. Di Giambenedetto¹
¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, ²Division of Infectious Diseases, "San Gerardo" Hospital, Monza, ³Infectious Diseases Unit, Siena University Hospital, Siena
- P 171 Central nervous system symptoms, mood disorders and sleep disturbances are associated with reduced quality of life among patients under long-term suppressive treatment including efavirenz: screening results from the SWEAR (Switch from Efavirenz/Atripla to Rilpivirine) Study**
G. Lapadula¹, F. Conti², M. Tosato³, M. Valsecchi², S. Compostella⁴, T. Bini⁵, M. Milesi⁶, M. Rossi¹, B. Saccani⁴, A. Di Biagio³, F. Bai⁵, M. Bani², E. Focà⁴, M. Fabbiani¹, S. Bonora⁶, A. Bandera¹, F. Castelli⁴, G. Di Perrì⁶, A. d'Arminio-Monforte⁵, C. Viscoli³, A. Gori^{1,2} for the SWEAR study group
¹UO Malattie Infettive, Ospedale San Gerardo, ASST Monza, Monza, ²Università di Milano-Bicocca, Milano, ³Clinica Malattie Infettive, IRCCS AOU San Martino-IST, Genova, ⁴Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia, Brescia, ⁵UO Malattie Infettive, Ospedale San Paolo, ASST Santi Carlo e Paolo, Università degli Studi di Milano, Milano, ⁶Clinica di Malattie Infettive, Università degli Studi di Torino, Torino
- P 172 Role of B12 vitamin and homocysteine levels in HIV-positive patients with neurocognitive disorders**
K. Falasca, C. Ucciferri, F. Vignale, R. Piarulli, G. Ruggieri, P. Carboni, A. Occhionero, L. Caiazzo, J. Vecchiet
Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy



OPPORTUNISTIC INFECTIONS

- P 173 CD4+ T-cell immune response against immunogenic JCV-VP1 peptides with PML-associated mutations**
L. Passeri¹, D. Mennona¹, J. Sydney⁴, A. Sette⁴, F. Ferretti¹, A. Lazzarin³, G. Casorati², P. Dellabona², P. Cinque¹
¹San Raffaele Scientific Institute, Division of Immunology, Transplantation, and Infectious Diseases, Neurovirology, Milan, ²San Raffaele Scientific Institute, Division of Immunology, Transplantation, and Infectious Diseases, Experimental immunology Unit, Milan, ³San Raffaele Scientific Institute, Department of infectious diseases, Milan, ⁴La Jolla Institute for Allergy and Immunology, California, United States
- P 174 The overlap between tuberculosis and HIV infection: a regional estimate in the last decade**
P. Scognamiglio¹, A. Mammona¹, M. Sanè Schepisi¹, M. D'Amato¹, G. Ferrara², V. Puro¹, V. Panella², G. Ippolito¹, E. Girardi³
¹SeRESMi, Servizio Regionale per l'Epidemiologia, Sorveglianza e controllo delle Malattie Infettive - INMI "L. Spallanzani" - IRCCS, ²Direzione Regionale Salute e Politiche Sociali - Regione Lazio, ³UOC Epidemiologia Clinica - INMI "L. Spallanzani" - IRCCS, Roma
- P 175 Baseline screening for Latent Tuberculosis Infection in people living with HIV in a low TB incidence setting**
S. Ianniruberto, E. Rosselli Del Turco, V. Guardigni, M. Tadolini, L. Calza
Infectious Diseases Unit, Department of Medical and Surgical Sciences, Sant'Orsola-Malpighi Hospital, Alma Mater University of Bologna, Italy



- P 176 Risk of reactivation of latent Toxoplasmosis in an HIV-infected population**
F. Brandolino, G. Iaini, L. Fontanelli Sulekova, S. Gabrielli, G. Milardi, M. Spaziante, G. Taliani
 Infectious and Tropical Diseases Unit, Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy, Parasitological Analyses Unit, "Sapienza" University, Rome, Italy Department of Public Health and Infectious Diseases, "Sapienza" University, Rome, Italy
- P 177 Salvage therapy with I-amphotericin B, miltefosine, fluconazole, allopurinol and aerosolized pentamidine for disseminated mucocutaneous and visceral leishmaniasis in HIV disease**
A. Mastroianni¹, S. Varani², F. Allegrini¹, E. Fiumana³, R. Zanelli⁴, E. Briganti¹, S. Di Cesare¹, C. Grosso¹, S. Brighi¹, P. Billi⁵, V. Sambri⁵
¹U.O. Malattie Infettive, Dipartimento di Medicina Specialistica, P.O. "G.B. Morgagni - L. Pierantoni", Forlì, ²U.O. Microbiologia, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Policlinico S.Orsola, Università di Bologna, ³Servizio di Igiene Epidemiologia e Sanità Pubblica, Forlì, ⁴U.O. Dermatologia, Dipartimento Testa-Collo, P.O. "G.B. Morgagni - L. Pierantoni", Forlì, ⁵U.O. Microbiologia, Laboratorio Unico di Area Vasta Romagna Pievesestina, Cesena
- P 178 Progressive multifocal leukoencephalopathy in a patient with visceral Kaposi Sarcoma treated with liposomal doxorubicin**
L.M. Saraca¹, A. Lavagna¹, L. Ruggeri^{2}, G. Priante¹, B. Tiri¹, C. Di Giuli¹, D. Francisci¹*
¹Infectious Diseases Clinic, "S. Maria" Hospital, Terni, ^{2*}CREO, "S. Maria della Misericordia" Hospital, Perugia
- P 179 Changing incidence of Opportunist Infections (OIs) in the era of antiretroviral combination therapy (HAART), observational study**
E.A. Piga¹, M. Motzo², M. Ligas², S. Piga¹
¹Department of Infectious Disease, ASSL Cagliari, Italy, ²University of Sassari, Infectious Disease, Sassari, Italy

PEDIATRIC, ADOLESCENT, MATERNAL, FETAL ASPECTS

- P 180 Effectiveness of "Task Shifting" from clinical officers to nurses in delivering pediatric antiretroviral treatment: a retrospective cohort study in Beira (Mozambique)**
F. Di Gennaro¹, D. Pizzol², K.D. Chhaganlal³, L. Monno¹, G. Putoto⁴, A. Saracino¹
¹Clinic of Infectious Diseases, University of Bari, Bari, Italy, ²Research Section, Doctors with Africa CUAMM; Beira, Mozambique, ³Center for Research in Infectious Diseases, Faculty of Health Sciences, Catholic University of Mozambique; Beira, Mozambique, ⁴Research Section, Doctors with Africa CUAMM; Padova, Italy
- P 181 Perinatally HIV-infected youths after transition from paediatric to adult care, a single-centre experience from Northern Italy**
I. Izzo¹, E. Quiros-Roldan¹, B. Saccani¹, E. Chiari¹, S. Casari¹, E. Focà¹, M.C. Pezzoli¹, M.A. Forleo¹, A. Bonito¹, R. Badolato², L. Dotta², F. Castelli¹
¹University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy, ²University Department of Paediatrics, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
- P 182 HIV and pregnancy. Outcome of newborns exposed to antiretroviral therapy during gestational age: analysis of 80 cases**
L. Trotta¹, L. Galli², G. Sterrantino³, M. Trotta³
¹Università degli Studi di Firenze, Facoltà di Farmacia, ²Azienda Ospedaliero Universitaria Meyer, ³Azienda Ospedaliero Universitaria Careggi, SOD Malattie Infettive e Tropicali



PHARMACOECONOMIC ISSUES

- P 183 Strategies for reducing Antiretroviral Therapy costs in Tuscany: the indications from the Regional Working Group and the integrated approach at Santa Maria Annunziata Hospital, Florence Area**
F.M. Fusco¹, L. Rabatti², A. De Luca³, M.C. Burla², C. Braccini⁴, B. Del Pin¹, F. Baragli¹, T. Corona⁵, F. Vichi¹, P. Blanc¹
¹SOC Malattie Infettive 1, Azienda USL Toscana Centro, Ospedale S. Maria Annunziata, Bagno a Ripoli (FI), ²Servizio di Farmacia Ospedaliera, Ospedale S. Maria Annunziata, USL Toscana Centro, Bagno a Ripoli (FI), ³Divisione di Malattie Infettive, Università e Policlinico Universitario di Siena, Siena, ⁴UOC Farmaceutica Territoriale, USL Toscana Nord-Ovest, Pisa, ⁵Struttura di Politiche del Farmaco ed Appropriatelyzza, Regione Toscana, Firenze
- P 184 Adherence to treatment, viral and immunologic response and healthcare resources use in HIV patients treated with single tablet E/C/F/TDF versus multi-tablet (PI or INI) regimens**
V. Perrone¹, D. Sangiorgi¹, L. Aledda¹, A. Chirianni², G. Di Perri³, N. Gianotti⁴, T. Quirino⁵, L. Degli Esposti¹
¹CiCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy, ²Dipartimento Malattie Infettive ed Urgenze Infettivologiche - Azienda Ospedaliera Ospedali dei Colli "Monaldi-Cotugno-CTO" Napoli, Italy, ³Clinica di Malattie Infettive, Università degli Studi di Torino, Italy, ⁴Malattie Infettive, IRCCS San Raffaele, Milano, Italy, ⁵U. O. Malattie Infettive ASST Valle Olona, Italy
- P 185 Cost-effectiveness of E/C/F/TAF in the Italian context**
L. Pradelli¹, G. Di Perri², G. Rizzardini³, M. Povero¹
¹AdRes, ²Clinic of Infectious Disease, Università degli Studi di Torino, ³Department of Infectious Diseases, Fatebenefratelli Sacco Hospital, Milan
- P 186 The medical cost of the Hepatitis C Virus: the difference between HCV mono-infected and HIV/HCV co-infected patients**
D. Croce^{1,2}, L. Ferrario¹, E. Foglia¹, E. Garagiola¹ on behalf of the DA VINCHI study
¹Centre for Research on Health Economics, Social and Health Care Management, LIUC-Università Cattaneo, Castellanza, Italy, ²School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa





PHARMACOLOGY, PHARMACOGENOMICS AND DRUG INTERACTIONS

- P 187 Vitamin D pathway gene polymorphisms and GS-331007 sofosbuvir metabolite plasma concentrations are able to predict hepatocellular carcinoma in patients treated with direct acting antivirals**
J. Cusato, L. Boglione, A. De Nicolò, F. Favata, F. Guido, S. Mornese Pinna, C. Carcieri, G. Cariti, G. Di Perri, A. D'Avolio
Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy
- P 188 Deficiency of vitamin D increases efavirenz plasma exposure in HIV-positive patients**
M. Tempestilli¹, J. Cusato², A. Vergori¹, A. Ammassari¹, A. Antinori¹, A. D'Avolio², C. Agrati¹
¹National Institute for Infectious Diseases "L. Spallanzani" I.R.C.C.S., Rome, Italy, ²University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
- P 189 Dolutegravir 50 mg thrice weekly plus unboosted Atazanavir daily in five long-term virologically suppressed HIV-infected patients**
M. Lanzafame^{1,2}, E. Lattuada¹, S. Nicolè¹, F. Rigo¹, G. Cucchetto¹, E. Concia¹, S. Vento³
¹Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy, ²Simple Unit of "Diagnosis and Therapy of HIV Infection", ³Department of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan
- P 190 Lactose intolerance doesn't influence plasmatic concentration of lactose-containing drugs and their efficacy: the case of an HIV/HCV coinfecting patient**
C. Pallotto¹, L. Malincarne¹, F. Favata², F. Di Candilo¹, A. De Nicolò², F. Baldelli¹
¹Infectious Diseases Unit, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy, ²Infectious Diseases Unit, Department of Medicine, University of Turin, Turin, Italy
- P 191 Antiretroviral plasma drug concentrations before and during DAA in a large, real-world-treated HIV/HCV co-infected population**
M. Tempestilli, G. Fabbri, I. Mastroiosa, L. Timelli, S. Notari, R. Bellagamba, R. Libertone, F. Lupi, M. Zaccarelli, A. Antinori, C. Agrati, A. Ammassari
National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy
- P 192 Association of vitamin D gene polymorphisms with serological and virological response to interferon alpha in patients with active HBV infection and E genotype**
J. Cusato¹, L. Boglione¹, A. De Nicolò¹, R. Imbornone¹, S. Mornese Pinna¹, C.S. Cardellino¹, V. Ghisetti², G. Cariti¹, G. Di Perri¹, A. D'Avolio¹
¹Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy, ²Laboratory of Microbiology and Virology, Department of Infectious Diseases, Amedeo di Savoia Hospital, Turin, Italy
- P 193 Evaluation of the switch to a dual ART regimen with lamivudine plus dolutegravir or protease inhibitors in HIV-infected virologically suppressed patients. A real life experience**
M. Maritati¹, A. Trentini², S. Lo Menzo¹, D. Segala³, C. Contini¹, L. Sighinolfi³
¹Section of Infectious diseases, Department of Medical Sciences, University of Ferrara, ²Section of Biochemistry, Department of Biochemical and Surgical Sciences, University of Ferrara, ³Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Cona, Ferrara
- P 194 Intracellular simeprevir concentrations are increased by the co-administration of darunavir/ritonavir (first clinical report from the Kinetic C study)**
A. Ariaudo, F. Favata, A. De Nicolò, L. Marinaro, C. Carcieri, E. Gontero, J. Cusato, S. Bonora, G. Di Perri, A. D'Avolio
Laboratory of Clinical Pharmacology and Pharmacogenetic, Amedeo di Savoia Hospital, Department of Medical Science, University of Turin, Amedeo di Savoia Hospital
- P 195 Intracellular penetration of dolutegravir (DTG) and unboosted atazanavir (ATV) administered as dual regimen in the clinical setting**
M. Ferrara, L. Marinaro, A. Ariaudo, C. Alcantarini, A. Barco, C. Montrucchio, A. De Nicolò, M. Tettoni, M. Milesi, C. Costa, A. Calcagno, G. Di Perri, A. D'Avolio, S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy
- P 196 A long-term retrospective observational study about switch strategies of antiretrovirals therapies in virologically suppressed patients: early results from the SO-CLOSE Study**
D. Mengato¹, S. Cavinato², F. Brera³, G. Marini², N. Realdon¹, A.M. Cattelan²
¹School of Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, ²Infectious and Tropical Diseases, University Hospital of Padova, ³Hospital Pharmacy Department, University Hospital of Padova
- P 197 Association between sofosbuvir trough plasma concentrations and virological failure in anti-HCV treatment**
A. De Nicolò, L. Boglione, C. Carcieri, J. Cusato, S. Mornese Pinna, F. Favata, A. Ariaudo, G. Di Perri, A. D'Avolio
University of Turin, Department of Medical Science, ASL Città di Torino
- P 198 Interactions between antiretroviral drugs and human Arginase 1**
L. Lisi¹, M. Pizzoferrato¹, G.M.P. Ciotti¹, F.T. Miscioscia², A. Topai², P. Navarra³
¹Institute of Pharmacology, Catholic University Medical School, Rome, Italy, ²Colosseum Combinatorial Chemistry Centre for Technology, Rome, Italy
- P 199 Cerebrospinal fluid abacavir penetration: once versus twice-daily administration**
A. Calcagno¹, C. Pinnetti², A. Ariaudo¹, E. Scarvaglieri¹, M. Tempestilli², A. D'Avolio¹, V. Fedele³, G. Di Perri¹, A. Antinori², S. Bonora¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, ²Clinical Department, National Institute for Infectious Diseases "Lazzaro Spallanzani", Roma, ³University of Rome Tor Vergata, Roma, Italy



P 200 The problem of interference between drugs and risk ADR in patients co-infected HIV/HCV in treatment with new Direct Acting Antivirals (DAAs)

G. Pensalfine, E. Meta, L. Appolloni, G. Piazza, M. Morotti, C. Puggioli
Farmacia Clinica, Policlinico S. Orsola-Malpighi, Bologna

P 201 Inadequate daclatasvir blood levels in a liver transplantation recipient treated with Sofosbuvir and Daclatasvir in association with ursodeoxycholic acid: a case report

L. Bussini¹, V. Guardigni^{1,2}, L. Badia^{1,2}, E. Francalanci¹, M. Rinaldi¹, M. Conti³, P. Viale^{1,2}, G. Verucchi^{1,2}

¹UO Malattie Infettive, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna, ²Centro di Ricerca per lo Studio delle Epatiti, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna, ³Metropolitan Laboratory, Maggiore Hospital, Bologna

P 202 Daclatasvir dosed at 60 mg/day in a patient taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate: case report

E. Rosselli Del Turco¹, L. Badia^{1,2}, S. Coladonato¹, V. Guardigni^{1,2}, E. Francalanci¹, L. Bussini¹, P. Viale¹, G. Verucchi^{1,2}

¹UO Malattie Infettive, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna, ²Centro di Ricerca per lo Studio delle Epatiti, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna

PROGRAMMATIC ISSUES, IMPLEMENTATION OF DIAGNOSIS AND CARE

P 203 FLEW: Free to live well with HIV in prison

G. Starnini¹, S. Dell'Isola², S. Babudieri³, A. Battistella⁴, M. Errico⁵, C. Frontini², F. Perocco⁴, FLEW group

¹Medicina Protetta-Malattie Infettive Unit- Belcolle Hospital, Viterbo, Italy, ²SIMSPE – Italian society of Penitential Medicine – Viterbo, Italy,

³Infectious Diseases Unit, University of Sassari, Sassari, Italy, ⁴University Ca' Foscari, Department of Philosophy and Cultural Heritage, Venice, Italy,

⁵NPS Italy onlus – Network of people living with HIV, Milan, Italy



P 204 A retention in care program in HIV patients: surprising results

M. Digaetano¹, A. Raimondi¹, A. Bonazza¹, A. Bianchi¹, A. Santoro¹, M. Menozzi¹, M. Rivasi², V. Borghi¹, G. Guaraldi¹, C. Mussini¹

¹Department of infectious diseases, University of Modena and Reggio Emilia, Modena, Italy, ²Azienda USL Modena

P 205 Adherence to lipid-lowering medication in HIV infected people in Modena HIV Outpatients Clinic: a Drug Direct Distribution experience

A. Raimondi¹, N. Riva¹, A. Bonazza¹, A. Santoro¹, M. Digaetano¹, I. Franconi¹, A. Bianchi¹, M. Rivasi², G. Guaraldi¹, C. Mussini¹, V. Borghi¹

¹Department of infectious diseases, University of Modena and Reggio Emilia, Modena, Italy, ²Azienda USL Modena, Italy

P 206 Retention in care of Italian HIV-positive patients at the Infectious Diseases Clinic of Perugia from 2005 to 2014

C. Gabrielli, G.G. Mina, G. Angeli, C. Pallotto, E. Schiaroli, M.B. Pastucci, D. Francisci, F. Baldelli

Ospedale S.M. della Misericordia, Clinica delle Malattie Infettive, Perugia

P 207 Measuring competent and reactivated HIV reservoir using TILDA

A. Bertoldi¹, M. Stoszko¹, I. Bon¹, G. Musumeci¹, S. Longo¹, V. D'Urbano¹, C. Fazio¹, T. Mahmoudi², M.C. Re¹, E. De Crignis²

¹Microbiology Section, Department Of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy, ²Department of Biochemistry, Erasmus Medical Center, Rotterdam, The Netherlands

P 208 Need for a better definition of "physical activity" among HIV infected population

E.N. Cavallari¹, I. Schietroma¹, G. Corano Scheri¹, C. Pinacchio¹, P. Vassalini¹, A. Salvati², P.E. Adami², M. Bernardi², G. Ceccarelli³, V. Vullo¹, G. d'Ettore¹

¹Department of Public Health and Infectious Diseases "Sapienza" University of Rome, ²Department of Human Physiology and Pharmacology "Sapienza" University of Rome, ³Department of Infectious Diseases Policlinico Umberto I "Sapienza" University of Rome

P 209 Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment

M. Borderi¹, G. Angarano², A. Antinori³, A. Chirianni⁴, P. Cinque⁵, A. D'Arminio Monforte⁶, A. di Biagio⁷, G. Di Perri⁸, M. Galli⁹, A. Gori¹⁰, A. Lazzarin⁵, C. Mussini¹¹, C.F. Perno¹², T. Quirino¹³, G. Rizzardini¹⁴, B. Acone¹⁵, M. Andreoni¹⁶

¹Infectious Diseases, S.Orsola Malpighi Hospital, University Bologna, Bologna Italy, ²Institute of Infectious Disease, University of Bari, Bari, Italy, ³Clinical Department, National Institute for Infectious Diseases, INMI "L. Spallanzani", Rome, Italy, ⁴III U.O.C. P.O. Cotugno, AORN OspedaledeiColli, Naples, Italy, ⁵Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, ⁶Clinic of Infectious and Tropical Diseases, Department of Health Sciences, University of Milan, Milan, Italy, ⁷Infectious Disease Clinic, IRCCS University Hospital, San Martino IST, Genova, Italy, ⁸Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, "Amedeo di Savoia" Hospital, Turin, Italy, ⁹Department of Biomedical and Clinical Science, University of Milan, Milan, Italy, ¹⁰Division of Infectious Diseases, Department of Internal Medicine, "San Gerardo" Hospital, University of Milan-Bicocca, Milan, Italy, ¹¹Infectious Diseases Clinic, University Hospital, Modena, Italy, ¹²Experimental Medicine and Surgery, Department of Systems Medicine, Tor Vergata University, Rome, Italy, ¹³Azienda ospedaliera Busto Arsizio, Busto Arsizio, Italy, ¹⁴Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, and School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa, ¹⁵Cartesia Solutions, Mirano, Venezia, Italy, ¹⁶Clinical Infectious Diseases, Department of Systems Medicine, Tor Vergata University, Rome, Italy

P 210 Ligurian Vaccination in HIV Program (LIV in HIV): the experience of Genoa metropolitan area

L. Sticchi^{1,5}, I. Barberis¹, F. Grammatico¹, V. Tisa¹, A. Di Biagio², G. Cenderello³, M. Giacomini⁴, B. Giannini⁴, F. Iavarone¹, V. Faccio¹, L.A. Nicolini^{1,2}, N. Riccardi², L. Taramasso², B. Bruzzone⁵, G. Mazzerello⁵, G. Cassola³, C. Viscoli^{1,2}, G. Icardi^{1,5}

¹Department of Health Sciences, University of Genoa, Italy, ²Infectious Disease Clinic, IRCCS San Martino - IST Hospital, Genoa, Italy, ³Infectious Diseases Unit, EO Galliera, Genoa, Italy, ⁴Department of Informatics, Bioengineering, Robotics and System Engineering, University of Genoa, Genoa, Italy, ⁵Hygiene Unit, IRCCS San Martino IST, Genoa, Italy



SOCIAL AND BEHAVIOURAL SCIENCE, COMMUNITY ASPECTS AND COMMUNITY SURVEYS

P 211 Comics against Stigma

L. Modesti, R. D'Emidio

Conigli Bianchi - www.coniglibianchi.it



P 212 Management of medications in people living with HIV

A. Battistella¹, D. Cattaneo², M. Errico³, R. Iardino⁴

¹Centro Studi "Gianni Grosso" NPS italia onlus, Milan, Italy, ²Luigi Sacco Hospital, Milan, Italy, ³President NPS - Network persone sieropositive, ⁴President of The Bridge Foundation

P 213 Italian "long-term survivors"

M. Zetti, A. Bianchi, M. Cernuschi

ASA-Associazione Solidarietà AIDS Onlus

P 214 HIV patients perceived quality of life: an analysis of QoL predictors

E. Foglia¹, E. Garagiola¹, L. Ferrario¹, D. Croce^{1,2}, F. Maggiolo³, T. Quirino⁴, P. Bonfanti⁵, G. Rizzardini^{6,7}, P. Meraviglia⁶, C. Atzori⁶

¹Centre for Research on Health Economics, Social and Health Care Management, LIUC-Università Cattaneo, Castellanza, Italy, ²School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³Infectious Diseases Department, ASST Papa Giovanni 23th, Bergamo, Italy, ⁴Infectious Diseases Department, ASST Valle Olona, Busto Arsizio, Italy, ⁵Department of Infectious Diseases, ASST Lecco, Lecco, Italy, ⁶Department of Infectious Diseases, Fatebenefratelli Sacco Hospital, Milan, Italy, ⁷School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg

P 215 Community Knowledge and Perception on MSM in BUEA the South West Region of Cameroon

P. Nguafac Temate Fongeh, C. Noutchie Nzesseu, G.I.L. Azegue

Vision in Action Cameroon, Association for Women in development

**P 216 So easy? A project towards the information about sexual transmitted diseases and administration of rapid HIV oral test".
The crucial role of the Family Doctors**

B. Bartocci, A.G. De Giorgio, S. Galeazzi, S. Guerrucci, C. Minelli, M. Nardi, B. Pilati, R. Tenca

Anlaids Umbria Onlus e Arcisolidarietà Ora d'Aria Perugia

P 217 Does HIV concern us? A preliminary study about HIV/AIDS risk perceptions and health Locus of Control in Italian general population

M.M. Ratti, F. Bertin, E. Soldi, V. Salverani, S. Ardenghi, M.G. Strepparava

Dipartimento di Medicina e Chirurgia - School of Medicine, Università degli Studi Milano Bicocca, Milan

P 218 Found your poetry

A. Infante

Policlinico Tor Vergata, Roma

P 219 The Socio-affective Network and Self-Efficacy in adherence to antiretroviral therapy

S. Giglio, V. Fortunato, A. Masiello, S. Leone, M. Talamo, N. Acone

AORN "S. G. Moscati" - Malattie Infettive- Avellino

P 220 AIDS Free Generation. Awareness-raising campaign to overcome stereotypes and promote a culture of safe and conscious sexuality. The project.

B. Bartocci, A.G. De Giorgio, S. Galeazzi, S. Guerrucci, M. Nardi, B. Pilati, R. Tenca

Arcisolidarietà Ora d'Aria Perugia, Anlaids Umbria

P 221 AIDS Free Generation. The awareness-raising campaign.

B. Bartocci, A.G. De Giorgio, S. Galeazzi, S. Guerrucci, M. Nardi, B. Pilati, R. Tenca

Arcisolidarietà Ora d'Aria Perugia, Anlaids Umbria

P 222 So easy? A project towards the information about sexual transmitted diseases and administration of rapid HIV oral test

B. Bartocci, A.G. De Giorgio, S. Galeazzi, S. Guerrucci, C. Minelli, M. Nardi, B. Pilati, R. Tenca

Anlaids Umbria Onlus e Arcisolidarietà Ora d'Aria Perugia

P 223 Low prevalence of HTLV1/2 infection in a population of sub-Saharan immigrants living in Southern Italy

L. Alessio^{1,2,3}, L. Occhiello¹, M. Caroprese², E. Sagnelli¹, C. Sagnelli^{1,2,4}, L. Gualdieri⁵, M. Pisaturo^{2,3,4}, C. Minichini¹, G. Di Caprio², M. Starace¹, L. Onorato^{1,2}, G. Scottò⁶, M. Macera^{1,2}, S. De Pascalis¹, N. Coppola¹

¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania, L. Vanvitelli, Naples, Italy, ²Medical Center, Centro Sociale ex Canapificio, Caserta; Medical Center, Centro di Accoglienza "La tenda di Abramo", Caserta, Italy, ³Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ⁴Medical center, Centro Suore Missionarie della Carità, Naples, Italy, ⁵Medical Center, Centro per la Tutela della Salute degli Immigrati, Naples, Italy, ⁶Infectious Diseases Unit, Foggia

P 224 Using Peer Educators Recruited from Populations at High Risk for HIV Acquisition to Improve HIV Testing and Counseling Uptak-KUMBA Cameroon


A. Fontu, N.G. Tanyi, Y.S. Chupiwoh

Head of HIV/AIDS Department Forestry and Environmental conservation Society (FECONS). Women in Action, Vision in Action



- P 225 A multidisciplinary approach by physician and clinical pharmacist to increase adherence to HAART in a cohort of HIV infected patients**
E. Meta, G. Pensalfine, L. Appolloni, G. Piazza, M. Morotti, C. Puggioli
Farmacia Clinica, Policlinico S. Orsola-Malpighi, Bologna
- P 226 Home-based care for HIV/AIDS patients: the experience of a Northern Italy Centre in the post HAART era**
M. Ficoni¹, S. Magrin¹, P. Di Ruscio¹, D. Signorelli², M. Malena¹
¹Centro Malattie Diffusive, ²Direzione Sanitaria, Azienda ULSS9 Scaligera, Verona, Italy
- P 227 The experience of Unità di Strada "Cabiria" with Rapid HIV Oral Test**
B. Bartocci, A.G. De Giorgio, S. Galeazzi, S. Guerrucci, M. Nardi, B. Pilati, R. Tenca
Arcisolidarietà Ora d'Aria e Anlaids Umbria
- P 228 The Case of Test Days in Modena: How can Psychology of Prevention Enhance HIV Counselling and Testing Impact**
A. Toscano¹, A. Bignardi², A. Santoro³, M. de Paola², C. Mussini³
¹Università degli Studi eCampus - Polo Universitario di Milano, ²Arcigay Modena - Matthew Shepard, ³Dept. of Medical and Surgical Sciences for Children and Adults, Infectious Disease Clinic - Università di Modena e Reggio Emilia
- P 229 From curing to caring. What do Italians know about HIV/AIDS?**
G. Bonadies, F. Corbisiero, M. Errico, S. Monaco, G. Ranisio
University of Naples Federico II, NPS Italia

VIROLOGY

- P 230 Description of clinical and molecular characteristics of a group of chronic hepatitis C infected patients who had undergone a DAA re-treatments: our region experience**
E. Rappazzo^{1,2}, P. Canepa^{1,2}, L. Nicolini³, S. Marengo⁴, B. D'Ambrosio^{1,2}, C. Arcuri^{1,2}, C. Dentone⁵, V. Bartolacci⁶, L. Bruzzone⁷, G. De Rosa², L. Sticchi^{1,2}, A. Picciotto⁴, C. Viscoli³, A. Grasso⁷, G. Icardi^{1,2}, B. Bruzzone²
¹Department of Health Sciences (DiSSal), University of Genoa, Italy, ²Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ³Infectious Diseases, IRCCS AOU San Martino-IST, Genoa, Italy, ⁴Hepatology and Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS San Martino - IST, Genoa, Italy, ⁵Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy, ⁶Infectious Diseases Department, Albenga Hospital, Albenga, Italy, ⁷Gastroenterology and Hepatology Unit, Savona and Pietra Ligure Hospitals, Italy
- 
- P 231 Virological patterns of HCV-patients with failure to Interferon-free regimens**
M. Starace¹, C. Minichini¹, S. De Pascalis¹, M. Macera¹, L. Occhiello¹, V. Messina², V. Sangiovanni³, L.E. Adinolfi⁴, E. Claar⁵, D.F. Precone⁶, G. Stornaiuolo⁷, T. Ascione⁷, R. Zampino⁸, G. Parrilli⁹, M. Stanzione¹, A. Federico¹⁰, I. Gentile¹¹, V. Iovinella¹², S. Martini¹³, M. Masarone¹⁴, L. Fontanella¹⁵, A. Masiello¹⁶, R. Punzi¹⁷, A. Salomone Megna¹⁸, R. Santoro¹⁹, G.B. Gaeta¹, N. Coppola¹
¹Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University L. Vanvitelli, Naples, Italy, ²Infectious Diseases Unit, AO Caserta, Caserta, Italy, ³Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, ⁴Internal Medicine, Clinical Hospital of Marcianise, University L. Vanvitelli, Naples, Italy, ⁵Internal Medicine Unit, Evangelical Hospital Villa Betania Naples, Italy, ⁶Internal Medicine unit A.O. Sarno, Sarno (SA), ⁷IX Interventional Ultrasound Unit for Infectious Diseases, AORN dei Colli, P.O. Cotugno, Naples, Italy, ⁸Internal Medicine, University of Campania L. Vanvitelli, & AORN Ospedali dei Colli- Monaldi Hospital, Naples, Italy, ⁹Gastroenterology Unit, AOU San Giovanni di Dio Ruggi d'Aragona, Salerno Italy, ¹⁰Hepato-Gastroenterology Unit, University L. Vanvitelli, Naples, Italy, ¹¹Infectious Diseases Unit, University Federico II, Naples, Italy, ¹²Internal Medicine Unit, P.O. S.Paolo - ASL Napoli 1, Naples, Italy, ¹³HIV Unit, University L. Vanvitelli, Naples, Italy, ¹⁴Internal Medicine and Hepatology Unit, PO G. Da Procida-AOU-San Giovanni e Ruggi D'Aragona, University of Salerno, ¹⁵Internal Medicine Unit, AO Madonna del Buon Consiglio Fatebenefratelli, Naples, Italy, ¹⁶Infectious Diseases Unit, A.O. S.G. Moscati, Avellino Italy, ¹⁷Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, ¹⁸Infectious Diseases Unit, AO G.Rummo, Benevento, ¹⁹Infectious Diseases Unit, AOU San Giovanni di Dio Ruggi d'Aragona, Salerno Italy
- P 232 Prevalence of integrase strand transfer inhibitors (INSTI) resistance mutations in INSTI-naive and INSTI-experienced HIV-1 infected patients: a single-Centre experience**
M.A. De Francesco¹, M. Properzi², F. Gargiulo¹, I. Izzo², F. Caccuri¹, F. Castelli², A. Caruso¹, E. Focà²
¹Institute of Microbiology, Department of Molecular and translational Medicine, University of Brescia, ²University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital
- P 233 Impact of resistance mutations in the protease and reverse transcriptase on the replicative capacity of HIV-1 in recent and nonrecent infections**
S. Caucci¹, P. Bagnarelli¹, M. Franzetti², M. Andreoni³, C. Balotta², S. Menzo¹
¹Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, ²Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Milano, ³Clinica di Malattie Infettive, Università di Tor Vergata, Roma
- P 234 HBsAg mutations in hematological patients with HBV reactivation**
P. Caligiuri^{1,2}, M. Mikulska³, L. Nicolini³, G. Barisone^{1,2}, G. Guarona^{1,2}, R. Cerruti², G. Icardi^{1,2}, B. Bruzzone²
¹Hygiene Unit, Department of Health Sciences, University of Genoa, IRCCS San Martino - IST, Genoa, Italy, ²Hygiene Unit, IRCCS San Martino - IST, Genoa, Italy, ³Infectious Diseases, Department of Internal Medicine, University of Genoa, IRCCS San Martino - IST, Genoa, Italy



P 235 Measurements of total, unintegrated and integrated cell-associated HIV-1 DNA in elite controllers, long-term nonprogressor, on ART progressors and treatment-naïve patients

C. Orlandi¹, F. Marras^{2,3}, F. Bozzano^{2,4}, B. Canovari⁵, M.L. Ascierio⁶, A. Di Biagio⁷, E. Pontali⁸, C. Dentone⁹, G. Orofino¹⁰, L. Nicolini^{7,11}, L. Taramasso¹¹, F. Marincola¹², E. Wang¹², L. Moretta¹³, F. Barchiesi⁵, A. De Maria^{2,7,11}, M. Magnani¹, A. Casabianca¹

¹Department of Biomolecular Sciences, Section of Biotechnology, University of Urbino "Carlo Bo", Italy, ²Center for Excellence in Biomedical Research, University of Genova, Italy, ³Istituto Giannina Gaslini, Genova, Italy, ⁴Department of Experimental Medicine, University of Genova, Italy, ⁵Azienda Ospedaliera Ospedali Riuniti Marche Nord; Presidio San Salvatore di Pesaro - Stabilimento di Muraglia; Malattie Infettive, Pesaro, Italy, ⁶Department of Oncology, Kimmel Cancer Center, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA, ⁷Clinica Malattie Infettive, IRCCS AOU San Martino-IST Genova, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, ⁸U.O.C. Malattie Infettive, Ospedale Galliera, Genova, Italy, ⁹U.O.C. Malattie Infettive, Ospedale Sanremo, Sanremo (IM), Italy, ¹⁰U.O.C. Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy, ¹¹Department of Health Sciences, DISSAL, University of Genova, Italy, ¹²Sidra Medical and Research Centre, Doha, Qatar, ¹³Pediatric Hospital Bambino Gesù, Rome, Italy

P 236 HTLV-I associated ATL: application of a SYBR GREEN real time PCR to evaluate size proviral reservoirs after chemotherapy and antiretroviral treatment

G. Musumeci¹, I. Bon¹, S. Longo¹, A. Bertoldi¹, V. D'Urbano¹, L. Marconi², L. Calza², M.C. Re¹

¹Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Microbiology Section, University of Bologna, Bologna, Italy, ²Department of Medical and Surgical Sciences, Section of Infectious Diseases, S. Orsola-Malpighi Hospital, University of Bologna

P 237 Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity following drug withdrawal in Chronically Infected Monocytes/Macrophages

A. Borrajo^{1,3}, V. Svicher¹, C. Alteri¹, C.F. Perno¹, S. Aquaro^{1,2}

¹University of Rome "Tor Vergata", Department of Experimental Medicine and Surgery, Rome, Italy, ²University of Calabria, Department of Pharmacy, Health and Nutritional Sciences, Rende, Italy, ³INIBIC-Complejo Hospitalario Universitario, Division of Clinical Virology, A Coruña, Spain

P 238 Prevalence of NS3, NS5A and NS5B resistance associated variants in patients experienced a virological failure

P. Canepa^{1,2}, E. Rappazzo^{1,2}, S. Marengo³, L. Nicolini⁴, S. Delucis^{1,2}, C. Arcuri^{1,2}, M. Lo Casto², G. Cenderello⁵, C. Dentone⁶, I. De Macina⁶, V. Bartolacci⁷, P. De Leo⁸, F. Malfatti⁹, E. Giannini³, M. Setti¹⁰, R. Prinapori¹¹, A. Di Biagio⁴, B. Bruzzone²

¹Hygiene Unit, Department of Health Sciences, University of Genova, IRCCS San Martino - IST, Genoa, Italy, ²Hygiene Unit, IRCCS San Martino - IST, Genoa, Italy, ³Hepatology and Gastroenterology Unit, Department of Internal Medicine, University of Genova, IRCCS San Martino - IST, Genoa, Italy, ⁴Infectious Diseases, Department of Internal Medicine, University of Genova, IRCCS San Martino - IST, Genoa, Italy, ⁵Infectious Diseases Department, Galliera Hospital, Genoa, Italy, ⁶Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy, ⁷Infectious Diseases Department, Albenga Hospital, Albenga, Italy, ⁸Infectious Diseases Department, San Paolo Hospital, Savona, Italy, ⁹Gastroenterology Unit, San Paolo Hospital, Savona, Italy, ¹⁰Internal Medicine and Clinical Immunology Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ¹¹Infectious Diseases Department, La Spezia Hospital, La Spezia, Italy



Genvoya[®]

elvitegravir 150 mg/cobicistat 150 mg/emtricitabina
200 mg/tenofovir alafenamide 10 mg compresse

Cod. HIV 1716

Depositato presso AIFA in data 17/02/2017


 **GILEAD**



9° CONGRESSO
NAZIONALE

12-14
GIUGNO 2017

Italian Conference on
AIDS and Antiviral Research



GENERAL INFORMATION

Conference Venues

Università degli Studi di Siena

Centro Didattico Policlinico S. Maria alle Scotte

Strada Le Scotte, 4
53100 Siena



ICAR Opening Session – Monday, June 12

Teatro dei Rinnovati

Piazza del Campo – 53100 Siena

Transfer from Policlinico S. Maria alle Scotte to Teatro dei Rinnovati at 15.00



How to reach the Centro Didattico Policlinico S. Maria alle Scotte



Public transportation

Bus n. 17 from Piazza del Sale (departures at minutes 22 and 52; return at minutes 1 and 31)

Bus n. 77 from Piazza del Sale (departures at minutes 8 and 38; return at minutes 23 and 53)

Bus n. 03 from Via F. Tozzi (departures at minutes 22 and 52; return at minutes 23 and 53)

Bus n. 10 from Piazza A. Gramsci (departures at minutes 10 and 40; return at minutes 15 and 45)



Car

From the North: A1 direction Roma, exit Firenze Impruneta, take Firenze – Siena Interchange 3 and exit at Siena Nord following directions to Policlinico

From the South: Highway A1 direction Firenze, exit Valdichiana, take SS715 NSA3 (Bettolle – Siena Interchange), exit Siena Est following directions to Policlinico



Airport

80 km from Florence airport

115 km from Pisa airport



Railway Station

2 km from Siena Railway

70 Km from Florence SMN Railway



Official languages

Italian and English. No simultaneous translation provided.

Pre-conference advanced courses and Congress dates

Pre-conference advanced courses: Monday, June 12 from 12.30 to 15.00

Conference: from Monday, June 12 at 16.00 to Wednesday, June 14 at 16.30

Conference Secretariat opening times

Monday, June 12	Tuesday, June 13	Wednesday, June 14
from 09.30 to 15.30	from 08.00 to 18.00	from 08.00 to 16.30

Lunches

Monday, June 12	Tuesday, June 13	Wednesday, June 14
only for Courses participants from 11.30 to 12.30	from 12.15 to 14.30	from 12.15 to 14.30

Exhibition Area opening times

Monday, June 12	Tuesday, June 13	Wednesday, June 14
from 12.30 to 15.30	from 08.00 to 18.00	from 08.00 to 16.30

ICAR 2017 official events

Sunday, June 11

Quick tests HIV-HCV: Piazza Matteotti, from 15.00 to 18.00

Monday, June 12

Quick tests HIV-HCV: Piazza Matteotti, from 15.00 to 18.00

Opening Session: Teatro dei Rinnovati, from 16.00 to 20.30

RaccontART HIV: Teatro dei Rinnovati from 17.40 to 18.00

ICAR-CROI Awards: Teatro dei Rinnovati, from 19.00 to 19.30

ICAR 2017 Welcome Reception: Tartarugone – Piazza del Mercato, from 20.30 to 22.30

Tuesday, June 13

Quick tests HIV-HCV: Piazza Matteotti, from 09.30 to 12.30 and from 15.00 to 18.00

ICAR Run: Piazza Matteotti, from 18.30 to 20.00

Wednesday, June 14

Quick tests HIV-HCV: Piazza Matteotti, from 09.30 to 12.30

ICAR 2017 Best Poster Awards: Centro Didattico Policlinico S. Maria alle Scotte, from 15.30 in Auditorium

SIMIT-ICAR Special Awards: Centro Didattico Policlinico S. Maria alle Scotte, from 15.30 in Auditorium

Instructions for Speakers

It is not possible to bring presentations directly to the lecture hall. All presentations have to be handed over at the Slide Center Room at least 2 hours before the session. At the Slide Center Room, Speakers will have the possibility of:

- Reviewing power-point presentations
- Last minute changes of power-point presentations
- Being supported by technical staff
- Uploading power-point presentation in the dedicated session conference room

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide

Oral Communication Sessions

Selected abstract will be presented in Oral Communication Sessions. The Authors of the selected abstract are requested to attend those sessions and provide max 7 (Microsoft Power Point) slides resuming their poster. **Time allowed for presentation: 7 minutes followed by 3 minutes for discussion.**

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.



Poster Discussion Sessions

Selected abstract will be presented in Oral Discussion Sessions. The Authors of the selected abstract are requested to attend those sessions and provide max 5 (Microsoft Power Point) slides resuming their poster. **Time allowed for presentation: 5 minutes followed by 2 minutes for discussion.**

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.

Authors can set up their posters according to the number received from the Organizing Secretariat on **June 12, 2017 from h. 9.30 and remove them on June 14, 2017 at the end of the Congress.**

Poster Exhibition

ICAR Poster exhibition will take place within a dedicated area of the Congress Center. Dimensions should not exceed 70x100 cm. Authors can set up their posters according to the number received from the Organizing Secretariat on **June 12, 2017 from h. 9.30 and remove them on June 14, 2017 at the end of the Congress.**



RaccontART HIV

The art competition launched by ICAR to students who are invited to present their views on HIV/AIDS through various forms of expression. During the Conference Opening Session (Teatro dei Rinnovati, Monday June 12, from 17.40 to 18.00) the winners will be awarded by the Jury composed of leading representatives of the national cultural world, ICAR Scientific Coordinators and Patients' Community.

The artistic Jury

- **Antonello Dose**, conduttore radiofonico, autore televisivo e attore
- **Andrea Adriatico**, regista di teatro e di cinema
- **Alessandro Gottardo** (alias Shout), illustratore
- **Enzo Porcelli**, produttore cinematografico
- **Guido Silvestri** (alias Silver), fumettista

The technical-scientific Jury

- **Andrea Antinori** INMI "Lazzaro Spallanzani" IRCCS, Roma
- **Francesca Ceccherini-Silberstein** Università Tor Vergata di Roma
- **Paola Cinque** IRCCS Ospedale San Raffaele, Milano
- **Andrea De Luca** Università degli Studi di Siena
- **Margherita Errico** NPS Italia, Milano
- **Massimo Galli** Università degli Studi di Milano
- **Sergio Lo Caputo** Università degli Studi di Bari
- **Bruno Marchini** ANLAIDS, Roma
- **Simona Nasta** NPS sezione Sicilia, Palermo
- **Stefano Rusconi** Università degli Studi di Milano
- **Domenico Salierno** NPS sezione Campania, Napoli
- **Filippo von Schloesser** NADIR, Roma
- **Francesca Vichi** Azienda Sanitaria di Firenze
- **Maurizio Zazzi** Università degli Studi di Siena

Unrestricted educational grant of Gilead Sciences



Community Village

A specific area of the Congress Venue dedicated to the Community Village: a meeting point for all the participants to visit the booths of HIV/AIDS and Hepatitis patient associations and meet the Community activists.



Quick test for HIV and HCV

Healthcare personnel from Infectious Disease Departments of Azienda Ospedaliera Universitaria Senese will perform free rapid testing for HIV and HCV at the request of citizens in a confidential and anonymous way. The test is noninvasive, requires few minutes and is highly reliable.

At Piazza Matteotti on:

Sunday, June 11 from 15.00 to 18.00

Monday, June 12 from 09.30 to 12.30 and from 15.00 to 18.00

Tuesday, June 13 from 09.30 to 12.30 and from 15.00 to 18.00

Wednesday, June 14 from 09.30 to 12.30

In collaboration with Meridian Bioscience Europe





Piazza ICAR

A dedicated area at the entrance of the Congress Venue, Centro Didattico Policlinico S. Maria alle Scotte.



Unrestricted educational grant of Gilead Sciences



ICAR Run

A non-competitive foot race, promoted by ICAR and the Community. ICAR Run will unfold for 3.5 km in the historical center of Siena: departure and arrival in Piazza Matteotti. **June 13**, from 18.30 to 20.00.

The event will conclude with the top three awards.

All registered participants will receive the numbered bib.

Departure from Centro Didattico Policlinico S. Maria alle Scotte at 18.00

Unrestricted educational grant of Janssen





Nice to ICAR you

The Secretary Meeting point where all registered participants can ask for ICAR T-shirt and "bandana".



Poster-4-you

A free service for selected posters' Authors to create and print their own posters and pick them up at the Poster exhibition area inside the Congress Venue. **Poster-4-you** USB Pendrive can be requested showing the coupon at the Bristol-Myers Squibb booth.

Unrestricted educational grant of Bristol-Myers Squibb

Abstract USB Pendrive

All registered participants can ask for the **ICAR Abstract USB Pendrive** showing the coupon at ViiV Healthcare booth: it contains all accepted abstracts.

Unrestricted educational grant of ViiV Healthcare

Website and Web Repository

After the Congress, the ICAR official website (www.icar2017.it) will publish the ICAR 2017 web repository with abstracts, presentations, oral communications, accepted posters, podcasts and photo gallery.

Social Media

 www.facebook.com/ICAR2017

 twitter.com/ICARSiena2017

Conference

The 9th ICAR Conference has been accredited to the Italian Ministry of Health for **14,7 CME Credits**.

Every single day has been accredited for the following professionals:



Id ECM Number	Credits	Professionals
Monday, June 12 150-179911	2,8	Medical Doctor Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine Gastroenterology Biologist, Pharmacist, Nurse, Medical laboratory technician, Psychologist
Tuesday, June 13 150-179912	6,3	
Wednesday, June 14 150-179915	5,6	

Pre-conference advanced Courses

The 9th ICAR advanced Courses have been accredited to the Italian Ministry of Health for each single course:

Id ECM Number	Credits	Professionals
La virologia clinica negli attuali contesti del paziente in trattamento antiretrovirale 150-185110	2	Medical Doctor Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine Gastroenterology Biologist Medical laboratory technician
Patient Reported Outcomes (PROs) in HIV e HCV 150-185117	2,3	Medical Doctor Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine Gastroenterology Nurse, Healthcare assistant, Professional educator, Psychologist
Corretta presa in carico "globale" del paziente HIV 150-185125	2	Medical Doctor Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine Gastroenterology Healthcare assistant, Professional educator, Psychologist, Neurophysiology technician
Conoscenze e sfide future: una visione sempre più olistica del paziente con HIV/AIDS 150-185126	2	Medical Doctor Hygiene, Epidemiology and Public Health Nurse, Healthcare assistant, Professional educator, Psychologist



Obtaining CME credits

Participants

To obtain credits, registered participants are required to:

- Wear the identification badge during working sessions
- Provide their signature and write entrance/exit times before and after attending working sessions
- Complete assessment and satisfaction questionnaires for each day

Speakers

Speakers will be given 1 credit for each half-hour of consecutive teaching.

Speakers, moderators and discussants can decide to obtain credits as participants (see Participants).

Attendance Tracking

Attendance will be tracked through participants' signature at the start/end of each day, and through assessment and satisfaction questionnaires.

CME Certificates

Credits will be given only if a participant attends 90% of the working sessions and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. The Provider will send CME certificates to the participants after the Conference.

Pre-conference advanced Courses

Free of charge (registrations available on a "first come, first served" basis).

Registration includes: congress kit (delegate bag, badge, certificate of attendance), CME registration and materials, working brunch and coffee breaks during the day of the course.

Conference

Conference Registration Fees (22% VAT non included)

Physicians	€ 700,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologis	€ 310,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

The registration fee includes: congress kit (delegate bag, badge, certificate of attendance), Opening Session and Welcome Cocktail on June 12, coffee breaks and lunches on June 13 and 14, CME registration, Conference USB/abstract and poster.

Daily Conference registration fees (22% VAT not included)

Physicians	€ 300,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologis	€ 150,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

The registration fee includes: attendance to the sessions of the day, congress kit (delegate bag, badge, certificate of attendance), Conference USB/abstract and poster, coffee break and lunch for the day, certificate of attendance for the sessions of the day.



ICAR 2017 Best Poster Award

Among abstracts accepted as "Poster", 33 have been selected to participate in the **"ICAR 2017 Best Poster Award"**. The winner will be announced on **Wednesday, June 14, 2017 from 15.30 to 16.00 in Auditorium**.

The 33 selected posters will be recognizable in the Conference Venue through a cockade. A dedicated Commission will judge the posters in two time-slots during the Conference:

- **Tuesday, June 13** from 12.30 to 13.30
- **Wednesday, June 14** from 12.30 to 13.30

Authors are requested to be close to their posters to meet the Commission during the time-slots above.



SIMIT-ICAR special Awards

The 9th ICAR Chairs, Scientific Secretariat and Organizing Secretariat wish to thank SIMIT for the Special Awards addressed to Young Investigators:

5 Awards of € 2.000,00 each for the best abstracts accepted as Oral Communications in Clinical HIV (3 Awards), Clinical HCV (1 Award), Virology and Immunopathogenesis (1 Award), presented by young Investigators (under 45 aa), regularly registered to SIMIT for years 2016 and 2017.

Abstracts will be selected at the Congress Venue by a dedicated SIMIT Commission and winners will be announced during the ICAR 2017 Special Awards Session, scheduled in Auditorium, on Wednesday June 14, from h. 15.30 to h. 16.00.



Guardiamo

Verso un futuro migliore per tutti. Perché noi in Bristol-Myers Squibb ci impegniamo a scoprire, sviluppare e rendere disponibili farmaci che aiutino pazienti affetti da gravi malattie. Una passione vera che guida



Bristol-Myers Squibb



al futuro.

il nostro lavoro e ci spinge a perseguire importanti risultati. I nostri successi si misurano grazie alla differenza che facciamo nella vita dei pazienti. È questo il nostro riconoscimento più grande.

bms.it



Vist our booth at ICAR 2017!

Let's shape the future of healthcare together

At Siemens Healthineers, our focus is to help healthcare providers succeed in today's dynamic environment.

Healthcare providers around the world have long relied upon our engineering excellence – leading-edge, high-quality medical technologies across a broad portfolio. Our technologies touch an estimated 5 million patients globally every day.* At the same time, they help hospital departments to continuously improve their clinical, operational and financial outcomes.

Engineering success. Pioneering healthcare. Together.



Atellica™ MDX 160 Molecular System†

Flexible, automated molecular system with maximum productivity for multiple sample types.

siemens.com/healthineers

†Under development. Not for sale. Product availability will vary by country.



9° CONGRESSO
NAZIONALE


12-14
GIUGNO 2017

Italian Conference on
AIDS and Antiviral Research



CONGRESS MAP

ENTRANCE



Auditorium



Exhibition area

Lunch area (piano -1)

ENTRANCE

Nice to ICAR you

Congress Secretariat

Aula 1

Aula 6

Poster area

Aula 2

Room AGORA B GILEAD


Room AGORA A Viiv Healthcare

Slide center (Aula 3)

Room AGORA C SIMIT/ICAR

coffee break

Poster Area






9° CONGRESSO
NAZIONALE

12-14
GIUGNO 2017

CONGRESS MAP

Exhibition Area

1	ViiV Healthcare	5	Bristol-Myers Squibb	1	SIEMENS
2	abbvie	6	MSD	2	Alere
3	ReAd files Fondazione Icona <small>Co-founded by Professor Mauro Maroni</small>	7	GILEAD		
4	Janssen <small>Pharmaceutical Division of Johnson & Johnson</small>				





9° CONGRESSO
NAZIONALE

12-14
GIUGNO 2017

THANKS TO THE SPONSORS

The Chairs, the Scientific Secretariat and the CME Provider wish to thank for the support given to the Congress, as unrestricted educational grants, to the following Companies:

PLATINUM SPONSORS



ViiV Healthcare S.r.l. è sponsor commerciale parziale del presente Evento; il presente Evento è soggetto a deposito ALFA ai sensi e per gli effetti di cui all'art. 124 del D.Lgs. 219/06

GOLD SPONSORS

abbvie



SILVER SPONSORS



OTHER SPONSORS



www.icar2017.it



CME PROVIDER and ORGANIZING SECRETARIAT

Effetti srl Via Gallarate, 106 - 20151 Milano, I

PHONE +39 02 3343281 FAX +39 02 38002105 MAIL: icar2017@effetti.it

CONGRESS VENUES

Università degli Studi di Siena

Centro Didattico Policlinico S. Maria alle Scotte
Strada Le Scotte, 4 - 53100 Siena I

OPENING SESSION

Teatro dei Rinnovati

Piazza del Campo - 53100 Siena I

QUICK LINKS

Organizing Secretariat icar2017@effetti.it

Abstract Secretariat abstract.icar2017@effetti.it

ICAR Website www.icar2017.it



www.facebook.com/ICAR2017



twitter.com/ICARSiena2017